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Abstract 
Compositae plants of the genus Erigeron have ca. 390 species, widely distributed in 
most temperate regions around the world. Erigeron annuus (L.) Pers. (fleabane) is 
one of the most valuable plants in this genus, used in Chinese folk medicine to treat 
indigestion, malaria, enteritis, hepatitis and hematuria increasingly since the 1970s. 
However, it is not an indigenous species in China and has not been officially recorded 
in the Chinese Pharmacopeia. Very little research has been published on its biological 
activity and no activity against MRSA has been reported. In this research, whole plant 
material was collected in Shanghai, China and its chemical composition, antibacterial 
activity, DNA gyrase inhibitory activity and mutagenicity assessment were evaluated 
on isolated compounds and extracts. 
 
Chapter I is an introduction to the plant E. annuus. A review of the literature relating to 
phytochemical studies and their biological applications is given. 
 
Chapter II describes the phytochemical separation of E. annuus. An ethanolic extract 
of the whole plant was suspended in water and partitioned against hexane, ethyl 
acetate and butanol respectively. Various chromatography techniques of column 
chromatography, preparative TLC, flash chromatography, HPLC, gel column filtration, 
solid phase extraction and also recrystallization methods were used in the separation 
process.  
 
Chapter III describes the antibacterial studies on E. annuus. Minimum inhibitory 
concentration assays were used in order to search for potential antimicrobial agents. 
Isolated compounds and fractions were tested against two Gram-negative and three 
Gram-positive wild type strains and a methicillin-resistant Staphylococcus aureus 
(MRSA) strain. Two compounds were found to have inhibitory activity against MRSA, 
while four hexane, one ethyl acetate and four butanol fractions showed inhibitory 
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activity against both Gram-positive and Gram-negative wild type strains. 
 
DNA gyrase is a type II topoisomerase, unique in prokaryotes, that regulates bacterial 
DNA topology structures. It is a good target for antibacterial agents. Potential gyrase 
inhibitors can be identified in DNA gyrase supercoiling assays against Gram-negative 
and Gram-positive gyrase. Chapter IV discusses the DNA gyrase inhibitory activity of 
isolated compounds and fractions. Five compounds, five ethyl acetate and three 
butanol fractions showed gyrase inhibitory activity and the IC50 of three of the 
compounds was evaluated. 
 
The final part of this thesis is a mutagenicity assessment of the plant extracts against 
Saccharomyces cerevisiae ade2. Mutagenicity tests were carried out against a 
haploid Saccharomyces cerevisiae ade2 (mating type a). However, the maintenance 
of the red mutant was difficult, and the background mutation frequency was very high 
giving inconsistent test results. During the tests, some cytotoxicity was observed in 
the hexane fractions which had a major influence on the cell survival rate. 
 
This study has demonstrated for the first time that E. annuus contains compounds 
with antibacterial activity against MRSA and inhibitory activity against DNA gyrase. 
Two of the compounds, erythrodiol and 4-pent-3’-ne-1’-ynyl-pyran-2-one were 
isolated from this plant for the first time, and both compounds were active against the 
MRSA strain. DNA gyrase inhibitors were also found including one naphthoquinone 
derivative and one 1, 4-benzopyrone derivative. This research supports the traditional 
use of E. annuus as a folk herbal medicine in China to treat fever and infections such 
as malaria, diarrhea, gingivitis, gastroenteritis. Further investigation of this plant’s 
biological activity is warranted. 
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1.1 Introduction 
1.1.1 Traditional medicine 
The earliest surviving records of medicine are from the ancient Egyptian civilization. 
The first records of ancient traditional medicine date back to 2900 BC in the form of 
clay tablets created by the Egyptian people. Western approaches to medicine are 
very different to those originating in the East (Rustamadji, 2000). The first record of 
Chinese Materia Medica was documented in 1100 BC in the book of <wu shi er bing 
fang> (containing of 52 prescriptions) (Cragg and Cragg, 2001). Unlike the western 
medicinal system, applications of Chinese medicines were performed under the 
instruction of the basic theory of traditional Chinese medicine in clinic (Li et al., 2014). 
The traditional Chinese medicine had many forms such as decoction, vinum and 
ointment. The most commonly used Chinese medicines were decoctions, but the 
chemical compositions and preparation methods could be different according to the 
different diagnosis of individual patient. Commonly, more than two herbs were used in 
one prescription and the final chemical components of the decoction were unclear. 
Sometimes the side effects of the decoctions were serious, as they might be 
contaminated with heavy metals or produce toxins during the preparation procedures 
(Yu et al., 2011, Sreejith et al. 2014). It is necessary to evaluate the validity of 
phytochemicals from herbal medicine, eliminating the risk of treatments and 
optimizing the applications. 
1.1.2 Phytochemicals 
Plants produce phytochemicals with a variety of structures and functions. They 
provide a wide range of foods, medicines and dietary supplements for humans 
(Osbourn and Lanzotti, 2009). They have numbers of biochemical functions, which 
had been proven to be effective against a range of human diseases. For example, 
over 200 years ago, the isolation of the first pharmacologically active compound from 
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Papaver somniferum was achieved by Germany scientist Friedrich Wilhelm Adam 
Sertürner. He successfully isolated and purified morphine in 1804 and published his 
findings in the German Journal der Pharmacie for the first time. As a consequence of 
this research, morphine became widely used from 1815 (Schmitz, 1985), the 
discovery of morphine initiated a new era of drug development. As a drug precursor 
(Hamilton and Baskett, 2000), morphine and other opioids were modified to reduce 
the side-effects, improve the drug’s effectiveness. Those semi-synthetic drugs include 
dihydromorphine, hydromorphone and heroin (Khazir et al., 2013, Klous et al., 2005). 
 
Phytochemicals had been isolated from natural plant sources and used to treat 
diseases instead of using mixed herbal decoctions. They provide a more precise 
treatment for certain diseases, for example, artemisinin, a first line anti-malarial drug, 
was first separated in 1972 from Artemisia annua L., and used for treating 
Plasmodium falciparum caused malaria (Tu, 2011). The synthesized derivatives of 
artemisinin are also used in artemisinin-combination therapies (ACTs) against all 
types of malaria (Gubaev et al., 2009). It could inhibit the early stages of plasmodium 
development in the red blood cells by inactivation of the PfATP6 calcium pump on the 
cell membrane (Haynes and Krishna, 2004, Shandilya et al., 2013). Another famous 
anti-malarial compound is quinine from genus Cinchonas which has been used in 
malarial treatment since the 1960s (Daikos et al., 1961). Quinine and its derivatives 
had been used as first line antimalarial agents almost 400 years until quinine 
resistance became widespread after 1950s (Achan et al., 2011).  
1.1.3 Secondary metabolites 
Plant cells can produce two types of metabolites: primary and secondary metabolites. 
A large proportion of phytochemicals are secondary metabolites, as they are 
produced by plants to defend themselves against pests and diseases and to adapt to 
their living environments. Unlike primary metabolites, secondary metabolites are not 
necessary for plant survival, but important for plant bioactivities (Leicach and Chludil, 
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2014) and benefits (Muller-Waldeck et al., 2010). For example, gibberellins are a type 
of plant hormones that can regulate plant growth (Martin and Hine 2008); 
Cinnamomum camphora can produce camphor, which they secreted to repeal the 
pests which used as an insect repellent agent and pesticide by human ( Martin and 
Mcferran, 2008).  
1.2 Erigeron annuus (L.) Pers 
Erigeron annuus (L.) Pers (also known as Herb of Annual Fleabane) belongs to the 
Compositae family, genus Erigeron (Stace, 1992). It is native to North America and 
was introduced to China in the 17th century. Since then, it has become popular in 
domestic gardens (Edwards et al., 2006).  
 
 
 
Figure 1.1 Erigeron annuus (L.) Pers. Copied from the web page (Pflanzenbilder, 2014). 
 
Erigeron annuus (L.) Pers (Figure 1.1) is a biennial herbaceous plant, 20-100 cm in 
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height with sparsely haired erect stems and alternate leaves (Daniel and Austin;, 
2004). Small clusters of daisy-like white flowers 1.5 cm in diameter occur at the apex 
of the plant. The flowers’ blooming period begins in early summer and continues until 
late autumn (Gedvilaite and Sasnauskas, 1994). The achene is covered with fine hair 
(ChineseAcademyofSciences, 1985).   
1.2.1 Phytochemicals form E. annuus 
Phytochemicals from E. annuus can be sorted into three major classes: terpenes 
(including sesquiterpenes, diterpenes and triterpenes); steroids; and flavonoids. 
Sesquiterpenes have been reported as the main constituents in this plant (Iijima et al., 
2003a) showed in Table 1.1 (Table 1.1). 
 
Table 1.1 Phytochemicals isolated from E. annuus 
Terpenoids 
Sesquiterpenes (Li et al., 2005, Iijima et al., 2003a) 
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Sesquiterpenes (Li et al., 2005, Iijima et al., 2003a) 
  
    
  
  
  
 
Diterpene (Iijima et al., 2003a) 
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Triterpenes (Li et al., 2004) 
 
Sterols (Mohamed and Abd, 2006, Kim et al., 2005) 
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Flavonoids (Mohamed and Abd, 2006, Jang et al., 2010, Yoo et al., 2008) 
 
 
 
 
 
Caffeic acid and derivatives (Jang et al., 2010) 
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γ-pyranone derivatives (Hashidoko, 1995, Li et al., 2006) 
 
 
 
 
 
 
Cyclopentenone Derivatives (Iijima et al., 2003b) 
 
 
 
Others (Li et al., 2006, Yang et al., 2008) 
 
 
 
 
Glu: glucuronoyl 
 
Compounds isolated from the aerial part of this plant include: sesquiterpenes 
(Mishima et al., 2005, Nazaruk and Kalemba, 2009, Ragasa et al., 1997, Li et al., 
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2005, Iijima et al., 2003a); triterpenes (Li et al., 2004); flavonoids (Mohamed and Abd, 
2006); caffeic acid (Jang et al., 2010) and its derivatives (Jang et al., 2008, Mishima et 
al., 2005); monosaccharide derivatives; polyacetylenic compounds (Pieribattesti et al., 
1981); cyclopentenone derivatives (Iijima et al., 2003b) and γ-pyrone derivatives 
(Hashidoko, 1995). Saccharides or polysaccharides were discovered in the roots of E. 
annuus (Roberfroid, 2005). In addition, over 60 constituents from the volatile oil of the 
whole plant were identified by Lis and Kumar (Lis et al., 2011, Kumar et al., 2014). 
1.2.2 Bioactivities of E. annuus 
E. annuus has been used as a folk medicine in southern China, India and some other 
Asian countries (Chinese Materia Medica, 1985). It is also commonly described as an 
ornamental plant and is used for improving soil conditions (Liu et al., 2008).  
1.2.2.1 Medical use 
E. annuus has some medical applications that have been reported in treating 
diseases in south China. In some villages in Zhejiang, Anhui and Hubei provinces in 
China, the local physicians told the malarial patients to chew on the aerial part of the 
plant or to ingest the water/ethanolic extracts of the E. annuus (100 g dried plant 
extracted by 300 mL solvent) 2-4 hours before the paroxysm. It has been used for 
treating malarial fevers caused by Plasmodium vivax and Plasmodium falciparum. 
(Shanghai Scientific Technological Publishers, 1985, Chinese Academy of Sciences, 
1985). The medicinal applications of this plant were first published in the 1970s in 
many Chinese folk medicine books by the local health committees, including treating 
diarrhea (Revolutionary Health Committee of Zhe jiang Province, 1970); gingivitis 
(Nanjing Military Ministry of Health, 1969, Fan and Zhu, 1975); gastroenteritis 
(Revolutionary Health Committee of Anhui Province, 1975); hepatitis; and 
cholecystitis (Shanghai People's Publishing House, 1972). However, mechanisms for 
these medicinal usages are still unstudied. 
  Chapter I: Introduction 
11 
 
1.2.2.2 In vitro test activities 
Antimicrobial activities were reported on the essential oils from flower, leaf, stem, and 
root extracts of E. annuus. The oils showed inhibitions at concentration of 153.2-660.0 
µg/mL against fungal pathogens such as Fusarium oxysporum, Helminthosporium 
maydis, Rhizoctonia solani, Alternaria solani and Sclerotinia sclerotiorum, compared 
to fungicide carbendazim (IC50 33.7-38.7 µg/mL)(Kumar et al., 2014). The flower 
extract also had been used in the synthesis of Ag-nanoparticle as a reducing and a 
capping agent against B. linens and S. epidermidis (Velmurugan et al., 2014). 
 
An ergosterol peroxide isolated from the flower extract might be used as a potential 
anti-hypercholesterolemic and anti-atherogenic agent. It was proven to have inhibitory 
activity against cholesterol acyltransferase (ACAT) by the acylating of cholesterol to 
cholesteryl esters in rat liver cells. From the cholesterol research results of Kim and 
Brown, the inhibitory value was observed at 51.6± 0.9% at 0.23 mM, compared to the 
positive control oleic acid anilide 45.2± 1.4 % at 0.3 mM (Kim et al., 2005, Brown et al., 
1975).  
 
Moreover, compounds separated from E. annuus were reported to have anti-cancer 
activities. Ethanolic extracts of E. annuus are tested for antiproliferative and 
antiprotein-glycation activities in a variety of cancer cell lines, including MCF7 (breast 
epithelial adenocarcinoma) cells. The IC50 were observed using MTT assay at 
62.54±1.63 µM (Kim and Kim, 2003). Caffeic acid and it’s derivatives were isolated 
from the EtOAc extract of E. annuus according to Jang’s research, it had inhibitory 
activity against Advanced Glycation End products (AGEs). The best inhibitory activity 
was recorded at IC50 12.8 µM for O-caffeoylquinic acid methyl ester, even better than 
the positive control aminoguanidine 961 µM (Jang et al., 2008, Jang et al., 2010).  
 
The antioxidant property had also been reported for the methanolic and butanol 
extracts of E. annuus. The antioxidant assay-guided fractionation led to an isolation of 
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three antioxidant compounds: apigenin, quercetin-3-O-glucoside and caffeic acid (Lee 
and Lee, 2006). The activity had been reported in another research that a flavanone 
derivative erigeroflavanone was separated from the flower’s ethyl acetate extract, it 
was proven to have potential cytoprotective effects against hyperglycemia-induced 
oxidative mouse mesangial cell death (Kim et al., 2009). 
 
Germination inhibitory activity was found in E. annuus in field tests. E. annuus is a 
hardy plant, tolerant of a wide range of soil conditions including gravels and clay. It 
can spread aggressively and compete for resources with other plants in its vicinity 
(Ling and Chen, 1985,Shanghai Scientific Technological Publishers, 1985, Trtikova, 
2009). The mechanism of the competitive growth was studied and a compound 
(5-Butyl-3-oxo-2,3-dihydrofuran-2-yl)-acetic acid was isolated from the flower. It was 
proven to be a strong inhibitor in plant growth by suppressing the germination. 
According to Oh’s study, the extract showed 50% inhibitory effects on the germination 
of lettuce seeds at the concentration 2.13± 0.03 mM (Oh et al., 2002). 
 
E. annuus was also reported to be used as a biological control for pests. The volatile 
extract from this plant could attract the females Lygus and female Peristenus. relictus 
(Halloran et al., 2013). 
1.2.2.3 In vivo test activities 
According to Jo’s research, oral administration of 0.3 g/k the methanolic root extract of 
E. annuus had anti-inflammatory effects against the carrageenan-induced acute paw 
edema in rat and could suppress the activation of rat macrophages ( 3 and 10 µg/mL) 
(Jo, 2013). 
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1.3 Aim and objectives 
E. annuus is a common plant although it is not officially recorded in the China 
Pharmacopeia, its extracts have been used as folk medicines in many treatments. 
Few results of the chemical components have been published, very little research has 
been published on the antimicrobial activity and no reports of antibacterial activity 
against Methicillin-resistant Staphylococcus aureus and DNA gyrase inhibitory activity 
have been published yet. The aim of this research was to investigate the chemical 
composition of this plant and look for potential antibacterial agents through bioassay 
guided fractionations. 
 
In order to study the antibacterial activity of E. annuus, enthanolic crude extract of 
whole plant was made, and then partitioned using hexane, ethyl acetate and butanol. 
Antibacterial assays and DNA gyrase supercoiling assays were employed in this 
research to guide the separation. It was an efficient approach to narrow down the 
range of fractionation. 
 
The aim of the antimicrobial study was to identify the antibacterial agents from the 
active fractions, and bioassay guided fractionations against wild type Salmonella 
enterica, Micrococcus luteus, Enterococcus faecalis, Staphylococcus aureus, 
Escherichia coli and Methicillin-resistant Staphylococcus aureus. 
 
Selected fractions from the antibacterial research were tested for DNA gyrase 
inhibitory and mutagenicity activities. The antibacterial mode of action would be 
studied by exhibiting DNA gyrase inhibition during the DNA gyrase supercoiling 
assays. The evaluation of the mutagenicity assessment of the potential antibacterial 
agent will be carried out against a yeast strain. 
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2.1 Introduction 
E. annuus is a hardy plant that can be found around the world. It is not a widely used 
herb and only a few reports have been published on its chemical compositions and 
biochemical activities. In previous studies of this plant researchers extracted the dry 
plant material of E. annuus by soaking in solvent and left at room temperature. the 
crude extract frequently partitioned into 4-6 main fractions using increasing polarity of 
solvents. Hexane, chloroform, diethyl ether, ethyl acetate, n-butanol and water are the 
six most frequently used solvents (Yoo et al., 2008, Oh et al., 2002, Mohamed and 
Abd, 2006). 
 
In order to extract all types of compounds from E. annuus, different solvents were 
selected. According to Lijima and Mohamed’s research, terpenes and flavonoids were 
two major classes of compounds in E. annuus. Terpenes were found in the hexane or 
chloroform fractions (Iijima et al., 2003a), while flavan derivatives were commonly 
found in ethyl acetate and butanol soluble fractions (Mohamed and Abd, 2006). 
Extraction and separation methods for other plants of the Erigeron genus can also 
help to build up the appropriate separation methods of E. annuus. For example, 
scutellarin could be isolated from methanol extract of E. multiradiatus on macroporous 
resins and Sephadex LH-20 columns (Luo et al., 2008); terpenoids and steroids could 
be obtained from diethyl ether and ethyl acetate extracts of E. naudini, and separated 
over silica columns. In the meantime, other separation methods had been involved in 
previous research publications. For example, scutellarin was separated from E. 
breviscapus by using high-speed counter-current chromatography (HSCCC), which is 
a liquid-liquid partition chromatography without any solid stationary phase (Gao et al., 
2006). Crude saponins would precipitate out from the hot butanol extract of E. naudini 
in the cooling process after hot solvent distillation (Pieribattesti et al., 1981). 
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2.2 Materials and instruments used in both China and UK 
Plant collection, crude extraction and large scale separation of the E. annuus extract 
were accomplished at Shanghai University of Traditional Chinese Medicine, Shanghai, 
China. Further chemical separations and identification works were carried out in 
London Metropolitan University, London, UK. The time line is shown in Table 2.1.  
 
Table 2.1 Research locations and timeline. 
  Locations 
 China UK 
Date  Sep.2010-Jan.2011 Jan.2011-Dec.2013 
 
2.2.1 Materials and instruments in China 
95% ethanol was purchased from Sino-Pharm Chemical Reagent Co., Ltd. Reagent 
grade methanol, hexane, ethyl acetate butanol, dichloromethane and chloroform were 
purchased from Fisher Scientific, China.  HPLC- grade water (resistivity=18.2 mΩ) 
was prepared using Millipore Mili-Q purification system, Milipore Corp., New Bedford, 
MA. Silica gel 100-400 mesh (pore size 60 Å.) for flash chromatography and silica gel 
TLC plates were obtained from Qingdao Haiyang Chemical Company, China. 
SephadexTM LH-20 was purchased from GE Healthcare, Sweden.  
 
HPLC analysis was carried out on an Agilent 1100 series: the system was equipped 
with a G1379A degasser, G1311A Quat pump, G1313A auto sampler, G1316A 
column and ChemStation software. TSK-GEL ODS-100V 5μL, 4.6 cm x 25 cm column 
was purchased from TOSOH, China. Flash chromatography was carried out on Dr 
Flash-II from LISUI (Shanghai) Chemical Engineering Co., Ltd with 3 kg capacity 
superclass column DN100 x 500 mm. 
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Plant material E. annuus (L.) Pers. was authenticated by Dr Li Hong Wu (Shanghai 
University of Traditional Chinese Medicine), collected from Zhangjiang High 
Technology Park, Shanghai Pudong district, China. Plants were carefully washed to 
get rid of the soil and dried at room temperature. Once dried, the whole plant was 
ground into powder and 9 kg powder was obtained.  
 
2.2.2 Material and instruments in UK 
Reagent grade methanol, hexane, ethyl acetate butanol, dichloromethane, chloroform, 
DMSO, iso-propanol, HPLC and LC-MS grade methanol and acetonitrile, were 
purchased from Fisher Scientific, Loughborough, UK. Silica gel 200-300 ( ALUG®, SIL 
G/UV 254 Kieselgel) and silica gel TLC plates (coated with 0.2 mm silicagel 60 Å pore 
size, F254) were obtained from Fisher Scientific, Loughborough, UK. Sephadex
TM 
LH-20 was purchased from GE Healthcare, Sweden. MCI GEL® CHP20P (75-150 μm, 
400-600 Å pore size) was purchased from Sigma-aldrich, Poole, Dorset, UK. 
Eppendorf centrifuge tubes were used for fraction collections and were obtained from 
Hamburg, Germany. BÜCHI rotary evaporator R-210, equipped with vacuum pump 
V-700 and heating bath B-491 was used for solvent evaporation, Flawil, Switzerland. 
 
HPLC separation and fractionation were carried out on Dionex, Agilent and 
PerkinElmer HPLC systems. The Dionex (Camberley, UK) HPLC system was 
equipped with P680 HPLC pump, ASI-100 auto sampler, thermostatted column 
compartment TCC-100, UV D340U detector and Chromeleon™ workstation; Agilent 
110 series (Santa clara, USA) system was equipped with G1379A degasser, 
quat-pump, auto sampler, column oven and ChemStation LC3D; PerkinElmer 
(Cambridge, UK) HPLC system was equipped with series 200 auto sampler, pump, 
UV/Vis detector, column oven and Total-chrom workstation Version 6.3.1. Semi-prep 
column (250 X 8 mm, 100-10 C18) for fractionation was purchased from KNAVER, 
Berlin, Germany.  
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HPTLC CAMAG system was equipped with ATS 4 auto-sampler, CAMAG TLC 
Scanner 3, ADC 2, TLC Visualizer and winCATs workstation, Hungerford, UK.  
 
Flash chromatography separation was carried out on 971-Fp flash purification system, 
with repacked super flash column SF10-4 g, SF15-12 g, and SF25-4 g, Varian, Agilent, 
Wokingham, UK.  
 
The SPE separation was carried out using vacuum manifold chamber and columns 
(strata SI-1 silica column, 55 μm, 70 Å, 10 g/ 60 mL Giga tubes), which were 
purchased from Phenomenex, Macclesfield, UK. 
 
GC-MS was carried on Trace DSQ GC 2000 series gas chromatography 
(ThermoQuest Corp, San Jose, CA, USA), interfaced with a TriPlus autosampler and 
joined to a quadruple mass spectrometer operated in electron impact (EI) ionization 
mode at 70 eV electron energy with browser software version 1.4 SRI. The NIST 
mass spectral search program for the NIST/EPA/NIH mass spectral library was 
version 2.0a, built in January 2002.  
 
LC-MS was carried on an automated Dionex/LC Pickings HPLC system consisting of 
Famos micro auto sampler connected to an Ultimate™ plus HPLC system 
(Camberley, UK). Separations were achieved on Phenomenex column- Luna C8 (2), 
3 μm, 150 x 2.0 mm with a gradient elution condition. LC system was coupled with a 
Waters Micromass Quadrupole Time of Flight MicroTM spectrometer V4.1, Waters Inc. 
2005, Milford, UK, with a MassLynx V4.1 work station. NMR spectrometer was from 
Bruker®, AV-500. NMR results were processed using MestReNova©, version 
6.1.0-6224, 2010 Mestrelab Research S.L. 
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2.3 Plant extraction 
The extraction of 9 kg plant powder was carried out at the Institute of Chinese Materia 
Medica, Shanghai University of Traditional Chinese Medicine, in January 2010. Due 
to health and safety requirements, 9 kg plant powder was divided into five portions, 
and each portion was soaked with 18 L of 95% ethanol in 20 L high-density 
polyethylene solvent buckets. All five buckets were left at room temperature for 2 
weeks, during which the supernatant from each bucket was sucked into a rotary 
evaporator with a 5 L capacity round bottom flask. Solvent were removed using rotary 
evaporation at 40oC and fresh solvent was poured back into the buckets for further 
extractions. After removing the solvent, crude extract was obtained in a dark oily paste 
format at the bottom of the round bottom flask. 
                                                   
 
The second part of extraction was liquid-liquid partition. In order to separate the crude 
extract into different groups, 4 L distilled water was added into the round bottom flask 
and heated on a water bath at 40 oC. The condensed crude extract was suspended 
into water to form a dark oily suspension. Liquid-liquid extraction (LLE) of the water 
suspension was carried out using n-hexane, ethyl acetate and n- butanol successively. 
The 4 L suspension was divided between two 5 L glass separating funnels, 1 L 
hexane was added to each funnel to extract: the step was repeated with 4 x 1 L 
hexane for each funnel. The funnels were gently shaken and left on the rack for 30 
min to let the emulsified layer disappear, followed by removing the water layer through 
the tap at the bottom. Then the process was repeated using ethyl acetate and 
n-butanol respectively. After separation, organic solvents were recycled and the 
condensed extracts were weighed, labeled as hexane (H), ethyl acetate (E), butanol 
(B) and water extracts (W).  
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2.4 Chromatographic separation methods 
2.4.1 Thin layer chromatography (TLC)  
Analytical thin layer chromatography (TLC) was used to characterize the fractions 
eluted from other chromatographic separations, such as flash, solid phase extractions 
and gel column filtrations. Silica coated aluminum analytic plates were used and 
samples were spotted along the baseline using capillary tubes, which was 1 cm from 
the bottom edge. Before each elution, a small amount of developing agent was 
poured into the tank for chamber saturation with a depth less than 1 cm. Filter papers 
were used to wrap the inner surface of the tank to help saturate the chamber when the 
developing solvent was not very volatile. Plates were removed from the tank when the 
solvent front reached 1 centimeter from the upper edge of the plate. The results were 
recorded under UV/fluorescent wavelength 254 and 366 nm. Fractions with same TLC 
profile were combined. 
 
Preparative TLCs were carried out using several 20 x 20 cm aluminum analytical TLC 
plates. In order to gain a better separation, elution for each sample was repeated 
twice on the same plate with same mobile phase. Samples were spotted onto the 
plates as a single line along the baseline with capillary tubes. Approximately 10 mg of 
sample could be loaded onto one 20 cm x 20 cm plate each separation. After viewing 
the results under the UV wavelength 254 and 366 nm, bands with good separation 
were scraped off the plate and soaked in the most polar solvent choosing from the 
mobile phase. The amount of the solvent was at least ten times more than the volume 
of the silica. The solvent was removed by rotary evaporation, and the purity of the 
residue was checked with analytical TLCs before carrying out structure elucidation. 
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2.4.2 Flash chromatography 
Normal-phase and reverse-phase flash chromatography were used in the separation 
of extracts. Flash chromatography technique was invented and described in 1978 by 
W. C. Still (University of Columbia) as a rapid and economical way to achieve 
separations of phytochemicals. It was designed with a pressurized eultion system, 
and the mobile phase was pumped through a pre-packed column at a high flow rate 
(Alcock et al., 1983, Still et al., 1978).  A pre-packed flash column was made of 
superglass packed with silica gel for normal phase separation, or octadecylsilyl (ODS) 
for reverse phase separation. For example, silica was packed using the dry method 
for a large column with capacity beyond 500 g, and the wet pack method was more 
convenience for smaller columns with a capacity under 50 g. Wet packing method 
was the only way to prepare a reverse phase column. ODS were pre-treated with 50% 
acetonitrile and 50% water, before being packed into the column. 
 
Sample inlet methods were different due to the different packing methods of the flash 
columns: for the wet pack, the samples were directly injected onto the column from 
the top. As for the dry packed columns, the samples must be absorbed by the silica 
gel first, and then loaded as part of stationary phase on the top of the column before 
sealed the top tap of the superglass column. 
 
Equilibration time was varied due to the different particle size of the stationary phase, 
different solvent and different elution methods. Step gradient elution was normally 
used to achieve better separation and group the compounds into different fractions 
according to their polarity. For example 100% hexane to 100% ethyl acetate solvent 
system was used for hexane and ethyl acetate extracts, while 5% methanol to 100% 
methanol with deionized water was used for reverse-phase elution of the butanol and 
water extracts. The ODS used in this research was one year old, and it was preserved 
in 100% acetonitrile and purged with water: acetonitrile 1:1 (v/v) before the elution. 
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2.4.3 Solid phase extraction (SPE) 
Solid phase extraction (SPE) was used to separate fractions obtained from flash 
chromatography and column separations. The SPE columns were pre-packed with 
silica as stationary phase in syringe-shaped cartridges, which were connected to a 
negative pressure chamber. Samples could be loaded as concentrated as possible in 
liquid form on the top of the column, in order to achieve a good separation. A 10 g 
capacity column could be loaded with no more than 250 mg sample. The column 
could be wetted with 10% ethyl acetate in hexane and equilibrated with 100% hexane. 
Negative pressure of the chamber was controlled by a vacuum pump which 
connected to the chamber through the vacuum port with a gauge. Fractions were 
collected using the boiling tubes on the rack inside the chamber. Each fraction could 
then be dried and elution profiles were produced using TLC. Fractions with the same 
profile were combined.  
 
2.4.4 Silica column separation 
Silica gel column separation was the most traditional method used to purify non-polar 
compounds from plant extracts. Glass analytical columns with a diameter from 5 mm 
to 25 mm were used for fraction purification in this study. All the columns were packed 
with wet silica slurry, which was prepared in mobile phase 24 hours before the 
separation. Samples were loaded onto the silica gel at the top of the column. After 
sample loading, a piece of glass wool was added to the top of the column to protect 
the integrities of stationary phase; solvent was then carefully poured into the column. 
Particle size of the stationary phase could affect the retention time: if necessary, a 
manual air pump could be added on top of the column to force the solvent through the 
column. Elution gradient could be adjusted by changing the ratio of different solvents 
in mobile phase, and the fractions were collected from the bottom tap. 
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2.4.5 Sephadex gel column filtration 
 
SephadexTM LH-20 was used to purify the sub-fractions which only contain one or two 
components. Sephadex LH-20 is a cross-linked dextran gel, prepared by 
hydroxypropylation of Sephadex G-25, which is composed of macroscopic beads 
synthetically derived from the polysaccharide, dextran (HealthcareGE, 2006). It is 
frequently used in the separation of natural products due to its broad spectrum of 
solvent tolerance (Chen and Wang, 2009, Murphy and D'Aux, 1975). Before packing 
the column, the Sephadex G-25 powder needed to be swollen for at least three hours 
without stirring at room temperature. The extent of swelling depended on the different 
mobile phase, and in this study, 50% dichoromethane with 50% methanol was used 
(Seki and Sugase, 1969). The columns used in Sephadex gel column filtration were 
glass columns with a diameter of 5 mm. After packing with the Sephadex slurry, 2-3 
bed volumes of mobile phase were used for equilibration before sample loading. If 
new solvent was added to the column, re-equilibration with at least 2 bed volumes 
was necessary. 
 
2.4.6 MCI gel column filtration 
MCI gel® (MCI GEL is a registered trademark of Mitsubishi Chemical Corp.) CHP20P 
is a macroporous adsorptive resin, a popular support material which is widely used to 
purify fractions from reverse-phase flash separations. CHP20P gel separation 
mechanism is based on polyaromatic adsorbent resin 
(Sigma-AldrichCHP20Pdatasheet). Pigments such as chlorophylls could be easily 
adsorbed and removed from the top of the column when eluted with 100% water to 
100% methanol. Acetone was often used to clean the column after each elution, as 
pigments and non-polar compounds can be removed by acetone; 2-3 bed volumes 
equilibrium would be needed before starting another elution. MCI gel column needed 
to be kept sealed and wet.  
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2.4.7 High performance liquid chromatography (HPLC) 
Three different HPLC systems, Agilent, Dionex and PerkinElmer, were used in this 
research in both China and UK. For sample separation and fingerprint chromatogram 
works, micro-column and analytical columns were used. The HPLC results were also 
displayed as 3D pictures recorded by photodiode array detectors (Agilent and Dionex). 
Fractionation works were mainly carried out on the PerkinElmer system with a 
semi-prep column and fractions were collected manually.  
 
2.5 Identification Methods 
2.5.1 Gas chromatography-Mass Spectrometry (GC-MS) 
Gas chromatography-mass spectrometry (GC-MS) was used for analysis of volatile 
fractions, eluted from the hexane extracts using SGE analytical GC capillary column 
BPX5 (30m x0.25 mm, 5% phenyl polysilphenlene siloxane). It was operated by Mr. 
Osman Erkek, technician of London Metropolitan University. Peaks identified in total 
ionic currents flow chromatograms were given selecting mass spectrums of each 
compound. An electron-impact ionization system with ionization energy of 70 eV was 
used. Total GC run time was 35 min for each fraction. The identification of each peak 
was assigned by comparison of the mass spectra fragmentation patterns in 
NIST/EPA/NIH mass spectral library version 2.0a, built in January 2002. 
 
2.5.2 Liquid chromatography Mass spectrometry (LC-MS) 
 
LC-MS was carried out on an automated Dionex/LC Packing HPLC system coupled 
with Micromass Quadrupole Time of Flight MicroTM spectrometer (Waters®). It was 
used for identifying the molecular weight of compounds isolated from the butanol 
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extracts. A gradient elution was started with 100% 0.5% formic acid in water to 100% 
methanol. Positive ion mode electrospray ionization was used for Q-Tof-MS and it 
was calibrated with Naics test solution set (Waters API test solution Kit, NaI: 2 μg/μL, 
CsI: 50 ng/μL). The capillary voltage, sample cone voltage and extraction cone were 
set at 3000 V, 30 V and 3V respectively. Source temperature was set at 150 oC. 
Collision energy was set at 3 V. 10-20 μL of each sample was injected, and total ion 
current chromatogram was displayed and extracted-ion chromatogram was 
processed using MassLynx 4.1 software. 
 
2.5.3 Nuclear magnetic resonance (NMR) 
 
Nuclear magnetic resonance spectroscopy was used for structure elucidation, 
1H-NMR, 13C-NMR, HMQC and HMBC spectroscopic analyses were carried out in 
deuterated water (D2O) and deuterated chloroform (CDCl3). It was operated by Mr. 
John Crowder, NMR technician of London Metropolitan University. 
 
2.6 Results and Discussion 
2.6.1 Pre-separation study 
 
In order to extract the whole plant without destroying the compounds, the total 
extraction was carried out by soaking the ground plant material into the solvent at 
room temperature. Pre-separation study was carried out in China. According to the 
previous research, E. annuus contains volatile oil and thermally labile compounds (eg. 
ergosterol peroxide) (Nazaruk and Kalemba, 2009, Kim et al., 2005), the temperature 
for solvent evaporation was set below 40 oC. Methanol and 95% ethanol were used in 
extraction, the recovery is compared in Table 2.2 below: 
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Table 2.2 Compare of the recovery of methanol and ethanol extraction. 
Solvent Plant material (g) Weight of Extract (g) Recovery % 
MeOH 12.1364 8.9499 73.74 
EtOH 95% 12.5290 10.4947 83.76 
 
Plant material was extracted by ultrasonication in the room temperature for 30 min in 
both solvents. From the research data, using 95% ethanol could give a higher 
recovery, up to 83.76%. After removing the solvent, both extracts were dissolved in 
MeOH at the same concentration and their chromatographic finger-print profiles were 
compared using reverse phase HPLC. 
 
HPLC results obtained from Agilent 1100 analysis are shown in Figure 2.1. The 3D 
plot of EtOH extract is displayed in Figure 2.1 A from UV wavelength 200 to 360 nm. 
There were many strong absorption peaks observed at lower wavelength, and the 
baseline was not clear. In order to compare the chromatographic finger-print profiles 
of EtOH and MeOH extracts, five monitoring wavelength were selected at 210, 240, 
254, 320 and 360 nm. Same elution method (TSK-GEL ODS 4.6 cm x 25 cm; flow rate: 
1 mL/min; 30 oC; deionized water and MeOH from 1:0 to 0:1; 60 min) was applied in 
both elutions. The chromatograms from this finger-prints analysis are compared in 
Figure 2.1 B and C. 
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A. 3D plot of EtOH extract from UV wavelength 200-360 nm.  
 
 
 
B. HPLC chromatogram of MeOH extract at UV wavelength 210,240,254,320,360 nm. 
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B. HPLC chromatogram of EtOH extract at UV wavelength 210,240,254,320,360 nm. 
 
Figure 2.1 Chromatographic finger-print analysis of E. annuus extracts. 
 
 
Main peaks showed same retention times at 28.9, 29.9, 33.8 and 41.8 min in both 
chromatograms, an extra peak showed in the EtOH extract sample at retention time of 
31.8 min. More peaks were observed in the EtOH extract chromatogram, indicated 
that better recovery could be obtained by using 95% ethanol. Thus, 95% ethanol was 
selected for the large scale plant extraction. 
 
2.6.2 Extraction of E. annuus 
Extraction of large scale plant material was carried out on 9 kg ground E. annuus 
using 95% ethanol. Dark oily paste crude extract 747.6 g was obtained and 
suspended in deionized water. Liquid-liquid partition was then carried out using 
hexane, ethyl acetate and butanol against the water suspension respectively. Four 
extracts were obtained. The weight of each extract is showed below in Table 2.3. 
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Table 2.3 Weight of different extracts 
Sample name sample weight (g) 
Hexane extract (H) 214.6 
EtOH extract (E) 105.1 
Butanol extract (B) 65.3 
Water extract (W) 289.6 
Total  674.6 
Recovery (%) 90.2 
 
The total weights of all four extracts were 674.6 g, total recovery was 90.2% from the 
crude EtOH extract. The organic solvents were removed by rotary evaporation and 
the water extract was freeze-dried. Once the extracts dried, they were all stored at -20 
oC. 
 
2.6.3 Separation of hexane extracts 
The hexane extract was a dark oily paste, to get a further separation, 214.6 g extract 
was dissolved in EtOAc and mixed with 200 g silica gel to make the sample in powder 
format for large scale silica column elution. After evaporated the EtOAc, the sample 
was loaded on top of the silica gel column (100-200 mesh) and flash 
chromatographed from 100% petroleum ether to 100% EtOAc using gradient elution.  
 
Nine fractions were obtained from the flash chromatographic separation (H1 to H9), 
and H5 was further fractionated (H5-1 to H5-9). Compounds H4 and H7 were 
precipitated out in the separation procedures and they were purified by repeatedly 
silica column separations and MCI gel filtrations. White oily precipitations were found 
in fractions H5-1 and H5-2, compound H5-1-1, H5-1-2 and H5-2 were isolated from 
those white precipitations over the silica column separations.  
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Figure 2.2 Separation of hexane extract. 
 
Fraction H1 was a brown oily paste, approximately 500 mg of H1 was used during 
each solid phase extraction separation. Nine fractions were collected and fractions 
H1-1 and H1-2 were further separated. 
 
Fraction H1-1 was an orange oil, it was analyzed by GC-MS and 16 compounds were 
identified. Fraction H1-2 was separated repeatedly over silica column and preparative 
TLC separation, finally seven fractions were obtained, and their TLC profiles are 
showed in Figure 2.3. The amount of compound H1-2-4, H1-2-6 and H1-2-7 were 
enough for the biological assays and their structures were elucidated using NMR and 
GC-MS. 
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Figure 2.3 TLC of fraction H1-2 (Mobile phase: EtOAc: Hexane, 1:9 v/v). 
 
2.6.3.1 Fraction H1-1 
Fraction H1-1 was an orange oil which had been eluted with 100% hexane. It was 
analyzed by GC-MS, the mass spectra fragmentation patterns were matched through 
the NIST/EPA/NIH mass spectral library version 2.0a; the closest matches are listed 
below: 
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Figure 2.4 Gas chromatogram of fraction H1-1. 
 
Sixteen compounds were identified by matching the known compounds structures 
through the mass library (compounds have match factors above 800 were listed). 
Most of them were terpenes, polyunsaturated fatty acids and their esters (Table 2.4). 
 
Table 2.4 Compounds characterized from fraction H1-1. 
 
Retention 
Time(min) 
 Closest Matching 
Structure/Name 
Match 
factor 
Molecular 
formula and 
Mass (m/z) 
20.38 
7,11-dimethyl-3-methylene-(Z)-1,6,10-dodecatriene  
 
926 C15H24=204.35 
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20.95 
1-(1,5-dimethyl-4-hexenyl)-4-methyl-benzene 
925 C15H22=202.34 
21.21 
 
α-farnesene 
916 C15H24=204.35 
21.36 
1-methyl-(S)-4-(5-methyl-1-methylene-4-hexenyl)-cyclohe
xene 
911 C15H24=204.35 
21.56 
 
1,2,3,4,4α,5,6,8α-octahydro-7-methyl-4-methylene-1-(1-m
ethylethyl)-naphthalene 
917 C15H24=204.35 
21.64 
3-(1,5-dimethyl-4-hexenyl)-6-methylene-cyclohexene 
909 C15H24=204.35 
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22.74 
O
aryophyllene oxide 
920 C15H24O=220.35 
25.86 
OH 
3,7,11,15-tetramethyl-2-hexadecen-1-ol 
880 C20H40O=296.53 
27.10 
O
O  
methyl hexadecanoate 
921 C17H34O2=270.4
5 
27.73 
O
OH  
n-hexadecanoic acid 
867 C16H32O2=256.4
2 
27.96 
O
O
 hexadecanoic acid 
915 C18H36
O2=28
4.48 
 
29.18 
O
O
  
methyl-(9Z,12Z) -octadecadienoate 
931 C19H24O2=284.3
9 
29.28 
O
O
 methyl-(9Z,12Z,15Z)- octadecatrienoate 
 
883 C19H32O2=292.4
6 
29.36 
HO
 
ethyl-9,12-octadecadienoate, phytol 
906 C20H40O=296.53 
29.95 
O
O
9,12-octadecadienoate 
919 C20H36O2=308.5
0 
30.05 
O
O  
ethyl-(9Z,12Z,15Z)- octadecatrienoate 
888 C20H34O2=306.4
8 
 
H1 and H1-1 had some antibacterial activities, however the amount for H1-1 was less 
than 5 mg, further chemical separation was not carried out on H1-1. Most of the 
compounds had been identified were terpenes, unsaturated fatty acids (UFAs) and 
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their esters. UFAs were reported to have inhibitory activity against wild type bacteria 
(Desbois and Lawlor, 2013), one compound eluted at 29.36 min, possessed a high 
matching factor to the known compound phytol. According to Inoue’s research, phytol 
had a inhibitory activity against Staphylococcus aureus at the concentration of 20 
μg/mL (Inoue et al., 2005). However, other antifungal activity had been reported, but 
none of those compounds were identified in this research. For example, in a study of 
essential oils from Erigeron species, essential oil of E. annuus was found highly active 
against fungi Fusarium. oxysporum, Curvularia. lunata and Albugo. candida. The IC50 
was obtained from 153-660 µg/mL compared with fungicide carbendazim at 33.7-38.7 
µg/mL (Kumar et al., 2014). 
 
2.6.3.2 Compound H1-2-4 
Compound H1-2-4 was separated from fraction H1-2. It was light green in colour, and 
showed d blue fluorescence under UV wavelength 254 and 366 nm (Figure 2.3). 
 
1H NMR, 13C NMR and 2D HMQC spectra of H1-2-4 are showed in Figure 2.5 and 2.6 
(500 MHz, CDCl3). In the 
13C NMR spectrum, 27 carbon peaks were counted, and 
compared to the DEPT, one methyl peak at δ14.14 and two quaternary carbon peaks 
at δ155.91 and 178.49 were identified.  
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Figure 2.5 
1
H NMR spectrum of compound H1-2-4. 
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In 1H NMR spectrum, a doublet at δ 7.32-7.34 was assigned to a sp2 hybridization 
carbon (C=CH-), correlated with carbon peak at δ 141.85 through HMQC (Figure 2.7). 
Peaks between δ 5.26-6.24 and 1.5-2.7 in proton spectrum might be caused by the 
vinyl methylene protons in the alkyl chain. Six protons were integrated at δ 2.29 for a 
triplet, they were assigned to three methylene groups (-CH2-). Other signal peak 
correlations could not be identified as there were too many impurity peaks showing in 
the spectrum, which was likely to be caused by contamination with other compounds. 
The solvent peaks at δ 1.25 and 7.19 were solvent peaks (caused by EtOAc and 
CHCl3 respectively).  
 
 
 
 
 
 
Figure 2.6 
13
C NMR spectrum of compound H1-2-4. 
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Figure 2.7 HMQC spectrum of compound H1-2-4.
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The proposed structure is showed in Figure 2.8 A, two quaternary carbons were 
labelled as carbon 1 and 2. The C-H correlation was showed in HMQC (Figure 2.7), 
however, not enough sample was left for HMBC and the structure of alkyl chain could 
not be fully elucidated, a close match of structure was proposed by software 
ChemDraw®. 
 
O
1
OH
O 2
R
OH
CH3
 
 
A. Proposed structure of compound H1-2-4. 
O O
OH
OH
177.0
35.8
24.4
96.9
143.2 70.3
31.2
27.0
23.1
97.1
156.1
40.9
27.1
128.5
129.8
33.4
30.3
33.4
129.1
131.8
33.3
30.3
30.4
30.1
32.5
23.1
14.0
 
B. 
13
C NMR chemical shifts of 5-(6-Hydroxy-docosa-5,9,14,20-tetraenyloxy)-pent-4-enoic acid. 
Figure 2.8 Proposed structures of compound H1-2-4, approximated by ChemDraw
®
. 
 
The estimated chemical shifts for terminal methyl group in 13C NMR was at δ 14.0 and 
chemical shift for quaternary carbons showed at δ 156.1 and 177.0, matched very 
closely to the NMR data from this study, δ 14.14, 155.91 and 178.49 respectively. The 
estimated sp2 and sp3 carbon peaks in the alkyl chain were showed between δ 20-40 
and 120-140, however, position and number of the double bonds could not be 
determined. The unknown portion was shown as R in Figure 2.8 A, it could be a 
saturated carbon china (-(CH2)n-) or had double bonds somewhere in the chain 
structure. H1-2-4 was suggested to be a fatty acid with an alkoxy group, this type of 
compounds have not been reported yet from E.annuus. 
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2.6.3.3 Compound H1-2-6 
Fraction H1-2 also yield compound H1-2-6. Compound H1-2-6 was a deep green 
paste, and showed deep blue fluorescence under UV wavelength 254 and 366 nm 
(Figure 2.4).  
 
 
 
 
Figure 2.9 
 13
C NMR spectrum of compound H1-2-6. 
 
1H NMR, 13C NMR spectra of H1-2-6 are showed from Figure 2.9 to 2.11(500 MHz, 
CDCl3). Twenty-eight carbon peaks were counted according to the 
13C NMR spectrum, 
three quaternary carbons were observed at δ 104.66, 156.60 and 168.95 after 
comparing to the DEPT, the quaternary carbons are labeled in Figure 2.9 as QC. The 
peak showed at 168.95 indicated a carboxyl group; one terminal methyl group peak 
was observed at δ 13.57 (Figure 2.9). 
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Figure 2.10 
1
H NMR spectrum of compound H1-2-6.
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In the 1H NMR spectrum, the peak at δ 1.03 was assigned to the methyl group, it splits 
into a triplet indicating that the adjacent carbon group might be a methylene group. 
Many multiplets between δ 1.5 and 2.8 were in different scale, suggested that this 
sample might not be pure. An alkyl side chain structure was involved. Peaks at δ 5.32, 
6.22 and 7.36 represented vinyl protons in the alkyl side chain (Figure 2.10). EtOAc 
and CHCl3 peaks were observed at δ1.25 and 7.19 respectively. 
 
 
 
 
Figure 2.11 HMQC spectrum of compound H1-2-6 (
13
C NMR: δ10-35; 1H NMR: δ 0.8-2.8).
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Figure 2.12 HMQC spectrum of compound H1-2-6 (
13
C NMR:δ 90-145; 
1
H NMR : δ 4.8-7.6). 
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Figure 2.13 HMBC spectrum of compound H1-2-6. 
 
 
 
 
Correlations from 2D NMR spectra HMQC and HMBC are showed in Figure 2.11 to 
2.13. The two quaternary carbons were both correlated with H8 and H9, suggested 
that these four carbons were on a ring structure. The estimated chemical shifts were 
compared in Table 2.5, estimated 13C-NMR chemical shift had a good match with for 
C10 and C11 at the δ 165 and 147 respectively (compare to δ 168.95 and 142.65 for 
H1-2-6). 
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Table 2.5 HMQC and HMBC correlations of compound H1-2-6. 
 δ 
13
C 
(ppm) 
δ
1
H  
 (ppm) 
Proposed  
structure 
HMBC 
Correlation 
1 13.57 1.01-1.04 -CH3 H2,3 
2 21.88 1.60-1.63, -CH2- H1, 4 
3 22.14 2.43 -CH2-  
4 24.70 1.62-1.64 -CH2- H5 
5 33.77 2.35 -CH2- H1 
6 95.14 5.31 C
H
C
 
H3 
7 104.66  quaternary carbon  
8 120.18 6.22 -CH=CH- H9 
9 142.64 7.36 -CH=CH- H8 
10 156.06  quaternary carbon H8, 9 
11 168.95  quaternary carbon H8, 9 
 
11
8
9
4
O
O
R
    
 
O
O
165.0
119.7
147.6
80.4 33.7
26.6
23.2
14.0 
 
 
Figure 2.14 Proposed structure and estimated 
13
C NMR chemical shifts of compound H1-2-6. 
 
 
However, number and the positions of methylene group could not be determined (R 
group in Figure 2.14), because the sample contains many impurities thus further 
structure investigation is warranted. The 13C chemical shifts estimation was carried 
out using a butyl group, proposed structure was showed as a butyrolactone. 
Butyrolactone has not been reported from the Erigeron genus yet. 
2.6.3.4 Compound H1-2-7 
Compound H1-2-7 was a brown powder, it gave brown colour under UV wavelength 
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254 nm and blue florescence under UV wavelength 366 nm (Figure 2.3). From the 
mass spectrum, molecular ion was observed at m/z 160 (Figure 2.15), and the mass 
loss between fragment peak m/z 160 and 131 was suggested to be a carbonyl group 
plus proton (-HC=O). 
 
 
 
 
 
Figure 2.15 MS spectrum of compound H1-2-7. 
 
 
1H NMR and 13C NMR spectra of H1-2-7 are showed in Figure 2. 16 and 2.17 (500 
MHz, CDCl3). From the 
13C NMR spectrum, 10 carbon peaks were counted, after 
comparing with the DEPT, one methyl peak at δ 16.52 and four quaternary carbon 
peaks at δ 87.98, 99.34, 155.91 and 168.83 were identified (Figure 2.16). No negative 
peaks found in DEPT, suggested that there were no methylene groups. 
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Figure 2.16 
3
C NMR spectrum of compound H1-2-7. 
 
 
In the 1H NMR spectrum (Figure 2.17), the peak at δ1.98 was assigned to a methyl 
group, it split into a doublet indicated that there was only one proton attached to the 
adjacent carbon, therefore the methyl group might link to a double bond (=CH-CH3). 
Doublet showed at δ 7.38-7.42 suggested an aromatic structure of H1-2-7. 
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Figure 2.17 
1
H NMR spectrum of compound H1-2-7.
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Figure 2.18 HMQC spectrum of compound H1-2-7
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Figure 2.19 HMBC spectrum of compound H1-2-7. 
 
The C-H correlations were obtained from HMQC and HMCB spectra (Figure 2.18 and 
2.19). Carbon C7 and C8 had chemical shifts at δ 87.97 and 99.35, which were likely 
caused by sp hybridization, an acetylene bond. C8 had a correlation with H1 in HMBC, 
suggested that the terminal methyl group might be attached or two bonds away from 
the acetylene carbon. C7 correlated with H1 and H2, and the correlation to H1 was 
weaker than it of C8, suggested the C8 was at the far end (from the ring structure) of 
the alkyl chain. The other two quaternary carbons C9 and C10 were both correlated to 
H4 and H6, indicating that these four carbon atoms were likely on the same ring 
structure. 
 
The C-H correlations were compared in Table 2.6, and the proposed structure of 
H1-2-7 was showed in Figure 2.20: a 2-pyrone derivative, 4-pent-3’-ne-1’ 
-ynyl-pyran-2-one. However, many impurity peaks were observed in the 1H NMR 
spectrum, sample H1-2-7 was not pure and the structure elucidation result might be 
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compromised, and more purification procedures were warranted. 
 
Table 2.6 C-H correlations of compound H1-2-7. 
 δ 
13
C  
(ppm) 
δ
1
H  
 (ppm) 
Proposed  
structure 
HMBC correlations 
1 16.52 1.98 CH3 H3, 5 
2 94.64 5.50-5.55 -CH=CH- H6 
3 109.83 5.71 -CH=CH- H1 
4 120.36 6.25 -CH=CH- H6 
5 141.84 6.14 -CH=CH- H1,3 
6 142.49 7.38 -CH=CH- H1, 2, 5 
7 87.97  quaternary carbon H1, 2 
8 99.35  quaternary carbon H1, 2 
9 155.91  quaternary carbon H2, 4, 6 
10 168.84  quaternary carbon H4, 6 
 
10
6
9
42
O
O
7 8
3
5
1
   
Figure 2.20 Proposed structure for compound H1-2-7. 
 
Other type of pyrone have been reported in the Erigeron genus, especially 4- pyrones 
(Yue et al., 1994, Li et al., 2005, Mathela D. K. et al.,1984), and two polyacetylenic 
esters: lachnophyllum ester and matricariaester were reported from the E.annuus by 
Kumar (Kumar et al., 2014), which might be the product of 2-pyrone’s ring open 
reaction. Both 2-pyrone and 4-pyrone structure carry one oxygen atom and a ketone 
functional group, which would be considered to be part of coumarin and chromone 
motif. 
 
2.6.3.5 Compound H4 
Compound H4 was obtained from hexane fraction H4 when eluted by petroleum ether 
ethyl acetate (3:1, v/v), it was then purified by recrystallization. Compound H4 was a 
white needle crystal, and 50 mg of H4 was collected. NMR spectra of H4 was clear 
and full structure of H4 was elucidated. 
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Figure 2.21 
1
H-NMR spectrum of compound H 4. 
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Figure 2.22 DEPT135 and 
13
C NMR spectra of compound H4. 
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From the 1H NMR spectrum of compound H4 (Figure 2.21), there were six methyl 
peaks in at δ1.03 that assigned to six methyl groups in the suggesting structure, they 
were H21 (δ 1.03), H26 (δ 0.85), H29 (δ 0.82), H27 (δ 0.81), H19 (δ 0.80), and H18 (δ 
0.55). Doublelts and multiplets observed between δ 4.9 and 5.2 were assigned to the 
unsaturated side chain in the molecule, they could be the signal of three carbon 
double bonds.  
 
Twenty nine carbon atom peaks were counted from the 13C NMR spectrum (Figure 
2.22) and only twenty six of them showed in the 13C DEPT NMR spectrum, which 
indicated that there were three quaternary carbon atoms in the structure (C8, 13 and 
20) From the 13C and DEPT NMR spectra, nine methylene (-CH2-) groups and six 
methyl (-CH3) groups were counted respectively. 
 
2
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Figure 2.23 Proposed structure of compound H4, α-spinasterol. 
 
 
The 2D NMR HMQC and HMBC correlations of compound H4 are showed in Figure 
2.24 and 2.25. Six eligible carbon peaks were identified from the 13C spectrum. 
Carbon peak at δ 12.27 (C18) was assigned to H18 (δ 0.55), it was coupled with H12, 
H17 and H14 (three bonds) and adjacent to C13 which indicated that the adjacent 
quaternary carbon was C13 (δ 139.56). Another methyl peak at δ12.05 (C19) 
correlated with proton peak H19 (δ 0.7), was adjacent to quaternary carbon C10 (δ 
43.27). Carbon peak at δ 21.38 (C21) correlated with H21, H21 split into a doublet 
indicated that the adjacent carbon C20 had one proton attached. C21 was coupled 
with H17 and H22 (three bonds) and H20 (two bonds). Carbon peak at δ 21.12 
correlated with H26 (δ 0.85) which was a doublet split by coupling with H25 (single 
proton), and C26 was coupling with H24 and H27 in three bonds. Carbon peak at δ 
18.99 was correlated with H27, and peak C27 was coupled with H24 and H26 in three 
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bonds. Carbon peak at δ 13.06 was correlated with H29 which split into a triplet by 
coupling with C28. The rest correlations of each identified peaks are listed in Table 
2.7. 
 
 
 
 
 
 
 
Figure 2.24 HMQC spectrum of compound H4,α-spinasterol. 
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Figure 2.25 HMBC spectrum of compound H4, α-spinasterol. 
 
 
 
The C-H correlations are listed in Table 2.7. Two double doublets at the low field (> 5 
ppm) were caused by the two vinyl protons from the double bond in the side chain 
(H22 and H23 in 1H NMR, Figure 2.21). Because they had a similar chemical 
environment, their chemical shifts were very close, the chemical shifts were C22 at δ 
138.19 and C23 at δ 129.40. There was another proton peak identified at the same 
chemical shift H7 at δ 5.15, it was assigned to carbon C7 (δ 117.45) and coupled with 
a methylene group in HMBC.  
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Table 2.7 NMR data of compound H4 and α-spinasterol 
 
C δ 13Ca 
(ppm) 
δ 13Cb 
(ppm) 
δ1H 
c
 
(ppm) 
m, 
J(Hz) 
HMBC correlations 
Two bonds (three bonds) 
1 37.1 37.12   H-2, 10, ( H-3,5,9,19) 
2 31.5 31.46   H-1, 3, ( H-4, 10) 
3 71.1 71.05 3.59 m, 5 H-2, 4, ( H-1, 5)
d
 
4 38.0 37.98   H-3, 5, ( H-2, 6, 10) 
5 40.2 40.23   H-4, 6,10, ( H-1, 3, 7, 9, 19) 
6 29.6 29.62   H-5, 7, ( H-4, 8, 10) 
7 117.4 117.45 5.15 s H-6, 8, ( H-5, 9, 14) 
8 139.6 139.56    H-9, 14, 12, ( H-11, 6, 15) 
9 49.4 49.41   H-8,10,11, ( H-1, 5, 12, 14, 7, 19) 
10 34.2 34.20   H-1, 5, 9, 19, ( H-2, 4, 6, 11) 
11 21.5 21.53   H-9, 12, ( H-8, 10, 12) 
12 39.4 39.44   H-11, 13, ( H9, 14, 18) 
13 43.3 43.27   H-18, 12, 14, 17, ( H-11, 15, 16, 20) 
14 55.1 55.11   H-15, ( H-7, H-9, H-12, H-17, H-18, H-16) 
15 23.0 23.01   H-14, 16, ( H8, 13, 17) 
16 28.5 28.53   H-15, 17, ( H-13, 14, 20) 
17 55.9 55.88   H-13,16, 20, ( H-18, 12, 14, 15, 21, 22) 
18 12.0 12.05 0.55 s H-13, (H-12, 14, 17) 
19 13.0 13.06 0.79 s H-10, (H-1, 5, 9) 
20 40.8 40.68   H-21, 22, 17, ( H-13, 16, 23) 
21 21.4 21.38 1.02 d, 10  H-20, ( H-17, 22,) 
22 138.2 138.19 5.816  dd, 10 H-20, 23, ( H-21, 17, 24) 
23 129.4 129.40 5.02 dd, 5 H-22, 24, ( H-20, 28, 25) 
24 51.2 51.24   H-23, 28, 25, ( H-22, 26, 27, 29) 
25 31.9 31.88   H-24, 26, 27, ( H-23, 28) 
26 21.1 21.12 0.85 d, 10 H-25, (H-27, 24,) 
27 19.0 18.99 0.80 d, 10 H-25, (H-26, 24,) 
28 25.4 25.41   H-24, 29, ( H-23, 25) 
29 12.2 12.27 0.81 t, 10 H-28, (H-24) 
a
  
13
C NMR of spinasterol (Kongduang  et al., 2008, De-Eknamkul and Potduang, 2003, 
Ragasa et al., 2012), 150 MHz, CDCl3. 
b   13
C NMR of H4, Bruker, 500 MHz, CDCl3. 
c
   Assignments by 
1
H–
1
H COSY spectrum. 
d    
Assignments by HMBC spectrum. 
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The NMR data of compound H4 showed a good match with NMR data of α-spinasterol, 
the structure is shown in Figure 2.23, the NMR data used in Table 2.7 was published 
by Schlitzer (Schlitzer, 2007).H4 belongedto Δ7-sterol family, they are phytosterols 
distributed widely throughout the plant kingdom. Compound α-spinasterol is known to 
be involved in the stabilization of cell membranes and possesses an additional 
unsaturation double bond in the side-chain of the molecule (Kongduang  et al., 2008, 
Dewick, 2001). 
2.6.3.6 Fraction H5-1 
Fraction H5-1 was sent for GC-MS analysis, it was a colorless oil and 2 mg of H5-1 
was obtained when eluted H5 with petroleum ether ethyl acetate 4:1(v/v). Two 
compound H5-1-1 and H5-1-2 were identified using GC-MS.  
 
 
Figure 2.26 MS spectrum of compound H5-1-1, eluted at 1.19 min from GC. 
 
From the mass spectrum of H5-1-1 (Figure 2.26), the molecular ion peak for 
compound H5-1-1 was observed at m/z 256 and base peak was observed at m/z 
56.98. The base peak was suggested to be a -(CH2)3CH3 group and m/z 14 difference 
between peaks from m/z 83 to m/z 167 suggested those fragmentations were seven 
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methylene groups. The mass difference between m/z 56.98 and 82.98 was 26 units 
mass lost indicating that the structure contained a double bond (-CH=CH-). Fragment 
peaks from m/z 213 to m/z 256 suggested to be a - (CH2)2CH3 group (43 mass units). 
Compound H5-1-1 was an aliphatic compound, however, more sample was required 
for further structure elucidations.  
 
 
 
Figure 2.27 MS spectrum of compound H5-1-2, eluted at 1.33 min from GC. 
 
The molecular ion peak of compound H5-1-2 (Figure 2.27) was found at m/z 256.15. 
Mass of the base peak was observed at m/z 56.98 which might be share the same 
fragment structure as H5-1-1, -(CH2)3CH3. The mass difference between m/z 56.98 
and 82.98 was 26 mass units indicating a double bond in the structure. Counting from 
the fragment peak m/z 82.98 to the m/z 195.12, six m/z 14 peaks (methylene groups) 
were found. Difference between m/z 211.09 and m/z 256.15 was 45 mass units which 
suggested to be a carboxyl group. The compound was proposed to be gondoic acid 
C20H20O2 which molecular weight was m/z 256.42 (Liu et al., 2011, Lwata et al., 2011). 
More samples are needed for further structure elucidation for the position of the 
double bond. 
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2.6.3.7 Compound H5-2 
Compound H5-2 was a white powder (5 mg) obtained from petroleum ether ethyl 
acetate elution (4:1,v/v). It was further purified by silica gel columns (400 mesh).The 
mass spectrum of H5-2 is shown in Figure 2.28. 
 
 
 
O OH
 
Figure 2.28 A. MS spectrum of compound H5-2. B. Structure of hexadecanoic acid. 
 
 
 
Molecular ion peak of compound H5-2 was observed at m/z 256 and the base peak 
was observed at m/z 72.87. Fragment ion peak m/z 59.85 was indicated a -CH2COOH 
group. From the peak m/z 59.85 to the peak m/z 241.13, twelve methylene groups 
were counted. From peak m/z 241.13 to m/z 256.09, the mass unit loss was 15 m/z, 
suggested to be a methyl group. 
 
 
Chapter II: Chemical separations of Erigeron annuus ( L.) Pers 
61 
 
 
 
 
 
 
Figure 2.29
 13
C NMR spectrum of compound H5-2. 
 
 
Sixteen carbon peaks were identified from the 13C NMR of H5-2 and one methyl peak 
at δ 14.15 and fourteen methylene peaks (between δ 22.72 and 34.13 p) were 
counted after comparing with the DEPT. 
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Figure 2.30 HMQC spectrum for compound H5-2. 
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Figure 2.31 HMBC spectrum for compound H5-2. 
 
 
According to the HMQC and HMBC spectra of H5-2 (Figure 2.30 and 2.31), a triplet at 
δ 0.83 in 1H NMR spectrum was assigned to the methyl group, another triplet at δ 2.33 
was observed. The oxygen atom in the carboxyl group applied a descreening 
magnetic field that caused the peak appeared in the low field, indicating those protons 
might be close to a carboxyl group. The quintuplet in 1H NMR at δ1.63 was assigned 
to the methylene group C3 (Figure 2.30), the protons were correlated with a 
methylene carbon in HMQC, and also coupling with the carboxyl group in bonds 
(Figure 2.31). The rest of the saturated aliphatic chain structure on the molecule 
contained thirteen methylene groups (counted from the mass spectrum), the proton 
NMR peaks for them appeared as a multiplet at around δ 1.25 (C4-13). The 
suggested structure for H5-2 was hexadecanoic acid (Figure 2.28 B), C16H32O2, m/z 
256.42. 
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2.6.3.8 Compound H7 
Compound H7 was a white precipitate (6 mg) eluted with petroleum ether and ethyl 
acetate (1:7, v/v) over silica gel column. Due to the seven characteristic methyl 
signals from 1H-NMR spectrum (δ 0.7-1.2, Figure 2.32), compound H7 was 
considered to be a pentacyclic triterpenoid. 
 
There were three main classes of skeletons of pentacyclic triterpenoid, oleanane 
skeleton, ursane skeleton, and lupane skeleton (Wu and Wu, 2003). For lupane, 
CH3-30 (atom number showed in Figure 2.33) was connected to a double bond, the 
methyl protons will coupling with the double bond and the CH3-30 showed a broad 
peak in 1H- NMR. In 1H- NMR spectrum of H7, there was no broad peak showed, that 
indicated the compound H7 did not have a lupane skeleton. There was a multiplet 
showed between δ 5.0 and 5.4, indicated that there was a single double bond 
structure at C12. If there was a diene in the structure, the chemical shift of the proton 
peak would move to the lower field, might be beyond δ 5.5, due to the descreening 
effect of the double bond. The compound H7 suggested being a 12-oleanene or a 
12-ursanene.   
 
 
 
 
Figure 2.32 
1
H NMR spectrum of compound H7. 
 
.  
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Figure 2.33 Proposed structure of compound H7, erythrodiol. 
 
In the13C NMR spectrum, thirty-four carbon atoms were counted and seven of them 
were quaternary carbon compared with the DEPT (Figure 2.34), which both the 
12-oleanene or a 12-ursanene structure have seven quaternary carbons. However, 
the chemical shift of the C12 and C13 were different: Chemical shifts of C12 and C13 
of 12-oleanene was at δ 122~124 and δ143~144, while chemical shifts of C12 and 
C13 of 12-ursanene was δ 124~125 and δ 139~140 (Wu and Wu, 2003). Compound 
H7 was suggested to have a 12-oleanene skeleton (Figure 2.33). 
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A. 
13
C NMR spectrum of compound H7. 
 
 
 
 
 
B. DEPT of compound H7. 
Figure 2.34 DEPT and 
13
C NMR spectra of compound H7. 
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A. HMQC spectrum for compound H7. The framed area was showed in B. 
 
 
B. HMQC spectrum of compound H7. (
13
C NMR: 20-80;
 1
H NMR: 0-3.6). 
 
Figure 2.35 HMQC spectra of compound H7. 
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Table 2.8 NMR data of H7 and erythrodiol. 
C δ 
13
C 
(ppm)
a
 
δ 
13
C 
(ppm)
b
 
δ
1
H  
(ppm) 
m, J(Hz) 
1 38.6 38.55   
2 27.2 27.20   
3 79.0 78.99   
4 38.8 38.76   
5 55.2 55.12   
6 18.4 18.33   
7 32.6 32.53   
8 39.8 39.75   
9 47.6 47.54   
10 36.9 36.92   
11 23.6 23.57   
12 122.3 122.35   
13 144.2 144.18   
14 41.7 41.69   
15 25.6 25.52   
16 22.0 21.95   
17 36.9 36.90   
18 42.3 42.31   
19 46.5 46.42   
20 31.0 31.02   
21 34.1 34.05   
22 31.0 30.96   
23 15.5 25.58 0.79 s 
24 28.1 28.07 1.00 s 
25,26 15.5, 16.7 15.52,16.70 0.94 d, 5 
27 25.9 25.94 1.17 s 
28 69.7 69.73   
29, 30 33.2, 23.6 33.20, 23.57 0.88 d, 5 
a 13
C NMR of erythrodiol, 100MHz, CDCl3 (Kagawa et al., 1998). 
b 13
C NMR of compound  H7, 500 MHz, CDCl3. 
 
From the HMQC of H7 (Figure 2.35), the proton peak at δ 5.0-5.04 assigened to C12, 
it coupled with the double bond on the ring structure and split into a multiplet. The 
peak was in low field because of the descreening effect of lone pair electron on the 
oxygen atom. The NMR data of H7 was compared with NMR of erythrodiol published 
by Kagawa (Kagawa et al., 1998), and H7 showed a good match to erythrodiol, 
C30H50O2, m/z 442.72. 
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2.6.4 Separation of butanol extract 
Fractions from butanol extracts were separated by reverse phase flash 
chromatography ten fractions were collected and fraction B3 were further separated 
over preparative reverse phase HPLC, 14 and 19 fractions were collected from B2 
and B3 respectively. The fractions were freeze dried and their structures were 
educated by 1H NMR specrutm.  
2.6.4.1 Compound B3-1 
B3-1 was a white powder, 0.8 mg was isolated from the fractionation and the 1H NMR 
was run in D2O. The post-processing water peak suppression 
1H NMR spectrum is 
shown below (Figure 2.37).   
 
From the 1H NMR spectrum of B3-1, many impurity peaks showed this sample might 
not pure. Singlet at δ 2.28, 4 triplets between δ 3.47 and 3.95 were suggested to be 
the signals of -CH2- groups or protons which had the same chemical environments on 
a glucose ring. The other two triplets from δ 3.71 to 3.95 showed characteristic signals 
for -OCH3 groups; each triplet integrated for 3 protons. The singlet at δ 5.09 was 
possibly the anomeric proton on the glycosyl group. The singlet at δ 8.46 was in a 
very low field that might cause by the strong electron-withdrawing effect from an 
oxygen atom on the aromatic ring structure. A triplet at δ 6.51 was likely to be caused 
by aromatic protons, hypothetically, if the multiplet between δ 7.22 and 7.43 were 
triplets that the proposed structure of the compound is showed in Figure 2.36.  
 
 
2
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O OH
OHHO
HO  
 
                   
 
 
 
Figure 2.36 Proposed structure of compound B3-1. 
 
No. 
1
H NMR chemical shift 
(ppm) 
Estimated 
value (ppm) 
2 8.76 8.73 
3 7.22-7.43 7.30 
7 6.51 6.65 
Glu 
Ring -CH2- 
3.47, 3.61, 3.74, 
3.93 
3.49-5.41 
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Figure 2.37 
1
H NMR spectrum of compound B3-1.
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The 13C chemical shifts of the proposed structure was estimated by ChemDraw® 
(Figure 2.37) and the estimated values were compared with 1H NMR data in Figure 
2.36.The nitrogen was a strong electro-withdrawing group that, the proton attached to 
the carbon next to it could resonate at very low field, such as δ 8.73 showed in 
estimation results.  
 
N
O
O OH
OHHO
HO
O
8.73
7.30
7.92 6.60
6.65
3.91
5.88 5.41
3.49
3.49
2.02.02.0
2.0
3.73
 
 
Figure 2.38 Estimation 
1
H NMR chemical shift of compound B3-1 (Estimation Quality: blue = 
good, magenta = medium, red = rough). 
 
This was a close match to the peak seen at δ 8.46 in the 1H NMR of B3-1. The 
substitution at position 5 (labeled as R in the proposed structure). The estimated 
chemical shift of hydroxyl groups were shown roughly at δ 2, which could not be 
observed in the original NMR data, since the spectrum was run in D2O, deuterium 
could exchange for the hydrogen in hydroxyl groups. The proposed structure for 
compound B3-1 was a glycoalkaloid as shown in Figure 2.38.  Glycoalkaloids have 
not been previously reported from the genus Erigeron. They are usually toxic and act 
like neural toxins to humans (Cantwell, 1996). To confirm the hypothesized deduction, 
the compound could be run on TLC and sprayed with Dragendorff’s reagent.  
Dragendorff’s reagent detects the presence of alkaloids giving an orange to red colour, 
therefore an orange or red band should be observed. 
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2.6.4.2 Compound B3-7 and B3-8 
Fraction B3-7 and B3-8 were brown pastes 0.5 mg and 0.3 mg were isolated from the 
HPLC fractionation respectively.  
 
The post-processing 1H NMR is shown below in Figure 2.40. The doublet at δ 3.36 
was integrated as 1 proton, and the compound contained at least six aromatic protons: 
two doublets at δ 6.36, δ 7.63 and two doublets at δ 6.94, δ7.58. Two triplets from δ 
5.43 to δ 5.56 might be caused by the protons on the double bond. As the peaks 
below δ 4.00 might be caused by the methylene groups or methoxyl groups. More 
sample was needed for further structure elucidation. 
 
R
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5
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A. Proposed structure for compound B3-7. 
 
HO
O
O H
H
H
5.0
7.02
7.63
7.27
7.84
7.59
7.75
6.63
5.61
5.18
 
B. Estimated 
1
H NMR chemical shift of compound B3-7. 
 
Figure 2.39.Proposed structure and estimated 
1
H NMR chemical shift of compound B3-7. 
 
The proposed structure of B3-7 is shown in Figure 2.39 as an anthraquinones 
(9,10-Anthraquinone), which could explain why there were two split singlets at δ 6.94 
and δ 7.58. The peak at δ 7.58 could be affected by an electron withdrawing group (R 
in the proposed structure) attached to the aromatic ring. 1H NMR of the structure was 
estimated by the program ChemDraw®, the estimated chemical shifts are shown in 
Figure 2.39 B. and data is compared in Table 2.9. 
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Figure 2.40 Post-processing water peak suppression 
1
H NMR spectrum of compound B3-7.
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Table 2.9 Estimation chemical shifts and chemical shifts of compound B3-7. 
No. 
1
H NMR chemical shift 
(ppm) 
Estimated value (ppm) 
1 7.59 7.75 
2 7.58 7.59 
4 7.66 7.84 
5 7.63 7.63 
6 6.36-6.39 7.02 
8 6.94-6.95 7.27 
 
Fraction B3-8 was also suggested to be a quinone derivative after comparing the 1H 
NMR spectra with compound B3-7. However, due to the limited amount of sample 
collected, the NMR spectra for B3-8 was not very clear, only few peaks could be 
assigned. More samples were request for further structure elucidation. The proposed 
structure of B3-7 was a close match to anthraquinone ring. Six aromatic proton peak 
from δ 7.02 to 7.87 were matched the peaks from δ 6.36 to 7.63 in the 1H NMR 
spectrum of B3-7, and also matched the double bond attached to the ring structure.  
 
Anthraquinone was abundant in Polygonaceae plants, like genus Reynoutria Houtt. 
and Rheum (Babu, et al., 2003.), and it was also found in some of the genus in 
Compositae family, such as genus Gynura (Seow et al, 2013), and Gnaphalium 
(Zheng et al, 2013), for example, emodin and physcioin were isolated and elucidated 
from Gnaphalium affine D. Don, they had been proved to have anti-inflammatory 
activity (Xi et al, 2011). However, no reports have been published for discovery the 
anthraquinones from genus Erigeron yet.  
 
2.6.4.3 Compound B3-9 
Fraction B3-9 was a brown paste, 0.8 mg B3-9 was isolated. The proposed structure 
of B3-9 is shown in Figure 2.42 A as a benzopyrone based analogue. The structure 
was estimated by the program ChemDraw®. 
 
The 1H NMR of B3-9 is shown in Figure 2.41. Four aromatic protons were identified 
from δ 5.48 to 7.07. Singlet at δ 5.48 was assigned to the proton on the pyrone ring 
H3. The double doublet at δ 6.38-6.49 was assigned to H8 on the benzene ring, it was 
adjacent to another aromatic proton, and spit into a doublet and due to the effect of 
the adjacent oxygen atom, the peak was split into double doublet.
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Figure 2.41 
1
H NMR spectrum of compound B3-9. 
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Two triplets at δ 7.12-7.14 were assigned for aromatic protons, chemical shift for H7 
and H6 and the H5 were observed from δ 7.19-7.22. One terminal methyl peak was 
observed at δ 0.93, and there were massive multiplets between δ 2 and 4.5 indicated 
that the 2 position substitution might be an alkyl side chain.  
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A. Proposed structure of compound B3-9. 
 
O OHO
OH
R
O OHO
OH
R
O
O
R
HO OH
 
 
B. C4-OH coumarin isomer. 
Figure 2.42 Proposed structures of compound B3-9 and coumarin tautomerism. 
 
B3-9 could also be an isomer of C4-OH coumarin. According to the previous studies of 
the tautomers, if a hydroxyl group is substituted at position 7 in a C4-OH coumarin, the 
coumarin undergoes a tautomerism (Figure 2.41 B): the proton dissociates from the 
hydroxyl group and the phenoxide anion conjugates with the benzene ring forming 2, 
7 -diyhdroxy chromone. This tautomerism is acid or base catalyzed, affected by 
solvent, pH value, and temperature (Porter and Trager, 1982, Alok et al., 2004).  
2.7 Conclusion 
Chemical compositions of hexane and butanol extracts from E. annuus were 
investigated. Sixteen compounds were identified from the volatile hexane fraction 
H1-1 using GC-MS method. The structures of isolated compounds were elucidated 
using MS and NMR spectroscopy. Five compounds were fully elucidated including 
gondoic acid (H5-1-2); hexadecanoic acid (H5-2); α-spinasterol (H4); erythrodiol (H7) 
and 4-pent-3’-ne-1’-ynyl–pyran-2-one (H1-2-7). The structures of the rest of the 
isolated compounds were not fully elucidated because the small amount of the 
samples isolated was not enough for further analytical analysis.
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3.1 Introduction 
Microorganisms can produce many products including food supplements, organic 
acids, functional proteins and antibiotics. The antibiotics in clinical use which are 
derived from nature are all produced by bacteria and fungi; rather than being plant 
derived (Perry et al., 2002c). Many plants contain antimicrobial compounds and are 
widely used in traditional medicines around the world to fight infections (Srivastava et 
al, 2014).  
 
The increasing trend of drug-resistant pathogens has demonstrated that new 
antimicrobial agents with new motifs are urgently needed. Plants contain a wide 
variety of secondary metabolites which have therapeutic values and could provide 
new aspects for investigation. Plant antimicrobial agents include flavonoids, alkaloids, 
terpenes, coumarins, phenolics and polyphenols (Savoia, 2012). An example is 
terpinen-4-ol, a monoterpene from Melaleuca alternifolia which is the main active 
ingredient of tea tree oil. This compound has modulation effects when applied with 
antibiotics against the resistant bacterial strains (Hammer et al, 2012); Another 
example, berberine, an isoquinoline alkaloid from the genus Berberis, is used as 
broad spectrum antimicrobial in traditional medicine in China. Berberine showed 
synergism with conventional antibiotics including oxacillin and ampicillin. It is also 
used as a substrate in studies on resistance-modifying agents and in the detection of 
efflux pump inhibitors (Abreu et al, 2011). The potential uses of phytochemicals as 
antimicrobial agents should be further evaluated. 
3.1.1 Antibiotics 
In the modern history of pharmacy, antimicrobial (anti-infective) agents were first 
described in the 19th century (Cassell, 2001), as a variety of chemicals that had been 
proved to have therapeutic functions (Saga and Yamaguchi, 2009), and defined as 
antibiotics by Selman Waksman in 1941 (Waksman, 1941, Waksman, 1943, 
Waksman, 1947)The first known natural antibiotic was beta-lactam antibiotic penicillin, 
discovered from Penicillium notatum by Alexander Fleming (Fleming, 1929), who 
shared a Nobel Prize in 1945 for these pioneering contributions to his field (Fleming, 
1945). The first synthetic antibiotics were a series of compounds called sulfonamides, 
discovered by Gerhard Domagk in 1932; he received his Nobel Prize in 1939 
(Domagk, 1895). Sulfonamide antibiotics have a broad antimicrobial spectrum, and 
they competitively inhibit the growth and multiplication of bacteria by inhibiting the 
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dihydropteroate synthetase activity in the folate synthesis pathway (Cohen and Cluff, 
1961, Domagk, 1950).  
 
Antibiotics are either bacteriostatic or bactericidal. They are generally 
well-characterized and target the microbes in many aspects, including interfering with 
the folate pathway, inhibiting bacterial membrane function, inhibiting the cell wall, 
protein, and nucleic acid synthesis (Cuddy, 1997, Kohanski et al., 2010). Some 
well-known antibiotics and their modes of action are listed in Table 3.1. 
 
Table 3.1 Modes of action and structures of antibiotics. 
Mode of 
action 
Classification of 
antibiotics* 
Characteristic Structure of examples 
Inhibition of 
folate 
metabolism 
Sulphonamides 
(Henry, 1943) 
Sulfanilamide 
 
Sulfamethoxazole
 
 
 
 
 
Inhibition of 
membrane 
function 
Polymyxins 
(Aronson et 
al., 2006b) 
Polymyxin B 
 
 
 
 
Inhibition of 
cell wall 
synthesis 
(peptidoglyc
an 
synthesis) 
Β-lactam 
antibiotic (Lee et 
al., 2001) 
Penicillins 
 
Cephalosporins 
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 Glycopeptides Vancomycin (Newsom, 1982) 
 
 
 
Inhibition of 
protein 
synthesis 
Aminoglycosides 
(binding to 30S 
ribosomal 
subunit)(Phillips, 
1982) 
 
 
 
 
 
 Macrolides 
(binding to 50S 
ribosomal 
subunit)(Blonde
au, 2002) 
Erythromycin 
 
 
 
 
 
Clarithromycin
 
 
 
 
 
Tetracyclines 
(binding to 30S 
ribosomal 
subunit)(Nelson 
and Levy, 2011) 
Tetracycline 
 
Doxycycline 
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*: The categories of well-known antibiotics and their mode of actions had published (Torrence 
and Isaacson, 2003, Walsh, 2000). 
 
In addition, some small antibiotic families have their own mode of action. For example, 
the ansamycin family, including streptovaricins and rifamycins, are particularly 
effective against mycobacteria and can interact with the bacterial DNA-dependent 
Lincosamides 
(binding to 50S 
ribosomal 
subunit)(Aronson 
et al., 2006a) 
Lincomycin 
 
 
 
 
 
 
Clindamycin 
 
 
Oxazolidinone 
(binding to 50S 
ribosomal 
subunit)(Diekema 
and Jones, 2001) 
Linezolid 
 
 
 
 
 
 Phenicols 
(binding to 50S 
ribosomal 
subunit) 
Chloramphenicol (Weeks, 1980) 
  
 
 
Inhibition of 
DNA 
replication 
(topoisomer
ase 
inhibitors) 
Quinolones (Neu, 
1988) 
Ciprofloxacin
 
 
 
Norfloxacin 
 
Aminocoumarins 
(Anderle et al., 
2008) 
Novbiocin 
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RNA polymerase (Milavetz and Carter, 1977, Wehrli et al., 1968).  
 
3.1.2 Bacterial structures 
Bacteria are prokaryotic organisms. According to the different compositions of cell 
walls (Betsy and Keogh, 2005), they can be classified into Gram-positive bacteria and 
Gram-negative bacteria using the Gram staining test (Friedman et al., 1995). As the 
bacterial cell wall is outside the cytoplasmic membrane (blue plasma membrane, 
Figure 3.1), it provides protection to the cells against osmotic stress and invasions 
from the antibiotics. It also provides rigidity and shape to the cells. The cytoplasmic 
membrane and the cell wall are usually described together as the cell envelope, and 
most of bacteria have a polysaccharide layer outside the cell envelope called the 
capsule (Kasper, 1986). Different cell wall compositions between Gram-positive and 
Gram-negative bacteria are compared in Figure 3.1. 
 
 
 
 
Figure 3.1 Gram-positive and Gram-negative bacterial cell walls. Gram-positive bacterial cell 
wall (left) consist of thick peptidoglycan layers; Gram-negative bacteria cell wall (right) consist 
of an outer lipid membrane and a thin peptidoglycan layer (SIigma-Aldrich, 2014). 
 
 
Gram-positive bacteria cell walls are thicker than the Gram negative cell walls, as the 
main component of the cell wall is peptidoglycan, which takes about 40%-80% of the 
cell wall’s dry weight, depending on different species. The rest of the cell wall 
components are teichoic acids, teichuronic acids and lipopolysaccharides (Stewart 
Tull, 1980). The Gram-positive call wall contains several layers of peptidoglycan 
which consist of two types of amino sugars, N-acetylmuramic acid (NAM) and 
N-acetylglucosamine (NAG) (Perry et al., 2002b). They link to each other by β-1,4 
glycosidic bonds, which are the cleavage site for lysozyme. N-acetylmuramic acid 
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links to peptide at the carboxyl group of the D-Iactic acid residue (Figure 3.2, orange 
bonds); the peptide links to a pentaglycine bridge through a diamino acid (L-lycine, in 
Figure 3.2). The pentaglycine can join two peptides together from glycan chain a and 
chain b (blue structures in Figure 3.2) to form an amino sugar backbone. This 
pentaglycine cross-link bridge can be used to distinguish the Gram-positive from 
Gram-negative peptidoglycan, which the glycan chain a and chain b link together 
directly without a pentaglycine cross-link bridge in Gram-negative cells(Schleifer and 
Kandler, 1972). 
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Figure 3.2 Peptidoglycan of Gram-positive bacterial cell wall. N-acetylmuramic acid (NAM) and 
N-acetylglucosamine (NAG); Pentaglycine of glycine is shown in blue. 
 
The Gram-negative bacterial cell wall is more complicated than the Gram-positive cell 
wall. It has an outer membrane which is similar to the cytoplasmic membrane but 
contains fewer proteins. Lipopolysaccharides (LPS) are covalently attached to the 
outer membrane on the surface, which consists of a lipid A (red in Figure 3.3) and a 
polysaccharide (green in Figure 3.3). Polysaccharides are often used to distinguish 
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different classes of Gram-negative bacteria. The LPS is also known as endotoxin; it 
can induce an inflammatory response when released from the cell wall (Silverman 
and Ostro, 1999).  
 
The outer membrane contains proteins called porins, which are selective and 
permeable transport proteins that can facilitate the influx of antibiotics or nutrients 
(Nikaido and Vaara, 1985). For example, the trimeric porin OmpF of Escherichia coli is 
a well-studied, non-specific transport channel that allows low molecular weight solutes 
passage across the outer membrane (Mahendran et al., 2010, Agafitei et al., 2010). 
There is another type of low molecular weight lipidpolypeptides, called 
Peptidoglycan-associated lipoprotein (Pal), which exists on the outer membrane 
towards the peptidoglycan layer (purple in Figure 3.3). The N-terminal end of the 
lipoprotein is a hydrophobic fatty acid chain, anchoring the protein down to the 
membrane. The C-terminal region attaches to the peptidoglycan covalently at the 
biamino acid (Lazzaroni and Portalier, 1992). 
 
 
 
 
 
Figure 3.3 Outer membrane of Gram-negative bacteria covalently bonds to peptidoglycan 
through Pal. 
 
 
The space between the cytomembrane and outer membrane in the Gram-negative 
bacteria envelope is called the periplasmic space: it contains variety of enzymes, 
proteins and a thin peptidoglycan layer (Bowden, 1990). The peptidoglycan consists 
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of only 5% of the cell wall’s dry weight and it attaches to many lipoproteins from the 
outer membrane. The breakdown of antibiotics are located in periplasmic space 
(Anba et al., 1988), for example, protease III is an Mg2+-dependent endopeptidase of 
Escherichia coli (Cheng, 1979) it can cleavage a small amount of polypeptides which 
are involved in bacterial metabolism (Kemshead and Kemshead, 1976). 
 
 
3.1.3 Bacterial pathogens 
 
Pathogenic bacteria can be classified into three categories: obligate, accidental and 
opportunistic pathogens (Perry et al., 2002a). Obligate pathogens live only inside the 
host cells. During the transmission to new host cells, they can be attacked by the 
host's immune system and cause symptoms of disease, such as Mycobacterium 
tuberculosis species (Comas et al., 2010). The accidental pathogens exist wildly in 
nature and the survival of the pathogen is not dependent upon the host cells. It will 
only cause severe diseases if it accidentally enters the host, such as Clostridium 
tetani (Agrawal, 1995). The opportunistic pathogens can be transmitted between the 
healthy cells without causing disease; however, if the host is unhealthy or the immune 
system is not functioning properly, the bacteria can cause an infection, such as the 
Staphylococcus species (Latorre et al., 1993). 
 
The pathogenesis virulence factors are described as substances that are produced by 
pathogens to facilitate the adhesion, colonization and invasion of the host cells 
(Wilson et al., 2002). Pathogens can also produce toxins, including endotoxins and 
exotoxins. Exotoxins are proteins released from the live bacteria in certain species 
and endotoxins are a lipopolysaccharide complex (Figure 3.3) in Gram-negative 
bacteria cell walls, regardless of different species, and only released on lysis of the 
bacteria cells. The exotoxins are heat labile (60 
o
C- 80 
o
C) and immunogenic sensitive, 
while the endotoxins are heat stable (>250 
o
C), endotoxins also can cause weakly 
immunogenic respond and caused a fever in the host (Baron, 1996). 
 
3.1.4 Antibiotic-resistance and antibiotic-resistance strains 
 
One consequence of the development of antimicrobial agents since the 1930s is the 
increasing threat antibiotic-resistance poses to public health 
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(CentersforDiseaseControlandPrevention, 2014). Sulfonamides-resistance, the first 
known antibiotic-resistance, was discovered in the 1950s when several Escherichia 
coli resistant mutants were isolated and the modes of action resistance were studied 
(Pato and Brown, 1963). The resistant mechanisms of commonly used antibiotics are 
listed below in Table 3.2. 
Table 3.2 Resistant mechanisms of commonly used antibiotics (Adapted from Davies’s 
publication, Davies, 2010). 
Antibiotic family Effect on 
bacteria 
Targets Resistance mechanisms 
Sulfonamides Bacteriostatic Folate metabolism Efflux, modify target 
β-lactam 
antibiotics 
Bactericidal Peptidoglycan 
biosynthesis 
Hydrolysis, efflux, modify target 
Glycopeptides Bacteriostatic Peptidoglycan 
biosynthesis 
Reprogramming peptidoglycan 
biosynthesis 
Aminoglycosides Bactericidal Protein synthesis Phosphorylation, acetylation, 
nucleotidylation, efflux, modify target 
Macrolides Bacteriostatic Protein synthesis Hydrolysis, glycosylation, 
phosphorylation, efflux, modify target 
Tetracyclines Bacteriostatic Protein synthesis Monooxygenation, efflux, modify 
target 
Lincosamides Bactericidal Protein synthesis Nucleotidylation, efflux, modify target 
Phenicols Bacteriostatic Protein synthesis Acetylation, efflux, modify target 
Quinolones Bactericidal DNA replication Acetylation, efflux, modify target 
Rifamycins Bactericidal Protein synthesis ADP-ribosylation, efflux, modify 
target 
Oxazolidinones Bacteriostatic Protein synthesis Efflux, modify target 
Pyrimidines Bactericidal Folate metabolism Acetylation, efflux, modify target 
 
 
General resistance mechanisms of the commonly used antibiotics include: enzyme 
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inactivation; target alteration (modification of the target site or overproduction of the 
target); decreasing cell permeability; and efflux (Davies and Davies, 2010). For 
example, the β-lactam resistant strains share the same resistant mode of action by 
inactivating or reducing the antibiotic activity, breaking the β-lactam ring, causing the 
modification of the PBPs and the efflux of the antibiotic molecule (Sun et al., 2014).  
 
The first bacterial enzyme discovered with the ability to destroy β-lactam antibiotics is 
β-lactamase, produced by the amp gene (Abraham and Chain, 1940). Production of 
β-lactamase is the most important and most common resistance found in both 
Gram-positive and Gram-negative bacteria (Jacoby, 2009). It can hydrolyze the 
β-lactam ring and deactivate the antibiotic molecule (Lee et al., 2001). In some 
Gram-negative resistant strains, β-lactam antibiotics were also found to be bonded by 
β-lactamase, and the complex was trapped in the periplasmic space (Antunes et al., 
2011). 
 
Another important drug resistant mechanism is to modify the bacterial enzymes. For 
example, beta-lactam antibiotic is a well characterized antibiotic family that can bind  
and deactivate the penicillin-binding proteins (PBPs), which are a group of enzymes 
responsible for the polymerization of peptidoglycan in both Gram-positive and 
negative bacterial cells (Bush, 1995). These proteins function as transpeptidases, 
carboxypeptidases and transglycosylases. Transpeptidase (green in Figure 3.4) can 
catalyze the final transpeptidation step in peptidoglycan synthesis (Georgopapadakou, 
1982). The β-lactam antibiotics can mimic the NAM D-Ala-D-Ala terminal (C-terminal) 
peptide residue and bind to the transpeptidase covalently at transpeptidase residue 
Ser403 (Figure 3.4). The β-lactam-PBP adduct is stable, and the enzyme is deactivated. 
In that case, the cross-link of the NAM and pentaglycine bridge (Gram-positive 
bacteria) or peptide residue on another NAM (Gram-negative bacteria) will not form. 
Deactivation of the transpeptidase leads to the termination of peptidoglycan synthesis, 
and eventually the death of the bacteria cell (Otero et al., 2013). 
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Figure 3.4 Transpeptidase function in Gram-positive bacteria and the acylation of serine by 
penicillin antibiotics, adapted from Lee’s publication (Lee, 2003). 
 
Some organisms also can efflux the antibiotic molecules from the periplasmic space 
back through the cell wall. The efflux pumps have been classified into five families, 
including: ATP-binding cassette (ABC) superfamily; the major facilitator superfamily 
(MFS); resistance-nodulation division (RND) superfamily; the small multidrug 
resistance (SMR) family; and the multidrug and toxic compound extrusion (MATE) 
family. ABC efflux pumps are ATP-dependent multidrug transporters with the ability to 
export a broad spectrum of compounds (Lubelski, 2007). MFS pumps are 
single-polypeptide transporters and only transport small solutes. This can be 
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regulated by chemiosmotic ion gradient (Pao, 1998). RND efflux pumps act as drug 
anti-porters and they are wildly present in Gram-negative bacteria (Nikaido and 
Nikaido, 2009). SMR efflux pumps are homodimer proteins, such as EmrE, found in 
E.coli. They only efflux the compounds into the periplasmic space, and then the 
compounds can be picked up by RND pumps (Jack et al., 2001). MATE efflux pumps 
are narrow spectrum transporters and they export multiple cationic-toxic compounds 
(eg. fluoroquinolones) (Kuroda, 2009). 
 
Table 3.3 Skeleton of different β-lactam antibiotics*. 
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*: Structures of the different β-lactam antibiotic classes (Worthington and Worthington, 2013). 
 
Methicillin-Resistant Staphylococcus aureus (MRSA) strains are those S.aureus 
strains that have developed β-lactam antibiotic resistance. Those β-lactam antibiotics 
(Table 3.3) include penicillins (methicillin, oxacillin), cephalosporins (cefepime, 
ceftaroline), carbapenems (imipenem, meropenem) and monobactams (tigemonam, 
nocardicin A) (Evans et al., 2014). The resistant strains carry a mecA gene, 
transferred by Staphylococcal cassette chromosome mec (SCCmec) chromosome. 
The mecA gene encodes protein PBP2a, which has three domains: transpeptidase 
domain, allosteric domain and an N-terminal extension residue. According to Otero’s 
research, when the transpeptidase domain and allosteric domain are occupied in 
PBP2a, a series of conformation changes would take place and allow the muramic 
acid saccharide to enter inside. Therefore the cross-link of peptidoglycan could still 
proceed (Oteroa et al., 2013, Leski, 2005, Fuda et al., 2005).  
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Two types of MRSA: health care-associated MRSA (HA-MRSA) and the 
community-associated MRSA (CA-MRSA). The HA-MRSA causes infections among 
patients who have contacts with hospitals or healthcare facilities, such as surgery and 
hospitalization; while CA-MRSA infections are most frequently spread through direct 
skin contacts (Benoit et al., 2008, Huang, 2006). Many tests are used for the detection 
of MRSA infection: traditional disk diffusion and screening, mecA PCR-based 
amplification (Araj et al., 1999) and colorimetric cycling probe technology (Bekkaoui et 
al., 1999). However, HAMRSA infection is often found in less healthy patients, and 
those patients who have open wounds are more susceptible to MRSA infection 
{Kallen, 2010 #4112}. Often, MRSA strains exhibit multidrug resistant profiles, such as 
kanamycin and erythromycin resistance (Bobba et al., 2011). The appearance of 
multi-drug resistant (MDR) strains could be the consequence of regular exposure to 
different types of antibiotics (Alekshun and Alekshun, 2007). Nonetheless, there is 
promising news that Dalvance™ (dalbavancin) was approved by the US Food and 
Drug Administration earlier this year to treat acute bacterial skin infections against 
susceptible gram-positive bacteria including MRSA (Fox, 2014). Dalbavancin is a 
mixture of semisynthetic lipoglycopeptides derived from vancomycin (Figure 3.1), it 
interferes with cell wall synthesis by binding to the D-Ala-D-Ala peptide, and 
preventing cross-link of peptidoglycan in the Gram-positive bacterial cell wall 
(DurataTherapeutics, 2014).   
 
3.2. Minimum inhibitory concentration (MIC) assay 
3.2.1 Material and Strains 
Nutrient agar, nutrient broth, Ringer’s solution tablets and Müller- Hinton broth (MHB) 
were purchased from Oxiod microbiology, Thermo Fisher scientific, Loughborough, 
UK. Thiazolyl blue tetrazolium bromide (3-[4,5-dimethylthiazol-2-yl] -2,5- 
diphenyltetrazoliium bromide, MTT), tetracycline, oxacillin, ciprofloxacin, norfloxacin, 
erythromycin, novobiocin and dextrose were purchased from Sigma-Aldrich® Dorset, 
UK. Ninety-six well microtitre plates were purchased from NunlconTM brand, 
Sigma-Aldrich®.  
 
Gram-negative strains Escherichia coli (E.coli) NCIMB 1119 and Salmonella enterica 
(S.enterica) ATCC 14579/4601217, Gram-positive strains Micrococcus luteus (M. 
luteus) ATCC 49732/4604080, Enterococcus faecalis (E.faecalis) ATCC 
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29212/4807030 were obtained from Culti-Loops®, Remel, Lenexa, USA. 
Gram-positive strains Staphylococcus aureus (wild type) ATCC 25923 (S.aureus) and 
Methicillin-Resistant Staphylococcus aureus ATCC 33591 (MRSA) were obtained 
from Oxoid, Culti-Loops®, Dartford, Kent, UK. The depositor of the MRSA strain ATCC 
33591 was S. Schaefler: the multi-resistant MRSA strain was obtained from A. W. 
Jackson, Ramsey St. Paul Hospital, Saint Paul, USA (Schaefler, 1979). 
 
3.2.2 Method 
 
MRSA related antibacterial works were carried out in the biohazard Level 2 lab with a 
Level 3 cabinet. All equipment was sterilized with 70% industrial methylated spirit 
before and after use. Nutrient agar, cation-adjusted Müller- Hinton broth and saline 
solution were autoclaved using pasteurization at 121oC, 15 min. 
 
Ninety-six well microtitre plates were used for the tests. The prepared concentration of 
test samples were 512, 256, 128, 64, 32, 16, 8, 4, 2, and 1 μg/mL in 3% DMSO. The 
turbidity of inoculum was compared with McFarland standard 1.0 (1X108 cfu/mL) and 
diluted with Müller- Hinton broth 8 times before inoculation. Tetracycline, oxacillin, 
ciprofloxacin, norfloxacin, erythromycin, novobiocin were dissolved in DMSO and 
diluted with MHB to the initial concentration used as positive controls. DMSO in 
Ringer’s solution was used as negative control. All controls and test samples were 
diluted within the two hours before each test. 
 
Strains were prepared from the freeze-dried culture loops. Overnight cultures of each 
strain were grown on nutrient agar plates. Colonies were transferred from the agar 
plates into 10 mL Ringer’s solution with a sterilized loop. The turbidity of bacterial 
suspensions were compared with a McFarland standard 1.0 (1X108 cfu/mL). Bacterial 
suspension was further diluted with Ringer’s solution to make the concentration 
around 5 x 105 cfu/mL.  
 
During the assay, 125 μL of MHB was dispensed into wells 1-11 of each 96-well 
microtitre plates (Figure 3.5), followed by dispensing of 125 μL positive controls and 
test samples in well 1, the assay for each sample were carried out in duplicate. Two 
fold serial dilutions across the plate from well 1 to well 10 were made, while well 11 
was omitted. The final volume from the two fold dilution was dispensed into row 12. 
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125 μL of bacterial inoculum were added into wells from row 1 to 11.  Row 11 was the 
bacterial growth control and row 12 was the sterile control (Figure 3.5). Entire 
preparation works and MIC tests were operated in a safety cabinet. 
 
 
Figure 3.5 Ninety-six well microtitre plates in MIC assays. 
 
All of the 96-well microtitre plates were incubated at 37 oC for 24 hours. After 
incubation, 20 μL of 5 mg/mL methanolic MTT solution was dispensed into every well 
of the test plates to give the bacterial growth result reading. 
3.3 Results and Discussion 
3.3.1 Screening of fractions against wild type strains 
All MIC tests results were confirmed by duplicate experiments. For the wild type 
strains, tetracycline was used as positive control at the start concentration of 512 
mg/mL; while for S. aureus tetracycline, oxacillin, erythromycin, ciprofloxacin, 
norfloxacin and novobiocin were used as positive control, concentrations were set at 
5.12 mg/mL. The hexane extract (H) and its 18 hexane fractions (H1~3, H4~9, H5-1-9) 
were tested against five selected strains (Table 3.4). Fractions H1, H2, H3 and H4 
showed some anti-bacterial activities against the Gram-negative strains. The best 
inhibitory concentration against E. coli was 128 μg/mL (H1, H2, H3, H4), while the 
best inhibitory concentrations against S. enterica strain was 128 μg/mL (H 1, H3, H4) 
as well. Candidates H1, H2, H3, H4, H5-1, H5-1 and H6 showed inhibitory activity on 
Gram-positive strains. M. luteus was sensitive to the test candidate H1-4, while the 
best MIC value was observed at 32 μg/mL. 
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Table 3.4 The MIC values of hexane fractions (μg/mL). 
 
Strains 
Test samples 
T H1 H2 H3 H4 H6 H7 H8 H9 H5-1 H5-2 H5-3 H5-4 H5-5 H5-6 H5-7 H5-8 H5-9 
E. coli 8 128 256 128 128 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 
S. enterica 32 128 >512 128 128 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 
M. luteus 2 32 256 64 64 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 
S .aureus 0.3 128 >512 128 256 256 >512 >512 >512 512 128 >512 >512 >512 >512 >512 >512 >512 
E. faecalis 64 >512 256 256 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 
T: Positive control, tetracycline. 
 
Fractions H1, H3, H4, H6, H5-1 and H5-2 showed mild inhibitory activity against S. aureus; the wild type S. aureus is very sensitive to 
tetracycline; the MIC value for positive control was 0.3 μg/mL. Other fractions did not show any inhibition in the assay.
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Apart from the fractions, some isolated compounds were tested in the antibacterial 
assays from the phytochemical research. However, most of them showed no activity 
against the selected strains. For example, many unsaturated fatty acids from the 
whole plant of E. annuus were identified, including myristic acid, oleic acid and linoleic 
acid. Meanwhile, one sterol, α-spinasterol, was isolated and tested against the 
selected strains and no antibacterial activities were found. Alpha-spinasterol belongs 
to Δ7-sterol family and is known to have anti-inflammatory activities (Jeong et al., 
2010). It is also a part of the plant cell components involved in plant metabolism. 
 
Fraction H1 and H4 were separated, fraction H4-2-1 showed MIC at 16 μg/mL and 32 
μg/mL against wild type S.aureus and MRSA respectively; and fraction H4-2-3 
showed MIC at 32 μg/mL against both strains. However, full structure elucidations 
were not obtained from the phytochemical study. 
 
The ethyl acetate crude extract was fractionated into 12 fractions. E1 was the most 
active fraction, demonstrating inhibitory activities at the concentration of 128 μg/mL 
against Gram-negative strain E.coli, and Gram-positive strain S. aureus (Table 3.5). 
The MIC value for E1 on M. luteus and E. faecalis was 256 μg/mL. Fraction E2, E5, 
E7 and E8 showed mild inhibitory activity against M. luteus and fraction E2 also 
showed some inhibitory activity against E. faecalis. Other test samples did not show 
any obvious activity during the tests. 
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Table 3.5 The MIC values of ethyl acetate fractions (μg/mL). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Through the antibacterial tests screening, active fractions were identified from hexane and ethyl acetate extracts: fractions H1-4 and E1 were 
active on both Gram-positive and Gram-negative strains. MIC results of wild type S. aureus fractions were used as comparison when testing the 
resistance profile of the selected MRSA strain. Fractions H1, H2, H3 and H4 were chosen to carry out further separations. 
 
 
 
 
 
 
Strains 
Test samples 
T E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 
E. coli 8 128 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 
S. enterica 32 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 
M. luteus 2 256 256 >512 >512 256 >512 256 256 >512 >512 >512 >512 
S. aureus 0.3 128 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 
E. faecalis 64 256 256 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 
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The MIC value of butanol fractions are listed in Table 3.6. Compared to the hexane 
and ethyl acetate extracts, butanol fractions had only mild inhibitory activity against 
the selected strains, except for fraction B1, which had a MIC value of 128 μg/mL 
against M. luteus. Fractions B1, B5, B6, B10 showed mild inhibitory activity against 
Gram-negative strains at the concentration of 256 μg/mL. 
 
 Table 3.6 The MIC values of butanol fractions (μg/mL). 
 
 
Strains 
Test samples 
T B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 
E. coli 8 256 >512 >512 >512 256 256 >512 >512 >512 256 
S. enterica 32 >512 >512 >512 >512 >512 >512 >512 >512 >512 >512 
M. luteus 2 128 >512 >512 >512 128 256 256 >512 256 256 
S. aureus 64 >512 256 256 256 256 256 >512 256 >512 >512 
E. faecalis 58 >512 ->512 >512 >512 ->512 256 >512 >512 >512 >512 
 
 
All of the butanol fractions showed Gram-positive bacterial inhibition, fraction B1, B5 
B6 and B10 also showed inhibition on Gram-negative bacterial strains. Few 
bioactivities on the butanol plant extracts have been published. According to the 
Chinese folk medicine book <Zhejiang common used herbal medicine>  whole plant 
butanol and water extracts had been used for treating diarrhea (Revolutionary Health 
Committee of Zhejiang Province, 1970), gingivitis (Nanjing Military Ministry of Health, 
1969, Fan and Zhu, 1975), gastroenteritis (Revolutionary Health Committee of Anhui 
Province, 1975), hepatitis, and cholecystitis (Shanghai People's Publishing House, 
1972). According to these books, the plant extract was ingested by patients after 
boiling with water or soaking with ethanol. These traditional methods were very 
common and simple, the administration of polar solvent extracts suggested that, the 
polar fractions from this plant might be the key to its medical use. 
 
In order to isolated the active compounds from butanol fractions, the fragmentation of 
butanol fractions was carried out on HPLCs. Fraction B2 and B3 were fractionated, 
and compounds were isolated by fraction collections (the structure information could 
be found in chapter II). However, after the structure elucidation, isolated compounds 
were sent for DNA gyrase supercoiling assay directly, due to the limited amount of 
each compound.  
 
Chapter III: Antibacterial activities of Erigeron annuus 
97 
 
Table 3.7 The MIC values of water fractions (μg/mL). 
Strains Test samples 
T W W1 W3 W4 W5 W8 W9 W10 
E. coli 8 >512 >512 >512 >512 >512 >512 >512 >512 
S. enterica 32 >512 >512 >512 >512 >512 >512 >512 >512 
M. luteus 2 >512 >512 >512 256 >512 >512 >512 >512 
S. aureus 0.3 >512 >512 >512 >512 >512 >512 >512 >512 
E. faecalis 64 >512 >512 >512 >512 >512 >512 >512 >512 
 
MIC values of water fractions are shown in Table 3.7. Most of the water fractions were 
not active in the MIC assay, and the only active found in water fractions was W4, at 
256 μg/mL against M. luteus.  
 
3.3.2 MIC of selected fractions 
3.3.2.1 Positive controls susceptibility tests 
Methicillin-Resistant Staphylococcus aureus ATCC 33591 is a resistant strain against 
beta-lactam antibiotics, which include penicillin methicillin, dicloxacillin, nafcillin, 
oxacillin, and cephalosporins. It was isolated in 1975 with penicillin, erythromycin and 
tetracycline resistant marker (Schaefler, 1979). In order to confirm the multi-drug 
resistant susceptibility profile, six antibiotics from different antibiotic families were 
tested. Wild type Staphylococcus aureus (ATCC 25923) were also tested along with 
the MRSA (ATCC 33591) strain. The starting concentrations for the antibiotics are 
listed in Table 3.4 in the preparation section. MIC results are shown in Table 3.8 
below. 
 
Table 3.8 Resistance profile of MRSA (ATCC33591). 
  
Antibiotics MRSA S.aureus 
Tetracycline 256 μg/mL 0.32 μg/mL 
Oxacillin 128 μg/mL 0.08 μg/mL 
Ciprofloxacin 0.32 μg/mL 0.32 μg/mL 
Norfloxacin 1 μg/mL 1.28 μg/mL 
Erythromycin > 512 μg/mL 0.64 μg/mL 
Novobiocin 0.02 μg/mL 0.16 μg/mL 
DMSO >3.13% 3.13 % 
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Ciprofloxacin could not be dissolved completely in DMSO, so it remained as a 
suspension when the MIC tests were carried out. Compared with wild type S.aureus 
strain test results, the β-Lactam antibiotic resistance feature was observed in 
Methicillin-resistant S. aureus strain ATCC 33591 and it was resistant to oxacillin at 
128 μg/mL. The rest of the resistant susceptibility profile for ATCC 33591 was 
identified in erythromycin (>512 μg/mL) and tetracycline (256 μg/mL) (Bold in Table 
3.8).  
 
The expression of tetracycline resistance of MRSA was reported by Trzcinski using 
polymerase chain reaction (PCR) for the expression and detection of resistant 
determined genes (Trzcinski, 2000). Two mechanisms of the tetracycline resistance 
were published: activate the bacteria cell efflux pump (encode by tetracycline efflux 
resistance gene tetK and tetL) and reinforce the protection of ribosomals (ribosome 
protection proteins encode by tetM or tetO genes)(Donhofer et al., 2012). In this assay, 
the MIC value detected against tetracycline was at 256 μg/mL, indicated this strain 
(ATCC 33591). 
 
The MIC value for erythromycin was >512 μg/mL in this assay, suggesting that this 
MRSA strain was strongly resistant to the macrolides antibiotics. There were three 
ways that bacteria became resistant to macrolide antibiotics: drug target modification 
(methylation or mutation of ribosomal); efflux; and drug deactivation (Leclercq, 2002).. 
The resistance genes for erythromycin were ermB, ermC and msrA confirmed by PCR 
analysis by Ding. msrA gene encodes macrolide efflux pump which belongs to the 
ABC transporter family; while genes ermB, ermC encode ribosome-RNA methylase 
and preventing the drug binds to rRNA (Ding et al., 2012). 
 
The MIC values for MRSA against ciprofloxacin, norfloxacin and novbiocin were ≤ 
1μg/mL almost the same compared with the wild type strain, which indicated that the 
MRSA resistant profile did not include quinolone and aminocoumarin antibiotics. 
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3.3.2.2 Selected fractions against MRSA and S.aureus 
 
From the MIC results of the fractions above, nine fractions had been selected to test 
against the MRSA strain. They were fractions H1, H3, H4, H5-1, H5-2, B1, E1, E8, 
and E12. The starting concentration used was 512 μg/mL. 
 
 
Table 3.9 MIC values of selected fractions against MRSA and wild type S.aureus, test sample 
starting at 512 μg/mL. 
 
 
Candidates MRSA S.aureus 
Oxacillin 256 μg/mL 0.32 μg/mL 
Tetracycline 256 μg/mL 0.64 μg/mL 
Novobiocin 0.04 μg/mL 0.16 μg/mL 
H1 128 μg/mL 125 μg/mL 
H3 512 μg/mL 256 μg/mL 
H4 512 μg/mL 256 μg/mL 
H5-1 256 μg/mL 512 μg/mL 
H5-2 256 μg/mL 128 μg/mL 
B1 512 μg/mL 512 μg/mL 
E1 128 μg/mL 128 μg/mL 
E8 >512 μg/mL >512 μg/mL 
E12 >512 μg/mL >512μg/mL 
 
 
According to the MIC results from Table 3.9, fraction H1 and E1 had inhibitory activity 
against both strains at 128 μg/mL. Since only a small amount of E1 was abstracted, 
no further study was carried out on fraction E1. In order to concentrate the activity, 
and remove those inactive components in the fraction H1, it was then separated into 
nine sub-fractions and labelled as H1-1 to H1-9. The MIC results are shown in Table 
3.10. 
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Table 3.10. MIC values for H1 fractions against MRSA and wild type S.aureus, test sample 
starting at 512 μg/mL. 
S.aureus MRSA S.aureus 
Oxacillin 256 μg/mL 0.16 μg/mL 
Tetracycline 256 μg/mL 0.32 μg/mL 
Novobiocin 0.02 μg/mL 0.16 μg/mL 
Fraction H1-1 512 μg/mL 512 μg/mL 
Fraction H1-2 64 μg/mL 128 μg/mL 
Fraction H1-3 64 μg/mL 256 μg/mL 
Fraction H1-4 128 μg/mL 128 μg/mL 
Fraction H1-5 64 μg/mL 128 μg/mL 
Fraction H1-6 16 μg/mL 128 μg/mL 
Fraction H1-7 128 μg/mL 128 μg/mL 
Fraction H1-8 >512 μg/mL >512 μg/mL 
Fraction H1-9 >512 μg/mL >512 μg/mL 
 
Compared to the MIC value of H1 at 128 μg/mL, Fraction H1-6 (47.2 mg) showed a 
very good inhibitory activity on MRSA strain, the MIC value was observed at 16 μg/mL. 
It was indicated that, the fraction H1-6 might contain anti-bacterial compounds which 
were not belong to penicillin, erythromycin or tetracycline family. Fraction H1-2 (946.7 
mg), H1-3 (43.0mg), H1-5 (48.6 mg) showed good inhibition activity on MRSA strain at 
64 μg/mL , H1-4 and H1-7 showed exactly the same MIC value as the fraction H1. 
Fraction H1-1, H1-8 and H1-9 showed no obvious activity. According to the test 
results, the MRSA seem to be less tolerable than the wild type strain when tested 
against H2, H3, H5 and H6. This might be because the fractions contain certain types 
of compounds that could target the proteins encoded by resistant genes: for example, 
inhibition of PBP2a protein could cause the termination of bacterial cell wall synthesis 
and lead to cell death.  
 
Fraction H1-2 (946.7 mg) was enough for further separation after the antibacterial 
assays, seven fractions were obtained from H1-2. Concentrated antibacterial activity 
was observed in fraction H1-2-6 and H1-2-7. After purification, structures of 
compound H1-2-6 and H1-2-7 were elucidated. 
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3.3.2.3 Compound H1-2-6 against MRSA and S.aureus 
Fraction H1-2-6 had a MIC value against MRSA and wild type S.aureus at 64 μg/mL 
and 256 μg/mL respectively. Compound H1-2-6 is a white paste; its proposed 
structure is a butyrolactone derivative (Figure 3.6 A).  
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Figure 3.6  Proposed structure of compound H1-2-6. 
 
The proposed structure was a butyrolactone. Number and the positions of methylene 
group could not be determined, because the sample contains many impurities and 
further structure investigation was warranted.  
 
Acyl-homoserine lactones molecules could mediate the bacterial quorum sensing, by 
interfering with bacterial communication (Diggle and Crusz, 2007). Some 
butyrolactone derivatives such as 2-isocapryloyl-3-hydroxy-methyl -butyrolactone and 
N-(3-Oxo-octanoyl)-L-homoserine lactone (Luo, 2003) were also share the same 
mode of action. They mimicked the signaling molecules and bind to the bacterial 
receptor (inducer)(Bassler, 1999). 
3.3.2.4 Compound H1-2-7 against MRSA and S.aureus 
 
Compound H1-2-7 was proposed to be a 2-pyrone derivative: 4-pent-3-ene-1’-ynyl- 
-pyran-2-one (Figure 3.7). The MIC value of H1-2-7 against both MRSA and wild type 
is 128 μg/mL. 
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Figure 3.7 Proposed structure of compound H1-2-7. 
 
 
Compound H1-2-7 did not possess very good antibacterial activity, which might be 
because the hydrophobic side chain on the position 4 is highly hydrophobic and may 
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not interact with the transport proteins on the cell membrane. This compound has a 
pyrone motif, which can be found in a number of phytochemicals such as coumarins. 
The bioactivities and synthesis route of a series of 4- substituted pyrones were 
published by Fairlamb (Fairlamb et al., 2004). The antibacterial activities of 
substituted-6-methyl-2-pyrones were reported using disk diffusion tests, where the 
diameter of zone of inhibition was 21-34 mm against S.aureus . 
 
3.4 Conclusions 
 
In this antibacterial research, two compounds were shown to have inhibition against 
MRSA: Compound H1-2-6 was suggested to be a butyrolactone derivative. It had the 
five-membered lactone ring and might be able to mimic the signaling molecules in 
bacterial quorum sensing system and interfere with bacterial communications. In this 
study, the compound 4-pent-3’-ne-1’-ynyl–pyran-2-one with a six-membered lactone 
ring was isolated. Both lactones have antibacterial activity against the MRSA strain.  
Their mode of action is not known, but they might both act as compounds which could 
block bacterial quorum sensing. They carry the same antibacterial motif as other 
some other classes of antibiotics, for example, coumarins. However, the sample 
isolated from this research was not enough for further investigation of inhibitory 
mechanisms. 
 
In addition, forty-six fractions from E. annuus extract were examined and screened by 
their bacterial inhibitory activity. Nine fractions (H1, H2, H3, H4, E1, B1, B5, B6, B10) 
were confirmed to have inhibitory activities against the Gram-negative strains.  
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4.1 Introduction 
Topoisomerases are enzymes that regulate the topology of DNA molecules by 
breaking the DNA strands. There are two types of topoisomerases, type I and type II 
(Forterre et al., 2007). Type I topoisomerases are monomeric and can induce an 
ATP-dependent relaxation of the DNA double helix by breaking, passing and rejoining 
a single strand DNA (Pommier, 1998, Reguera et al., 2006). Type II topoisomerases 
can transiently break both strands of DNA by passing another segment through, 
rejoining the break (Watt and Hickson, 1994) and releasing the DNA supercoiling. 
 
The unwound topological structure of DNA molecule is recognisable by the twist of the 
DNA helix and the number of times the double helix crosses over itself around its 
helical axis (Wu and Wu, 1996); together they constitute the DNA supercoil (Figure 
4.1) described using linking numbers. DNA supercoiling is important to reduce the 
length of DNA molecule so that a large amount of genetic material can be compacted 
inside a single cell. Type II DNA topoisomerase are ubiquitous ATP-dependent 
enzymes in prokaryotes, lower eukaryotic and mammalian organisms (Burden and 
Osheroff, 1998). It has two subclasses: type IIA (topoisomerase II or gyrase, and 
topoisomerase IV) and type IIB (topoisomerase VI)(Watt and Hickson, 1994). Type IIA 
topoisomerase is essential in DNA growth-dependent processes (McClendon and 
Osheroff, 2007, Roca, 2009); it can relax the DNA supercoiling by breaking both 
strands and facilitate the replication and transcription process (Mukherjee et al., 
1993).. Type IIB topoisomerases are heterodimers and their function mode is similar 
to that of type IIAs, but they have only been found in archaea and some higher plants.  
 
During the DNA replication and transcription process, DNA double helix is unwound 
by helicase to form a tracking complex and each DNA strand is a template (Figure 4.1). 
In most prokaryotic circular DNA molecules, torsional strains are increased on both 
single strands and the rest of the double helix during DNA replication and transcription. 
In addition, they can be released by topoisomerases catalyzed unknotting 
decatenation and supercoiling (Watt and Hickson, 1994).  
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Figure 4.1. DNA supercoiling. 
 
 
 
DNA gyrase is a unique type IIA on, replication and recombination in most bacteria. It 
allows both DNA chains to have free negative supercoils and relax the DNA double 
helix, so that the replication of DNA can continue. DNA gyrase is present in bacteria 
and some lower eukaryotes, like yeast, which makes it a good target for many 
antibiotics (Maxwell, 1997, Watt and Hickson, 1994) . 
 
4.1.1 DNA gyrase structure 
 
Gyrase is a heterotetramer, it has an A2B2 primary protein complex structure, 
containing equivalent amounts of protein A (GryA) and B (GryB) encoded by gyrA and 
gyrB genes (Adachi et al., 1987). It containing four subunits (Figure 4.2), two GyrA 
subunits (97 kDa each) and two GyrB subunits (90 kDa each)(Janid et al., 1993). 
Protein A (GyrA) (A protein in Figure 4.2) consists of an amino-terminal domain (59 
kDa) and a carboxyl-terminal domain (33 kDa) (Hockings and Maxwell, 2002). The 
amino-terminal domain (GyrA59) is involved in DNA breakage and the reunion 
process, while the carboxyl-terminal domain (GyrA33) is involved in wrapping, binding, 
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and stabilizing the enzyme-DNA complex (Maxwell, 1997, Heddle et al., 2004, 
Corbett et al., 2004). 
 
 
 
 
Figure 4.2 DNA gyrase constitution, adepted from Maxwell’s publication (Maxwell, 1997). 
 
 
Protein B (GyrB) consists of two different domains: amino-terminal domain (GyrB43) 
and carboxyl-terminal domain (GyrB47) (Heddle et al., 2004). The GyrB43 is fully 
active as an ATPase and very thermally stable (Akanuma et al., 2011b, Friedman et 
al., 1995), while GyrB47 can interact with GyrA33 and DNA and ensure the stability of 
the gyrase-DNA complex (Akanuma et al., 2011a, Ali et al., 1995). 
 
The complex operates three different protein interfaces: N-gate, DNA-gate and C-gate 
(Illustrated in Figure 4. 3). These protein gates were the functional portions which 
could bond or grab the DNA molecules.  
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Figure 4.3 Three protein interfaces (N-gate, DNA-gate and C-gate) adapted from Gubaev’s 
publication (Gubaev et al., 2009). 
 
Subunit GyrB form a N-gate through which the other DNA strand (tDNA segment) can 
enter in the heterotetramer (Gubaev et al., 2009), C-gate is formed by subunit GyrA. 
The yellow spot shown in Figure 4.3 is the ATP binding site in GyrB (Basu et al., 2012), 
and tyrosines is shown as red spots in Figure 4.3 which gDNA can covalently attach to 
it and form a 5'-phosphotyrosine intermediate. 
 
 
4.1.2 DNA gyrase function mode 
 
Gyrase can change the topology of double-stranded DNA by a strand-passage 
mechanism (Martin and Dagmar, 2011). The original state of the N-gate is open (state 
1 in Figure 4.4) and the gDNA segment binds to the DNA-gate forming an 
intermediate (two light gray arms area in state 2 Figure 4.4). The second DNA 
segment, transfer DNA (tDNA segment, black in state 2 Figure 4.4) binds to the GyrB, 
enters the N-gate and induces a nucleotide dimerization on the N-gate in GyrB (blue 
in state 2 in Figure 4.4). 
 
Two molecules of ATP bind to the GyrB and the 5’ -end of DNA binds to the tyrosines 
to form a covalent phosphotyrosine bond this binding can cut the gDNA segment 
(gray lane in state 3 Figure 4.4) and a four-base gap is generated, resulting in the 
closure of the N-gate. The tDNA becomes trapped in the complex and then passes 
through to enter the C-gate (state 3 in Figure 4.4). 
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The rejoining of gDNA leads to the opening of the C-gate, and in the meantime, the 
N-gate stays closed and forms a closed protein-operated pocket during the passage 
(state 4.4 in Figure 4.4). 
 
Once the passage is completed, a GyrB47 catalyzed ATP hydrolysis is required and 
ADP and inorganic phosphate are released from the GyrB (Jensen et al., 1995). This 
leads to a reopening of the N-gate (state 5 in Figure 4.4) and tDNA leaves the 
complex completely (Kampranis et al., 1999). The heterotetramer resets to the initial 
state.  
 
 
 
Figure 4.4. DNA-induced strand passage, directly copied from Gubeava and Klostermeier’s 
publication (Gubaeva and Klostermeier, 2011). 
 
In the entire strand pass through process, GyrA33 domain helps the tyrosine bind with 
gDNA, and helps the complex to capture the tDNA. The process introduces negative 
supercoils and decreases the linking number by 2 (Basu et al., 2012, Corbett et al., 
2004).  
 
4.1.3 Gyrase inhibitors 
 
DNA gyrase has been identified as a good drug target in many therapies, since it 
plays an important role in bacterial DNA topological modifications (Maxwell, 1997). 
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There are many gyrase inhibitors which can be classified into three categories by their 
inhibitory modes of actions (Claudio et al., 2013): DNA-gate inhibitors, 
ATPase-domain inhibitors and the inhibitors that can form a cleavage complex. The 
most famous gyrase inhibitor family is the quinolone family. 
 
 
    (a)                                      (b) 
 A. Mechanism of quinolone gyrase inhibitor. 
 
(a) : Front, top and side views of quinolone cleavage complex. Moxifloxacin is shown in red, 
DNA helices are shown in blue, g-DNA is shown in green, the active site tyrosines (Tyr119) is 
shown in orange, the sites responsible for drug resistance are shown in yellow and the 
magnesium ion is shown in purple (b): Top, bottom and side views of the cleaved g-DNA 
residue. Moxifloxacin is shown in red, DNA is shown in green, active site tyrosines in shown in 
orange. Directly copied from Laponogov’s publication (Laponogov et al., 2009). 
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B. 4-oxo-1, 4-dihydroquinolane skeleton. 
 
Figure 4.5 Quinolone gyrase inhibitor.  
 
Quinolones are DNA-gate inhibitors, one of the most powerful classes of antibiotics, 
and have been used in clinic since 1967. They have a 4-oxo-1, 4-dihydroquinolane 
skeleton (Figure 4.5 B), include moxifloxacin, ciprofloxacin, nalidixic acid, norfloxacin, 
and oxolinic acid (Kim et al., 2011, Malik et al., 2011, Faye and Anthony, 2001). The 
structural based function mode was unknown until 2009. The quinolone-gyrase 
binding complex is shown in Figure 4. 5 A. There is a 4 base pair gap between the 
gate DNA (blue) and Try188 (orange) after the gate DNA and Tyr188 residues of the 
enzyme covalently link together at the 5’ phosphate terminal of the DNA and hydroxyl 
oxygen of the Tyr188 residues (P-O bond). At this point DNA is pulled away, a 
covalent enzyme-DNA cleavage complex is formed. Two molecules of moxifloxacin 
(red) intercalated in the 4 bp gap on each DNA strand prevent the rejoining of the 
DNAs and stabilize the complex (Laponogov et al., 2009, Faye and Anthony, 2001, 
Sissi et al., 2001). The fluoroquinolones, quinazolanediones and isothiazolones 
families are quinolone derived families and share the same mode action of inhibition 
(Oblak et al., 2006, Hockings and Maxwell, 2002, Malik et al., 2011). 
 
Another famous gyrase inhibitor family is the coumarin family, including novobiocin, 
clorobiocin and coumermycin. They are ATP analogues and bind to or bind near to 
the ATP binding site of the GyrB subunit. For example, novobiocin (Streptonivicin) 
was reported in the 1950s (Smith et al., 1956) as a powerful antibiotic. The gyrase 
inhibitory activity was then studied that novobiocin could bind to 24kDa N-terminal 
fragment of GyrB with hydrogen bindings (Lewis et al., 1996); the 24KDa fragment is 
inside the 43KDa N-terminal domain which is the site of ATP hydrolysis (Heide, 2013, 
Ali et al., 1993, Gilbert and Maxwell, 1994, Janid et al., 1993). 
 
There are many other inhibitors which do not belong to the quinolone or coumarin 
families; they are listed in Table 4.1 below: 
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Table 4.1.Gyrase inhibitors. 
 
Type Antibiotics Structure Binding Method 
Kibdelomycin 
O
N
O
O
O
NH2
O
O
O
O
HO
H
O
H
O
H
OH
HO
NH
O
HN
Cl
Cl
 
GyrB inhibitor (Singh et 
al., 2012, Phillips et al., 
2011, Sawa et al., 2012). 
Cyclothialidines Cyclothialidine 
14-benzoyl- 
cyclothialidine 
O
HN
SOH
HO
O
O
HN COOH
O
N
H N
O OH
NHR
HO
H
H
H
H
H
O
 
ATPase inhibitor (Nakada et al., 1994). 
Cinodine Cinodine 
O
RO
RO
NH
NH
O
NH2
NH
O
O
H3C
NH
O
NH2
HN
HO
O
NH(CH2)3NH(CH2)4
NH2                                  
DNA-gate inhibitor 
 (Osburne et al., 1990, Greenstein et al., 1981). 
Clerocidin Clerocidin 
3
11
4
H
O
13
14
15
O
OH
O
O
 
DNA-gate inhibitor, induce 
gyrase-mediated DNA damage 
(Gatto et al., 2001).  
Albicidin Albicidin Unknown 
structure 
DNA-gate inhibitor, form a cleavage Intermediate 
(Hashimi et al., 2007, Royer and Costet, 2004). 
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Nybomycin Nybomycin 
N N
O
O O
OH  
DNA-gate inhibitor 
(Hiramatsu et al., 2012). 
Simocyclinone 
D8 
OHO
Cl
O
OH O
O
O
O
O
O
HO
OHO
OHOH OH
H
N O
 
Binds to the N-terminal 
GyrA domain (Flatman et 
al., 2005) 
Gyramides  
F
S
NH
N
O
O O
 
ATPase inhibitor (Rajendram et 
al., 2014). 
Pyrazole 
derivatives 
HN
NN
R1
R2
 
HN
NN
R1
R2
 
Unknown (Tanitame et al., 2004). 
Quercetin 
derivatives 
 
OHO
OOH
OH
OH
OH
 
ATPase inhibitor and interact with 
DNA (Tan et al., 2009, Plaper et 
al., 2003) 
Macromolecular 
inhibitors 
YacG 
GyrI 
MurI 
Qnr/MfpA 
 DNA binding (Sengupta and 
Nagaraja, 2008, Chatterji and 
Nagaraja, 2002, Sengupta et al., 
2006, Tran et al., 2005). 
Macromolecular 
inhibitors 
microcin B17 
microcin CcB 
microcin ParE 
 
 DNA-gate inhibitor, stabilizing 
covalent complex (Maxwell, 
1997). 
 
 
There are very few natural compounds acting as gyrase inhibitors which do not belong 
to the quinolone or coumarin family. As listed above, quercetin derivatives have 
shown dual inhibition activities. They can bind to the DNA GyrB subunit inhibiting the 
ATPase activity and it can also interact with DNA. Though the DNA-binding mode is 
still not clear, the binding method was suggested by Tan that quercetin derivatives 
can bind to DNAs by intercalation and prevent the DNA bonds to gyrase (Tan et al., 
2009, Hossion et al., 2011).  
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Cyclothialidine inhibits the ATPase function (Nakada et al., 1994), while compound 
2,3-dihydroisoindol-1-one is structurally related to cyclothialidine; these compounds 
are cyclic peptides with antibacterial activity by inhibiting bacterial DNA gyrase 
(Lubbers et al., 2007). Cinodine is a glycocinnamoylspermidine antibiotic that can 
inhibit DNA gyrase in both Gram-positive and negative strains (Osburne et al., 1990, 
Greenstein et al., 1981). Clerocidin is a diterpenoid and can induce gyrase-mediated 
DNA damage and produce a cleavage between DNA and gyrase complex (Gatto et al., 
2001). Albicidin is a family of potent antibacterial polypeptide-peptide phytotoxins 
isolated from Xanthomonas albilaneans, which inhibit the prokaryotic DNA replication 
by cleaving DNA intermediate (Hashimi et al., 2007, Vivien et al., 2007, Royer and 
Costet, 2004).  
 
4.2 Material and methods 
 
The supercoiling assay kits were purchased from Inspiralis, including, E.coli, S. 
aureus gyrase, DNA pBR322 (4361 base pairs (Watson, 1988)), gyrase supercoiled 
assay buffer and dilution buffer, Norwich, UK. (S. aureus DNA gyrase was purified 
after heterologous expression in E.coli and supplied as A2B2 complex from Inspiralis). 
All gyrase were aliquoted into 40 U/tube batches and stored at -85oC. DNase and 
RNase protease free, electrophoresis tested agarose, Tris-base, EDTA, were from 
Fisher Bioreagents®, Loughborough, UK. Novobiocin, ciprofloxacin, bromophenol 
blue and glacial acetic acid were purchased from Sigma-Aldrich®, Dorset, UK. HPLC- 
grade water (18 MΩ) was prepared using a Millipore Mili-Q purification system, 
Milipore Corp., New Bedford, MA. HPLC grade chloroform and n- isopentyl alcohol 
were obtained from Fisher Scientific, Loughborough, UK. Eppendorf centrifuge (0.5, 
1.5 mL) tubes were used for incubation, Hamburg, Germany. Electrophoresis results 
were documented by UVP BioSpectrum® Imaging System, equipped with High 
performance transilluminators and VisionWorks® LS Software, Cambridge, UK. IC50 
results are digitalized by software ImageJ 1.47v, National institutes of health, USA 
Cures are estimated by software GraphPad Prism 6.04. 
 
4.3 Experiment preparation 
 
TAE buffer was prepared as a 50 X stock solution. A 1 L 50 X stock solution was 
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prepared by adding 242 g Tris-base, 57.1 mL glacial acetic acid and 100 mL of 500 
mM EDTA (pH 8.0) solution into a 1 L volumetric flask. The final volume was fixed up 
to 1 liter with deionized water. This stock solution was diluted to 1 X solution with 
deionized water for use. Loading dye was prepared as 6 X solution containing 10 mM 
Tris-HCl (pH=7.6), 0.03% bromophenol blue, 60% glycerol and 60mM 
Ethylenediaminetetraacetic acid (EDTA). The loading dye was stored at room 
temperature, covered with tinfoil. Dilution buffer for DNA gyrase supercoiling assay 
contained 40% (v/v) glycerol, 0.6% (w/v) Tris-HCL, 0.015% (w/v) dithiothreitol (DTT) 
and 0.03% (w/v) EDTA. Assay buffer for DNA gyrase supercoiling assay contained 
1.1 % (w/v) KOH (pH7.6), 0.2% (w/v) magnesium acetate, 0.15% (w/v) DTT, 0.1% 
(w/v) ATP, 10% (w/v) potassium glutamate and 0.05% (w/v) albumin. Both buffers 
were obtained as supercoiling assay kit from Inspiralis. 
 
 
4.4 DNA gyrase supercoiling assay 
4.4.1 Test candidates and controls 
 
Sterilized 1.5 mL Eppendorf centrifuge tubes were used for making 1 mg/mL of test 
candidates stock solution dissolved in 100% DMSO. 0.6 μL of 10% DMSO sample 
solution was used in each reaction volume (30 μL, 20 μg/mL in 2% DMSO).  
 
The DNA control contained 0.5 μL pBR322 relaxed DNA only. 100 mM novobiocin and 
ciprofloxacin solution were used as positive control in 2% DMSO; both drugs were 
diluted 500 times and the final concentration used in the test was 20 μM in 2% DMSO. 
2% DMSO solution was used as negative control.  
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4.4.2 Titrations 
Both E.coli and S. aureus gyrase were titrated using the same method. The reaction 
volume was 30 μL as recommended by the supplier Inspiralis. 1 U of gyrase was 
incubated with 0.5 μg of relaxed pBR322 DNA. Titrations for both E.coli and S. aureus 
gyrase were carried out using 1U to 6U of DNA gyrase. The assay started with 
incubating DNA gyrase with 0.5 μg of relaxed pBR322 DNA in a reaction volume of 30 
μL at 37 oC for 30 min in assay buffer. Reactions were stopped by taking the reaction 
tubes out of the water bath and treated with 20 μL of loading dye and 30 μL organic 
solvent (chloroform: n- isopentyl alcohol 24:1). Test tubes were mixed, excessive 
proteins and test compounds were extracted by the organic solvent and rejected. 
 
The gel was prepared by dissolving 1.5 g agarose powder in 150 mL 1 X TAE (1% gel 
was used (Lewis, 2011)). The gel particles dispersed by heating until near boiling 
point. The melted gel was cooled down before pouring it into a cast and the cast was 
set with two 12-well combs and wrapped with tapes at the opening side. 15 μL 
supernatant of each candidate was loaded on the agarose gel electrophosis in 1 X 
TAE buffer, which was run overnight under 20 volts for 15 hours. After 15 hours, the 
gel was stained by soaking into 6.5 μL ethidium bromide in 100 mL of 1 X TAE buffer 
for 40 minutes, followed by 100 mL fresh 1 X TAE de-staining for 20 minutes.  
 
4.4.3 Method of supercoiling assays 
 
After the titration, E.coli and S. aureus gyrase supercoiled assays were carried out on 
hexane, ethyl acetate, butanol and water extracts from plant E. annuus following the 
protocol. 9 hexane extractions, 12 ethyl acetate extractions, 10 butanol extractions 
and 7 water extractions were tested. All test groups candidates were run on agarose 
gel electrophoresis in 1 X TAE buffer overnight under 20 volts for 15 hours.  
 
4.5 Half maximal inhibitory concentration (IC50) of selected 
compounds 
Functional antagonist IC50 assay was a quantitative measurement to indicate how 
much of a single compound was required in the inhibitory reaction. It was designed to 
construct a dose-response curve as a result and to test the efficiency of the 
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compounds under different concentrations. According to the positive controls there 
were 20 μM in 2% DMSO and 40 μM for the concentrations of the candidates used in 
the positive supercoiling assays. Selected test candidates were diluted to 300, 100, 
30, 10, 3, 1, 0.3 and 0.1 μg/mL. 0.6 μL of diluted samples were added to 30 μL 
reaction volume using the same assay method.  
 
Three independent experiments were carried out using the same method and material: 
the results from all groups were documented and digitalized using ImageJ: three sets 
of data of inhibition density were obtained for each gel photo; and their mean±
standard error mean (SEM) were calculated. IC50 was valued and the curves were 
estimated by plotting inhibition density against log (concentration), [μg/mL] from three 
groups using GraphPad Prism 5 software. 
 
4.6 Results and discussion 
4.6.1 Titration and supercoiling assay for Gram-negative gyrase 
 
Titration result of Escherichia.coli gyrase from 1U to 4U units, is shown in Figure 4.6. 
pBR322 plasmid appears in different conformations, which gives a series of bands on 
an agarose gel. They are topoisomers of pBR322 (DNAs of different linking number or 
different conformations)(Inspiralis). The Nicked open-circular DNAs and relaxed 
circular DNAs have floppy structures and have difficulty in going through the agarose 
gel; their bands can be observed at the top of the each lane. Linear DNAs also have 
difficulty in passing through the agarose particles, since they are unknotted and string 
out between the agarose particles. However, both strands of linear DNA are cut and 
they can move through the agarose from one end, hence their bands migrate further 
than the circular DNAs. Supercoiled denatured DNAs are like supercoiled DNAs, both 
strands are uncut but not correctly paired (Lyubchenko and Shlyakhtenko, 1988, Sen 
et al., 1992). The supercoiled DNAs have very good conformation mobility; their 
bands can be observed at the bottom of the gel (Figure 4.6, Sc). In the titration, DNA 
Gyrase converts the relaxed plasmid pBR322 into a supercoiled form. The 
supercoiled DNA is tightly coiled and very easily passes through the agarose bundles. 
The supercoiled bands migrate the fastest on the electrophoresis gel, therefore their 
bands can be observed as the furthest single band under the UV light. 
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DNA  1U  1.25U  1.5U  1.75U  2U  2.5U DNA   1U   2U    3U   4U  DNA 
                                                           
Rel 
 
 
Sc 
    
      1     2     3    4     5    6     7            8    9     10   11   12   13 
 
Figure 4.6 Titration of E.coli DNA gyrase. Rel: relaxed DNA bands, Sc: supercoiled DNA band. 
 
 
From the titration result, lane 1, 8 and 13 were DNA controls, containing pBR322 
plasmid only. Bands for different pBR322 topoisomers could be observed except 
supercoiled DNA bands. Along with the increasing concentration of the enzyme, 
relaxed DNA bands disappeared at 2 U of E.coli gyrase (lane 6) and a single 
supercoiled DNA band could be observed in lane 6, 7, 10, 11 and 12. Lane 6 and 10 
were the cutting point of the titration, containing 2 U of enzyme. 
 
 
Thirty-eight fractions from hexane, ethyl acetate, butanol and water extracts were 
tested against 2 U of E.coli gyrase at the concentration of 20 μg/mL in the supercoiling 
assay. The supercoiling assay result for butanol fractions are shown below in Figure 
4.7. 
 
 
DNA  Neg    Nov  Cip    B1    B2    B3   B4     B5    B6   B7   B8 
 
 
Rel 
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 1     2      3     4     5    6     7    8     9    10    11    12 
 
Figure 4.7 DNA supercoiling assay on fraction B1-8 against E.coli gyrase. Rel: relaxed DNA 
bands, Sc: supercoiled DNA band. 
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In the E.coli gyrase supercoiling assay, the positive controls novobiocin and 
ciprofloxacin (lane 3 and 4) could inhibit the gyrase function and no supercoiled DNA 
band was observed. Test groups from lane 5 to 12 showed negative results; 
compared with the negative control, they all showed a single heavy supercoiled DNA 
band. This indicated that all relaxed DNA had been compacted by the gyrase 
completely; therefore, none of the test samples were active against E.coli bacterial 
DNA gyrase. 
 
Many black dots were observed in the result pictures. This was most likely caused by 
impurities in the agarose powder, for example, dust and paper fibers. 
 
4.6.2 Titration for Gram-positive DNA gyrase 
 
S. aureus gyrase was titrated from 0.1 U to 3 U (Figure 4.8). The pBR322 plasmid 
was used as the substrate in the assay. 
 
      DNA  0.1U  0.25U 0.5U  0.75U  1U  1.25U 1.5U  1.75U   2U  2.5U   3U 
 
Rel 
 
 
 
Sc 
          
1      2       3      4     5       6     7       8      9      10     11      12 
 
Figure 4.8 Titration of S.aureus DNA gyrase. Rel: relaxed DNA bands, Sc: supercoiled DNA 
bands. 
 
From the S. aureus gyrase titration, the supercoiled DNA bands migrated as a single 
band observed from lane 7 to 12. However, in lane 7, the supercoiled band has a 
blurry edge which suggested that not all the plasmid DNA were supercoiled in the 
presence of 1.25 U of S. aureus gyrase. Thus, 1.5 U of the enzyme was used for the 
assay. 
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4.6.3 S.aureus DNA gyrase supercoiling assays 
 
During the assay, fractions E3, E4, E5, E6, E11, B2, B3 and B9 showed inhibitory 
activity against S.aureus gyrase at 20 μg/mL (Figure 4.9). No activity was observed in 
lipophilic hexane fraction and hydrophilic water fraction groups. 
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1        2        3        4        5        6        7        8        9       10       11 
 
Figure 4.9. DNA gyrase supercoiling assays on ethyl acetate and butanol fractions against 
S.aureus gyrase. Rel: relaxed DNA bands (topoisomers with different configuration or linking 
number), Sc: supercoiled DNA bands. 
 
In the DNA gyrase supercoiling assays of ethyl acetate and butanol fractions, the first 
lane was DNA control, in which all the bands for pBR322 topoisomers were observed. 
The second lane was the negative control. It gave a single heavy band of supercoiled 
DNA, which indicated that the relaxed DNA was completely supercoiled. The DNA 
control was repeated in the last lane on the same agarose gel. 20 μM of the gyrase 
inhibitors novobiocin and ciprofloxacin were used as positive controls in lane 3 and 4; 
the gyrase activity was completely inhibited and the DNA bands appeared like the 
DNA control and no supercoiled DNA band was observed.  
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Eight fractions from ethyl acetate extract and butanol extract: E3, E4, E5, E6, E11, B2, 
B3 and B9 showed inhibitory activity in the triplicated assays; no supercoiled DNA 
band was observed. All the bands on the left side of the gel pictures were darker; this 
was caused by the uneven UV light of the gel camera, as both negative controls on 
one gel came from the same reaction tube, but they were observed in a different 
intensity. 
 
Further chromatographic separation works were carried out on eight fractions: E3, E4, 
E5, E6, E11, B2, B3 and B9. 
 
4.6.4 S.aureus DNA gyrase supercoiling assays on isolated 
compounds 
Fractions B2 and B3 were separated by reverse-phase HPLC; 19 and 14 peaks were 
collected respectively and followed by NMR structure characterization. 20 μg/m of 
fraction B2-3, B2-4, B2-5, B2-7, B2-9, B2-10, B2-11, B3-1, B3-5, B3-7, B3-8, B3-9, 
B3-10, B3-11 and B3-12 were tested in the S.aureus gyrase supercoiling assay, and 
only fraction B3-1, B3-7, B3-8, B3-9, B3-11 and B3-12 showed inhibitory activity 
(Figure 4.10).  
 
 
DNA    Neg     Cip   Nov   B3-1   B3-7  B3-8    B3-9  B3-11  B3-12 
    
      Rel 
       
       
        Sc 
 
1      2      3     4     5     6     7     8     9    10 
Figure 4.10 DNA gyrase supercoiling assay on B3 fractions against S.aureus gyrase. Rel: 
relaxed DNA bands, Sc: supercoiled DNA bands. 
 
The first lane was the DNA control in which all nicked DNA and relaxed DNA bands 
could be observed. The second lane was the negative control. Relaxed DNAs were 
supercoiled by the gyrase completely, which could be determined by the single heavy 
supercoiled DNA band at the bottom edge of the gel. 20 μM of gyrase inhibitors 
novobiocin and ciprofloxacin were used as positive controls in lane 3 and 4, in which 
no supercoiled DNA bands were observed. 
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For fraction B3-1, B3-9 and B3-12, gyrase activity was likely to be inhibited completely, 
no supercoiled DNA bands were observed. While B3-7, B3-8 and B3-11 showed faint 
supercoiled DNA bands, indicated that parochial plasmid had been coiled and very 
blurred supercoiled DNA bands in lane 6, 7 and 9 could be observed. 
4.6.4.1 Gyrase inhibitory activity of B3-1 
Fraction B3-1 was a white powder separated from butanol extract. It showed good 
inhibition activity against S. aureus gyrase in the supercoiling assay. It was proved to 
b e a single compound from the NMR results. The proposed structure of B3-1 was 
estimated by the program ChemDraw® and is shown in Figure 11A.  
2
3
4
N
1
5
6
7
8
OCH3
O
O OH
OHHO
HO  
A. Proposed structure of compound B3-1. 
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 B. Structure of flavone-based analogues. 
Figure 4.11 Proposed structure of B3-1 and structure of flavone-based gyrase inhibitor. 
 
The inhibitory mode of action of B3-1 might be different depending on the different 
substitutions at position 1 and 5. If the atom at position 1 is an oxygen atom, then it 
could mimic a flavone-based gyrase inhibitor. According to Vergheses’s research, the 
flavone-based DNA gyrase inhibitors share a motif structure shown in Figure 4.11 B. 
They have dual inhibition activities: binding to the DNA GyrB subunit inhibiting the 
ATPase activity (forming a stopping complex), or interacting with DNA, acting as a 
DNA intercalator (Verghese et al., 2013, Heide, 2013, Reece et al., 1991). The 
compound B3-1 could also be a quinolone derivative if a nitrogen atom substitute at 
position 5, a carbonyl at position 8 and the carbon double bond at position 6. The 
double bond conjugate with the carbonyl to form a pyridine ring, which could imitate 
the quinolone, acting with DNA gyrase and the DNA molecule to form the cleavage 
Chapter VI: DNA gyrase inhibitory activity of Erigeron annuus 
122 
 
complex. 
 
4.6.4.2 Gyrase inhibitory activity of B3-7 and B3-8 
Fraction B3-7 was a brown paste and the structure was estimated by the program 
ChemDraw®; the proposed structure of B3-7 is shown in Figure 4.12 A as an 
anthraquinone (9, 10 -Anthraquinone). Fraction B3-8 was also a quinone derivative 
but more sample was required for full structure elucidation. The proposed structure of 
B3-7 was a close match to anthraquinone. In the proposed structure, the chemical 
shift of H6 and H8 protons were high, they were most likely to be affected by the 
decreening effect of the R group. However, the R goupr could not be determined 
because of the insufficient sample for 13C NMR. 
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B. Structure of diospyrin. 
Figure 4.12 Proposed structure of B3-7 and structure of anthraquinone.  
 
Though there are a number of reports on the anti-bacterial activities of 1,4- 
naphthoquinone (Nair and Anchel, 1972, Ignacimuthu and Pavunraj, 2009, Rahmoun 
et al., 2012), there are few gyrase inhibitors that have been studied based on the 
naphthoquinone structure. For example, according to Karkare’s studies, 
naphthoquinone diospyrin (Figure 4.12 B) provides a 15 µM IC50 value of inhibition in 
the gyrase supercoiling assay. It also gives a distinct inhibition mode: the binding site 
of diospyrin lies in the N-terminal domain of subunit B, but does not affect the ATPase. 
However, the mechanism of naphthoquinone-GyrB binding is not clear (Karkare et al., 
2012), but the identification of the mode of action would contribute towards finding 
new antibacterial agents. 
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4.6.4.3 Gyrase inhibitory activity of B3-9 
Fraction B3-9 was a brown paste, and had been identified as a single compound 
through the NMR elucidation. The proposed structure of B3-9 is shown in Figure 4.13 
A as a 1, 4-benzopyrone based analogue. The structure was estimated by the 
program ChemDraw®. 
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A. Proposed structure of compound B3-9. 
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C. Structure of novobiocin. 
 
 
Figure 4.13 Proposed structure of compound B3-9, C4-OH coumarin tautomerism and 
structure of nobobiocin. 
 
 
The R group for B3-9 has not been determined. If the R group is a benzene ring, B3-9 
would be a flavonoid and it would be expected to be a mode action of flavone-based 
analogues against gyrase. The inhibition is most likely based on their interaction with 
DNA. For example, a quercetin metal complex was shown to have two modes of 
inhibitions: DNA gyrase poison and DNA intercalator. From Verghese’s research 
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reports, the flavone-based analogues can act as isosteric replacement for the 
coumarin drug, binding to the gyrase causing the deactivation of the enzyme (Tan et 
al., 2009, Verghese et al., 2013, Plaper et al., 2003). However, the binding mechanism 
is not known and the mode of inhibitory action of flavone-based compounds was only 
suggested by Tan as a DNA interaclator (Tan et al., 2009). 
 
B3-9 could also be an isomer of C4-OH coumarin. As previous studies of the 
tautomers have showen (Porter and Trager, 1982, Alok et al., 2004), when a hydroxyl 
group is substituted at position 7 in a C4-OH coumarin, the coumarin undergoes a 
tautomerism (Figure 4.13 B): the proton dissociates from the hydroxyl group and the 
phenoxide anion conjugates with the benzene ring, forming 2, 7 -diyhdroxy chromone.  
 
If the hydroxyl group is substituted at present on position 2 and 7, B3-9 could interact 
with the subunit B as a coumarin derivative. According to Janid and Gilberts’ research, 
the drug-gyrase binding was studied using drug-affinity column screening, and the 
mode of action proposed for coumarin drugs was ATPase inhibition. Compounds like 
novobiocin (Figure 4.13 C) and coumermycin bound at the 24 kDa sub-domain in the 
43 kDa N-terminal domain of GyrB to form monomer and dimer respectively, which 
has been detected in molecular mass studies. (Ali et al., 1995, Reece et al., 1991, 
Janid et al., 1993) The protein-drug binding interactions are still not clear. However, as 
described in Gilbert’s research, only non-ionic eluent (25% v/v tertiary butanol) could 
be used to elute the protein-drug polymer through the coumarin-affinity column. Due 
to the hydrophobic nature of the protein-drug binding, the interaction was suggested 
to be a non-polar interaction. 
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4.6.5 Half maximal inhibitory concentration (IC50) tests  
The IC50 values on the tested compound against S.aureus gyrase were expressed as 
the mean of triplicated experiments (experiment 1 to 3). Eight concentrations were 
selected: 300, 100, 30, 10, 3, 1, 0.3 and 0.1 μg/mL (Figure 4.14, A) in order to 
construct a dose-response curve, and IC50 values were calculated from the dose 
inhibition curve. Three gel pictures were digitalized for each experiment group. 
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Figure 4.14 Measurement of DNA gyrase inhibition. A. Invert colours image; B. Subtract 
background; C. Adjust threshold. 
 
 
The results pictures of all gels were documented and digitalized using software 
ImageJ® by measuring the supercoiled DNA band densities on the gel photos (yellow 
frame areas, Figure 4.14 C). The original gel photos had very noisy backgrounds, the 
direct measurement of lane 1 (DNA control) supercoiled DNA band density was even 
higher than the negative control (as can be seen, there were no supercoiled bands in 
00 
Chapter VI: DNA gyrase inhibitory activity of Erigeron annuus 
126 
 
the DNA control lane). In order to eliminate the effect of the background, all 
backgrounds were subtracted: 
 
 
Step  1:  every 15 pixels of the background was subtracted into a dark 
background (Figure 4.14, B). 
Step  2:  the resolution was reduced to 8-bit to remove the remaining 
background color.  
Step  3:   the color threshold was adjusted to change the picture into inverted 
colours (Figure 4.14, C).  
 
 
The density measurements were taken from Figure 4.14, C using the same size check 
box (W=0.6, H=0.3 mm). Before taking the measurements, picture size, quantity and 
colour were not changed, as this might have affected the final density value. 
Independent experiments were carried out testing positive control novobiocin, sample 
B3-1, B3-9 and B3-12 respectively using the same method and material; the results 
from all groups were documented and digitalized using ImageJ. Three photos from 
each experiment were measured, and the density mean was calculated. 
 
 
IC50 value and the curves were estimated by plotting inhibition density against log 
(concentration), [μg/mL], using software GraphPad® Prism 5. The dose-response 
nonlinear fit curve was fitted by the software and the regression curve is shown in 
Figures 4.15-4.18. The X axis values are concentrations. However, since first 
concentration is really 0.0, the X values would be transformed to logarithms and the 
log (0) is not defined. Thus, a low concentration (in this case 0.01 ng/mL) is entered 
instead of zero.  
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4.6.5.1 Half maximal inhibitory concentration assay of 
novobiocin 
The inhibition of gyrase was examined by measuring the density of supercoiled DNA 
bands in the presence of decreasing concentration of novobiocin (300-0.1 µg/mL). 
(Figure 4.15 A). 
 
A. IC50 value of novobiocin. 
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B. IC50 assay of novobiocin. 
 
Figure4.15 IC50 assay of novobiocin; from 3.97-7.18 μg /mL. Test concentration of novobiocin 
was from 0.1 to 300 μg /mL on the relaxation plasmid pBR322 DNA (0.5 μg) incubating with 1.5 
U of S. aureus gyrase. Rel, relaxed DNA bands; Sc, supercoiled DNA bands. 
 
 
Novobiocin is an aminocoumarin antibiotic compound, used as positive control in this 
gyrase assay. The IC50 values of novobiocin are from 3.97 to 7.18 μg /mL. The IC50 
value from this test was not in the same range when compared with the other 
published works in the gyrase supercoiling assay: Alt and their research team had 
tested the IC50 of novobiocin and other amimocoumarin drugs, obtaining 6-10 nM 
(3.672 ng/mL-6.12 ng/mL) inhibitory concentrations against S. aureus (Alt et al., 2011). 
However, the activity of the gyrase and the components of the assay buffer (35 mM 
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Tris-HCl (pH=7.5), 24 mM KCl, 700 mM K-Glu, 4 mM MgCl2, 2 mM DTT, 1.8 mM 
spermidine,1 mM ATP, 6.5% (w/v) glycerol and 0.1 mg/mL albumin) was different 
from this research and the activity of the enzyme was considered to be a decisive 
factor in the supercoiling assay.  
 
S. aureus gyrase could be inhibited completely in the presence of a high 
concentration of novobiocin. From 3-300 μg/mL (Figure 4.15 B, lane 3-6), the nicked 
and relaxed DNA bands could be observed as the same as they were in the DNA 
control (lane 1) and there were no supercoiled DNA bands that observed in lanes 3-6. 
The software calculated inhibition values were tended to 0; therefore the inhibition of 
the gyrase was complete. From lane 7 to 10, the enzyme activity was affected by the 
novobiocin, the supercoiled bands observed was not clear. 0.5 μg plasmid pBR322 
DNA was used as substrate; not all the plasmid had been supercoiled in lane 9 and 10 
and several relaxed DNA bands were observed very clearly, representing relaxed 
DNAs with different linking numbers. Compared with the single heavy supercoiled 
DNA band in the negative control (lane 1), only partial substrates were supercoiled by 
the enzyme in lane 7 to 10 and no clear supercoiled bands were observed. 
 
DNA gyrase is a validated clinical target for novobiocin, which is an aminocoumarin 
ATPase inhibitor (Heide, 2009). Novobiocin act by targeting the DNA gyrase 
ATP-binding domain GyrB or the Hsp90 C-terminal binding site (a swich control of 
ATPase)(Sti, 2002). This feature has been proven in many antimicrobial assays in 
screening a novobiocin resistance S. aureus strain (Mika et al., 2005). This nature of 
“target selection” of novobiocin is also used to overcome quinolone and other drug 
resistance to reduce the risk of resistance development in antibacterial combination 
therapies. 
 
4.6.5.2 Half maximal inhibitory concentration assay of 
compound B3-1 
 
The inhibition of gyrase was examined by measuring the density of supercoiled DNA 
bands in the presence of decreasing concentration of B3-1 (300-0.1 µg/ /mL). Two 
independent experiments were tested and the results were confirmed by constructing 
a dose-response curve using Prism 5 (Figure 4.16 A). 
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A. IC50 value of B3-1. 
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B. IC50 assay of B3-1. 
 
Figure 4.16. IC50 assay of compound B3-1; from 31.27-34.03 μg /mL. Test concentration of 
B3-1 was from 0.1 to 300 μg /mL on the relaxation plasmid pBR322 DNA (0.5 μg) incubating 
with 1.5 U of S. aureus gyrase. Rel, relaxed DNA bands; Sc, supercoiled DNA bands. 
 
The calculated IC50 value for B3-1 using dose-response curve fit analysis is from 
31.27 to 34.03 μg /mL (Figure 4.16), compared with the DNA control, no supercoiled 
DNA bands were observed in lane 5 and 6, S. aureus gyrase could only be fully 
inhibited in the presence of a very high concentration of B3-1 (100-300 µg /mL, lane 5, 
6). Supercoiled DNA bands could be observed in lane 10-12, but the edges of the 
supercoiled bands were indistinguishable, which indicated that the enzyme could be 
partially inhibited by compound B3-1. As discussed in section 4.6.4.1, the inhibitory 
mode of B3-1 might be different depending on the substitution atom at position 1 and 
5; the compound could either mimic the structure of quinolone or quercetin derivative.  
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4.6.5.3 Half maximal inhibitory concentration assay of 
compound B3-9 
The inhibition of gyrase was examined by measuring the density of supercoiled DNA 
bands in the presence of decreasing concentration of B3-9 (300-0.1 µg/ /mL) (Figure 
4.17 A). 
 
A. IC50 value of compound B3-9. 
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B. IC50 assay of compound B3-9. 
 
Figure 4.17. IC50 assay of compound B3-9; from 5.39-6.18 μg /mL. Test concentration of B3-9 
was from 0.1 to 300 μg /mL on the relaxation plasmid pBR322 DNA (0.5 μg) incubating with 1.5 
U of S. aureus gyrase. Rel, relaxed DNA bands; Sc, supercoiled DNA bands. 
 
The inhibitory activity could be observed at high concentration of B3-9, from 30-300 
μg /mL, faint supercoiled DNA bands and strong relaxed DNA bands were observed in 
lane 5, 6 and 7, indicated that, the gyrase activity could not be inhibited or reduced by 
B3-9. It proposed to be a coumarin derivative and had a good IC50 value of 5.39-6.18 
μg /mL, compared to the positive control novobiocin (3.97-7.18 μg /mL).  
 
The mode of action of the inhibitory activity might be bound with the GyrB by 
interfering the ATPase activity. The interaction was between the compound and 
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24KDa fragment on GyrB could be intermediated by the hydroxyl groups on the 
proposed ring structure. The mode of action was illustrated using a known gyrase 
inhibitor, novoamine is shown in Figure 4.18 (Lewis et al., 1996). 
 
 
A. The substituted resorcinol structure skeleton binds to the hydrophilic protein pocket on GyrB 
through water-mediated hydrogen bonds systems, directly copied from Lewis’s publication 
(Lewis et al., 1996). The structure of novobiocin is shown in purple, water molecules are 
shown in yellow. Directly copied from Lewis’s publication. 
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B. Structure of novoamine (Berkov-Zrihen et al., 2012). 
 
Figure4.18 Proposed mode of action of compound B3-9 and structure of novoamine 
 
The hydrogen bonds system of novobiocin was suggested by Althaus and showed in 
Figure 4.18, with three molecules of water-mediated hydrogen binding system., The 
resorcinol skeleton is the vital moiety that interacts with the enzyme’s amino acids and 
interfering with the gyrase activity (Althaus et al., 1996, Reusser and Dolak, 1986). 
However, the sugar moiety of the structure may help the molecule structure wrap 
around the hydrophobic amino acids pocket of the enzyme, but play no part in 
anti-gyrase and anti-bacterial activities. 
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4.6.5.4 Half maximal inhibitory concentration assay of 
compound B3-12 
 
The inhibition of gyrase was examined by measuring the density of supercoiled DNA 
bands in the presence of decreasing concentration of B3-12 (300-0.1 µg/ /mL). 
(Figure 4.19 A). 
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B. IC50 assay of compound B3-12. 
 
Figure 4.19. IC50 assay of compound B3-12; from 475-2065 μg /mL. Test concentration of 
B3-12 was from 0.1 to 300 μg /mL on the relaxation plasmid pBR322 DNA (0.5 μg) incubating 
with 1.5 U of S. aureus gyrase. Rel, relaxed DNA bands; Sc, supercoiled DNA bands. 
 
Gyrase activity could not be fully inhibited at the proven test concentration (300 μg 
/mL); some supercoiled bands could still be seen in lane 6. More relaxed DNA bands 
with more linking numbers could be observed in lane 6-8. In lane 9-12, a single heavy 
band of supercoiled DNA bands could be seen at the bottom of the gel, indicated that 
the sample was not active. The IC50 value of B3-12 was calculated from 475-2065 μg 
/mL, confirming that the compound B3-12 was not very active as a potential gyrase 
inhibitor.  
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4.7 Conclusion 
Compounds isolated from the butanol extract from E. annuus exhibited potential 
gyrase inhibitory activity against S. aureus gyrase. The IC50 values were observed at 
B3-1: 31.27-34.03 μg/mL; B3-9: 5.39-6.18 μg/mL and B3-12: 475-2065 μg/mL. 
Compared to the positive control novobiocin 3.97-7.18 μg/m, compound B3-9 had a 
good IC50 value against S. aureus gyrase suggested that, the 1, 4-benzopyrone based 
analogue B3-9 could be used as Gram-positive bacterial gyrase inhibitor.Compounds 
isolated from hexane fractions this research were proven to have anti-bacterial 
activities against S.aureus strain. However, they did not show any activity in the DNA 
gyrase supercoiling assays.  
 
DNA gyrase is an essential enzyme required during the replication and transcription of 
the bacterial chromosome. It is a natural target of antibiotics. However, the 
investigations of gyrase inhibitory activity of these compounds are still need to be 
carried out in the future and their full structure elucidation was warranted. 
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5.1 Introduction 
5.1.1 In vitro mutagenicity assays 
Genotoxic chemical agents can induce both direct and indirect effects in DNA, leading 
to somatic cell effects or heritable mutations. Most genotoxic damage can be repaired 
and the cells never show mutagenesis, however, some mutations may develop from 
this damage (Sen et al., 2011). The occurrence of mutations can be enhanced by 
certain compounds, and these compounds are defined as mutagens. Mutagens can 
be categorized into three types according to their mutagenic mechanisms: base 
analogues, modifying DNA and intercalating DNA.  
 
Ethylmethane sulfonate (EMS) (CH3SO3C2H5) is a strong mutagen, frequently used as 
a positive control in mutagenicity tests. EMS is a alkylating agent that can modify the 
structure of guanine by adding a methyl group to the O6 position and forming O6 
-methylguanine (Rhaese and Rhaese, 1973). The O6 –methylguanine can weakly pair 
with thymine during DNA replication, leading to a base-pair mispairing from GC to AT 
(Figure 5.1 A). 
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A. EMS Methylation of guanine(red) into O
6
 –methylguanine (pink)(Brown and Brown, 1992). 
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B Nitrous acid deaminates cytosine and adenine (red). Hydrogen bonds shown in dotted lines. 
 
Figure 5.1 Modes of action of mutagen EMS and HNO2. 
 
 
Another frequently used mutagen is nitrous acid (HNO2), which was first reported by 
Steinberg and Thom in 1940 when it was used as a mutagen on fungi (Steinberg, 
1940). It acts through the oxidative deamination of amines to replace an amino group 
by a hydroxyl group (Zimmermann, 1977). For example, nitrous acid can deaminate 
cytosine and adenine to uracil (pair with adenine) and hypoxanthine (pair with 
cytosine), leading to GC to AT and AT to GA transition. 
 
Mutagenicity assays are genetic tests for detecting mutagens which can cause 
heritable DNA damage in cells or organisms (Eastmond et al., 2009). In vitro assays 
include bacterial tests for gene mutations (eg. Ames tests) (Claxton et al., 2010), tests 
for chromosomal mutations (eg. chromosomal aberration tests) (Cao et al., 2002), and 
mammalian cell mutation assay (eg. comet assay) (Sasaki et al., 2007). The 
technique of the Ames test is simple and sensitive (Figure 5.2). 
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5.1.2 The Ames test 
 
The Ames test is one of the most frequently used bacterial mutagenicity assays. It can 
be used to assess the genotoxicity/mutagenicity of potential carcinogens (Wexler, 
2014). The procedures were described in the 1970s by Bruce Ames and his research 
team in the University of California, Berkeley (Ames et al., 1975, Dorothy and Bruce, 
1983). Different Salmonella typhimurium (Joyce et al., 1975) or Escherichia coli  
amino acid auxotrophic mutants (Watanabe et al., 1998) are employed in the assay. 
Further mutations can restore the ability to synthesize the specific amino acid: these 
mutations are reverse mutations. An increase of two-fold or more in mutation 
frequency can suggest that a test compound is acting as a mutagen, and many 
mutagens have also been shown to be carcinogens. The Ames test has proven to be 
very sensitive and reliable in detecting mutagenic activities (Flückiger-Isler and 
Kamber, 2012, Lo et al., 2004, Maron et al., 1981). However, Samonella typhimurium/ 
Escherichia coli are prokaryotic, and are not a perfect model for mammalian cells. 
They contain only a single circular chromosome, and they cannot represent diploid 
cells which undergo meiosis (Masters, 1989). Supernatant fraction S9 from rat liver is 
often incorporated in the assay which provides a source of monooxygenase activity 
for the metabolic activation of pro-carcinogens (Lewis and Lewis, 2005), for example, 
metabolites of benzo[α]pyrene by cytochrome P450 enzymes are mutagenic and 
highly carcinogenic (Wong, 1998). The test is described in Figure 5.2. 
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Figure 5.2 Ames test. A. preparation of the histidine requiring Salmonella strain, and the test 
compounds are added. B. plate out on glucose-minimal medium (no histidine). C. low back 
ground mutation rate of Salmonella His
-
to His
+
. D. some compounds showed no mutagenic 
activity and some plates with a higher number of His
+
 colonies indicate mutagenic activity. This 
picture was adapted from the published book (Perry et al., 2002b). 
 
A histidine requiring Salmonella strain is normally used, as it has a single mutation in 
the Salmonella genome of an enzyme involved in histidine biosynthesis. The bacterial 
cultures are treated with test compounds and plated on the minimal media lacking in 
histidine. The control has no test compounds and is plated on the same minimal 
media plates. After incubation, a low colony count would be expected in the control 
group, and it will be seen if the His- Salmonella can mutate back to the original 
genotype, produce their own histidine and survive on the minimal media. If the test 
compound is mutagenic, an increasing frequency of back mutation colonies will be 
observed on the minimal media.  
 
5.1.3 Yeast test systems 
Yeast is a unicellular and uninuclear eukaryote, auxotrophic yeast strains are often 
used by yeast geneticists for testing mutagens (Fink, 1969). Growing yeast is rapid 
and simple. It provides a rapid and sensitive response to the mutagenic compounds. 
Mutagenicity and carcinogenicity are closely correlated (Benigni and Benigni, 2011), 
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and as eukaryotes, studying in yeast cells could help to discover the potential 
carcinogens which only showed their carcinogenicity after metabolized by cytochrome 
P450 system. Necessitating the testing of chemical agents to help to discover 
potential carcinogens. Mutagenicity tests of yeast strains share the same in vitro 
procedures (Rao et al., 2000). 
. 
 
5.1.4 Saccharomyces cerevisiae ade2 
 
Saccharomyces cerevisiae, usually known as fermenting yeast, has both haploid and 
diploid strains (Zimmermann, 1975). The haploid cells are either an a or an α mating 
type. The diploid cell is formed by conjugation of an a-cell and an α-cell. In the rich 
medium, the yeast cells reproduce by mitosis, while under carbon and nitrogen 
starvation, the diploid cell undergoes meiosis to produce two a type spores and two α 
type spores (Figure 5.3). 
 
 
 
Figure 5.3 Life cycle of Saccharomyces cerevisiae: budding; conjugation; sporation (directly 
copied from Saccharomyces Genome Database). 
 
Saccharomyces cerevisiae is commonly employed in eukaryotic mutagenicity tests to 
detect the mutagenic potential of chemical compounds. This method was first 
developed by Zimmermann in the 1970s (Zimmermann, 1973). Culturing yeast cells is 
simple, economical and rapid (Paul, 2001) , and mutagenesis could develop during 
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the processes of replication, recombination and repair of the yeast DNA. Additionally, 
S.cerevisiae has identical porosity in it’s cell wall which, when distinguished from 
prokaryotic bacteria, contains more membrane protein components.  
 
  
 
Figure 5.4 Yeast cell wall, picture copied from McClanahan’s publication (McClanahan, 2009).  
 
The cell wall makes up 15 - 30 % of the dry weight of the cell  and is mostly 
mannoprotein and β-glucan (Lipke, 1998)(Figure 5.4). β-glucan-chitin complex is the 
matrix for mannoproteins and provides the skeleton of the cell wall (Kollár, 1997). 
 
Yeast cells do not make adenine as a separate compound: the adenine appears as 
adenosine monophosphate (AMP) attached to the sugar-phosphate compound called 
phosphoribosylpyrophosphate (PRPP)(Figure 5.5). AMP is a nucleotide, a component 
of DNA, RNA and ATP. The synthesis of AMP requires a 12 step purine biosynthetic 
pathway. However, if adenine is applied in the medium, the cell can convert it to AMP 
by a one-step salvage pathway of purine nucleotide biosynthesis, catalyzed by 
adenine phosphoribosyltransferase. Wild type yeast cells are able to carry out the 12 
step biosynthetic pathway, catalyzed by different gene coded enzymes, while mutants 
with any adeX gene mutations require adenine in the medium as they can convert 
adenine to AMP by the salvage pathway only.  
 
Many mutants of S. cerevisiae have been isolated which have mutations in genes in 
the adenine biosynthetic pathway, and some of the genotypes are good markers for 
mutagenicity tests (Stotz and Linder, 1990). The ade2 gene encodes for 
AIR-carboxylase (5’- phosphoribosylaminoimidazole) which catalyzes the sixth step of 
the purine biosynthetic pathway in S.cerevisiae (Figure 5.5) (Gedvilaite and 
Sasnauskas, 1994). S. cerevisiae ade2 is unable to precede the synthetic pathway by 
repressing the enzyme transcription and leading to an accumulation of the metabolic 
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intermediate AIR. AIR can be oxidized to a red pigment giving a red phenotype to 
mutant colonies (K. Rébora et al., 2001). 
 
 
 
.Figure 5.5 Purine biosynthetic pathway in S.cerevisiae.This picture was copied from Renora’s 
publication (K. Rébora et al., 2001). 
 
 
Mutagenesis can be detected when mutagens induce a forward or reverse mutation 
on the synthetic pathway genes (ade/ADE genes). For example, if the ade2 mutant 
mutates backwards to the wild type by removing the repression of the ade2 gene, the 
yeast cell would be able to synthesize AMP, and no more AIR accumulations would 
appear in the cell. The colonies would be able to grow on the adenine-limited medium, 
and form white colonies. Forward mutations refer to those mutations in the other 
genes in the purine metabolism pathway (eg. ade8 gene in the pathway shown in 
Figure 5.5). The ade2 gene will not repress in the pathway, and no more AIR will be 
accumulated. However, the cells still cannot synthesize AMP and the forward mutant 
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colonies will not grow on minimal medium. This may also lead to a change in 
phenotype, in which case the colony will change back to white. Strains which have 
auxotrophic mutations upstream in the adenine biosynthetic pathway include 
S.cerevisiae ade4, ade5, ade6, ade7 and ade8. 
 
The prototrophic colonies for wild type S.cerevisiae are white; in the mutant S. 
cerevisiae ade2, the haploid ade2 colonies are phenotypically red, while the diploid 
colonies may produce sectored colonies after mating. A sectoring assay is used on 
the detection and separation of different mutants (Gedvilaite and Sasnauskas, 1994, 
Abdulovic et al., 2006), and mutagenicity assays are used to characterize the 
mutation frequency and type of the selected mutants. 
 
  
A                              B 
Figure 5.6 Haploid colonies of S. cerevisiae A. ade2 mutant colonies. B. wild type colonies. 
 
In the haploid strain, the wild type colonies are white and the ade2 mutant colonies 
are red (Figure 5.7). This phenotypic change has been used as an assay for 
monitoring genetic events and will be used to determine mutagenicity in this work 
(Couteau et al., 2008).  
 
5.2 Materials and Experiment preparation 
 
Haploid adenine and tryptophan requiring Saccharomyces cerevisiae ade2 mutant 
NCYC830 (mating type a) were obtained from the National Collection of Yeast 
Cultures (NCYC), Norwich, UK. Haploid adenine requiring Saccharomyces cerevisiae 
ade2 mutant Ha2/WF17-3624 (mating type a) was obtained from Blades Biological 
Ltd, Cowden, UK. 
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Yeast extract agar CM0019, technical agar (agar No.3) LP0013 and Yeast extract 
LP0021, dextrose (for bacterial culture), Ringer’s solution tablets BR0052 were all 
purchased from OXOID microbiology, Thermo Fisher scientific, Loughborough, UK. 
Ethyl methanesulfonate, sodium nitrite and adenine were purchased from 
Sigma-Aldrich® Dorset, UK. Ninety-six well plates were acquired from NunclonTM 
brand, Sigma-Aldrich®. Eppendorf centrifuge (0.5, 1.5 mL) tubes were used for fraction 
collections and originated from Hamburg, Germany. 
 
Different media and solutions were prepared before the mutagenicity tests. Yeast 
extract liquid (YEL) was made of 1% yeast extract and 2% dextrose in water. Yeast 
extract agar (YEA) was made of YEL supplemented with 2% agar. Extra adenine was 
added to YEA to allow growth of adenine requiring mutants, however, in the medium 
the mutant will not develop the characteristic red pigment (YEDA). Extra peptone was 
added to YEDA to make a very rich medium for storing yeast strains (YEPAD). 
Minimal plus vitamin medium was made up with minimum of chemical ingredients, 
include 0.52% ammonium sulfate, 2% dextrose with 2% agar in water. It is necessary 
to support growth of wild type yeast (MV). Minimal plus vitamins adenine medium 
(MV+Ade) had excess adenine added to allow growth of adenine auxotrophic mutants, 
however, the mutants will not develop the characteristic red pigment. 
 
5.3 Mutagenicity assay on haploid S. cerevisiae ade2 
5.3.1 Mutagenicity assay method 
 
A culture of S. cerevisiae ade2 was prepared from a freeze-dried culture, sealed in a 
glass ampoule. 0.5 mL of YEL was added to the dried culture, the ampoule was gently 
suspended and the mixture was transferred to a culture bottle containing 10 mL YEL. 
The culture was incubated at 25 oC for five days before the test (protocol from the 
NCYC).  New cultures were grown for the test from the generation 1 culture on YEA.  
 
Ninety-six well microtitre plates were used for the tests. The designated concentration 
of test samples were 500, 250, 125, 62.5, 31.3, 15.6 and 7.8 μg/mL in 1% DMSO. The 
turbidity of inoculum was compared with McFarland standard 1.0 (1X108 cfu/mL) and 
diluted with yeast extract liquid eight times before inoculation. EMS solution and 
nitrous acid solution were used as positive controls at 500 μg/mL (National Toxicology 
Program, 2011). 1% DMSO in Ringer’s solution was used as a negative control. 
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125 μL of YEL were dispensed to every well in 96 well microtitre plates, followed by 
dispensing 125 μL of controls and test samples in the first well of every two rows. 
Samples and controls were double diluted across the plate, followed by adding 125 
mL of yeast inoculum. The plate was incubated at 28 oC for 48 hours. 
 
After 48 hours incubation, the cells in each well of the test plate were transferred into 
200 μL of Ringer’s solution centrifuged at 2500 r.p.m and washed twice before 
suspending in 200 μL of Ringer’s solution. Every 20 μL of yeast suspension were 
diluted from 10-1 to 10-4 across 96 well plates; 40 μL of yeast suspension were spread 
onto two half yeast extract agar (YEA) plates for counting the white colonies; 20 μL of 
the suspension was spread onto a quarter platse and diluted for assessing total viable 
count. All test plates were incubated at 28 
o
C for 72 hours to allow the red pigment to 
accumulate. 
 
After 72 hours of incubation, colony counting of white mutants was obtained by 
counting the white colonies on the red adenine requiring colony backgrounds from the 
test plates. Enumeration from the 10-4 plates was used to calculate colony forming 
units (cfu) for red colonies in each well. The mutation frequencies were calculated as 
follows: 
 
Colony forming units (cfu/ cm3)= colony count x 1/dil. factor x 1/vol. 
Mutation Frequencies (MF) = number of viable white colonies / total number of viable 
colonies x106 . 
 
5.3.3 Characterization of mutants 
 
After the colony counting, all agar plates were kept at 28 oC for another 48 hours to let 
the white colonies develop. After 48 hours, white colonies from the test plates were 
transferred with care on to minimal medium agar (MV) and minimal medium agar 
+adenine (MV+ade) plates using sterilized toothpicks. Those mutants with forward 
mutations in the purine metabolism pathways would not grow on MV, and were still 
adenine requiring strains. 
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5.4 Results and Discussion 
5.4.1 Mutagenic response of S. cerevisiae ade2 
Extracts H1-4, E1-4, and B1-4 were tested against S. cerevisiae ade2. The starting 
concentration of each extract was the same as the positive controls (500 μg/mL in 1% 
DMSO). 1% DMSO was used as the negative control and samples were plated on 
YEA. Calculation of cfu/cm3 was obtained from 10-4 dilutions. The results are 
presented in Table 5.1 A-D. 
 
Table 5.1 Mutagenic assay against S. cerevisiae ade2. 
 
A. Number of white colonies (cfu/cm
3
). 
Sample   7.8  15.6 31.3 62.5 125 250 500 
μg/mL 
Neg Exp.1 925 700 575 1850 475 500 275 
 Exp.2 400 650 300 1775 625 775 450 
EMS Exp.1 1025 1275 1675 1050 950 1050 2850 
Exp.2 875 925 2000 1275 1025 1150 1850 
HNO2 Exp.1 400 525 525 475 325 275 825 
Exp.2 175 350 250 325 525 225 475 
H1 Exp.1 425 225 525 250 0 0 0 
Exp.2 25 50 275 200 275 0 0 
H2 Exp.1 500 525 475 225 50 0 0 
Exp.2 + 875 1300 + 425 0 0 
H3 Exp.1 475 150 75 200 50 0 0 
Exp.2 350 350 575 550 350 0 0 
H4 Exp.1 300 300 50 50 0 0 0 
Exp.2 + 2250 1050 450 375 0 0 
E1 Exp.1 625 25 0 2550 300 50 0 
E2 Exp.1 200 150 0 175 675 50 125 
E3 Exp.1 200 625 100 25 325 350 100 
E4 Exp.1 0 50 1175  + 25 50 50 
B1 Exp.1 2350 675 700  + 775 1025 1050 
B2 Exp.1 400 25 0 175 25 0 50 
B3 Exp.1 675 1000 775 1050 975 50 200 
B4 Exp.1 750 475 475 1075 375 425 925 
+: over growth of the mutant colonies. 
Exp: experiment. 
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B. Number of viable cells (cfu/cm
3
) X 10
6.
 
Sample   7.8  15.6 31.3 62.5 125 250 500 μg/mL 
Neg Exp.1 12.5 10.5 11.0 12.0 20.0 14.0 10.0 
Exp.2 17.5 10.5 12.0 12.5 16.0 7.5 12.5 
EMS Exp.1 8.5 10.0 10.5 11.0 6.0 10.0 3.0 
Exp.2 6.0 7.5 9.0 5.5 4.5 5.0 7.5 
HNO2 Exp.1 5.5 8.5 7.5 8.0 8.5 5.0 6.5 
Exp.2 7.0 8.0 6.0 7.5 6.0 4.5 9.0 
H1 Exp.1 10.0 8.5 4.5 3.0 6.5 0.5 0.0 
Exp.2 9.0 4.0 5.0 6.0 7.5 1.0 0.0 
H2 Exp.1 4.0 6.0 6.5 4.0 3.5 3.5 0.0 
Exp.2 13.0 10.0 12.0 12.5 10.0 2.5 0.0 
H3 Exp.1 6.5 4.0 5.5 5.0 3.0 1.5 0.0 
Exp.2 9.5 10.0 10.5 12.5 9.0 2.5 0.0 
H4 Exp.1 2.5 8.0 2.0 1.5 1.0 0.0 0.0 
Exp.2 11.0 10.0 6.0 2.5 2.5 0.0 0.0 
E1 Exp.1 24.5 12.0 12.5 10.5 15.0 13.0 7.0 
E2 Exp.1 8.0 5.5 4.5 12.0 3.0 4.5 0.5 
E3 Exp.1 8.5 5.5 9.0 3.0 7.5 1.5 5.5 
E4 Exp.1 10.0 11.5 8.5 9.5 3.0 3.0 8.0 
B1 Exp.1 10.5 10.0 6.5 8.0 10.5 12.0 5.0 
B2 Exp.1 7.0 4.5 10.5 8.5 7.0 5.0 2.5 
B3 Exp.1 11.0 13.0 7.5 31.5 15.5 22.5 9.5 
B4 Exp.1 3.0 7.0 6.0 11.0 2.0 9.5 9.0 
 
C: Number of mutants/ 10
6
 survivors. 
Sample   7.8 15.6 31.3 62.5 125 250 500μg/mL 
Neg Exp.1 74.0 66.7 52.3 154.2 23.8 35.7 27.5 
Exp.2 22.9 61.9 25.0 142.0 39.1 103.3 36.0 
EMS Exp.1 120.6 127.5 159.5 95.5 158.3 105.0 950.0 
Exp.2 145.8 123.3 222.2 231.8 227.8 230.0 246.7 
HNO2 Exp.1 72.7 61.8 70.0 59.4 38.2 55.0 126.9 
Exp.2 25.0 43.8 41.7 43.3 87.5 50.0 52.8 
H1 Exp.1 42.5 26.5 116.7 83.3 0.0 0.0 0.0 
Exp.2 2.8 12.5 55.0 33.3 36.7 0.0 0.0 
H2 Exp.1 125.0 87.5 73.1 56.3 14.3 0.0 0.0 
Exp.2 0.0 87.5 108.3 0.0 42.5 0.0 0.0 
H3 Exp.1 73.1 37.5 13.6 40.0 16.7 0.0 0.0 
Exp.2 36.8 35.0 54.8 44.0 38.9 0.0 0.0 
H4 Exp.1 120.0 37.5 25.0 33.3 0.0 0.0 0.0 
Exp.2 0.0 225.0 175.0 180.0 150.0 0.0 0.0 
E1 Exp.1 25.5 2.1 0.0 242.9 20.0 3.8 0.0 
E2 Exp.1 25.0 27.3 0.0 14.6 225.0 11.1 250.0 
E3 Exp.1 23.5 113.6 11.1 8.3 43.3 233.3 18.2 
E4 Exp.1 0.0 4.3 138.2 0.0 8.3 16.7 6.3 
B1 Exp.1 223.8 67.5 107.7 0.0 73.8 85.4 210.0 
B2 Exp.1 57.1 5.6 0.0 20.6 3.6 0.0 20.0 
B3 Exp.1 61.4 76.9 103.3 33.3 62.9 2.2 21.1 
B4 Exp.1 250.0 67.9 79.2 97.7 187.5 44.7 102.8 
-: cannot be calculated because of overgrowth. 
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D. Survival (Number of viable cells / Number of viable cells of negative control, %). 
Average 
survivors in 
Negative control 
(x106) 
7.8 15.6 31.3 62.5 125 250 500 
μg/mL 
15.0 
 
10.5  11.5 
 
12.25 
 
18.0 
 
10.75 
 
11.25 
 
EMS Exp.1 56.7 95.2 91.3 89.8 33.3 93.0 26.7 
Exp.2 40.0 71.4 78.3 44.9 25.0 46.5 66.7 
HNO2 Exp.1 36.7 81.0 65.2 65.3 47.2 46.5 57.8 
Exp.2 46.7 76.2 52.2 61.2 33.3 41.9 80.0 
Neg Exp.1 83.3 100.0 95.7 98.0 111.1 130.2 88.9 
Exp.2 116.7 100.0 104.3 102.0 88.9 69.8 111.1 
H1 Exp.1 66.7 81.0 39.1 24.5 36.1 4.7 0.0 
Exp.2 60.0 38.1 43.5 49.0 41.7 9.3 0.0 
H2 Exp.1 26.7 57.1 56.5 32.7 19.4 32.6 0.0 
Exp.2 86.7 95.2 104.3 102.0 55.6 23.3 0.0 
H3 Exp.1 43.3 38.1 47.8 40.8 16.7 14.0 0.0 
Exp.2 63.3 95.2 91.3 102.0 50.0 23.3 0.0 
H4 Exp.1 16.7 76.2 17.4 12.2 5.6 0.0 0.0 
Exp.2 73.3 95.2 52.2 20.4 13.9 0.0 0.0 
E1 Exp.1 163.3 114.3 108.7 85.7 83.3 120.9 62.2 
E2 Exp.1 53.3 52.4 39.1 98.0 16.7 41.9 4.4 
E3 Exp.1 56.7 52.4 78.3 24.5 41.7 14.0 48.9 
E4 Exp.1 66.7 109.5 73.9 77.6 16.7 27.9 71.1 
B1 Exp.1 70.0 95.2 56.5 65.3 58.3 111.6 44.4 
B2 Exp.1 46.7 42.9 91.3 69.4 38.9 46.5 22.2 
B3 Exp.1 73.3 123.8 65.2 257.1 86.1 209.3 84.4 
B4 Exp.1 20.0 66.7 52.2 89.8 11.1 88.4 80.0 
 
The mutagenicity tests showed inconsistent results against S. cerevisiae ade2, and 
showed high background mutation frequencies in the negative control groups. According 
to Ohnishi’s research, the spontaneous mutation rate of haploid S.cerevisiae should be in 
the range of 10
-7
, and the mutation rate of diploid cells could reach the range of 10 
-4
 
(Ohnishi et al., 2004). However, the highest background mutation frequency value was 
observed at 154.2 x 10
-6 
(Table 5.1 C Neg. exp. 1) in this research, which is higher than 
the lowest mutation frquency value in positive control nitrous acid (Table 5.1 C nitrous acid) 
and 10-fold higher than the expected value range. Further experiments were carried out to 
investigate these results. The highest mutation frequency value for the positive control 
EMS, was 950 X10
-6
 (Table 5.1 C EMS exp. 1), while the highest mutation frequency 
value of nitrous acid was 126.9 X 10
-6 
(Table 5.1 C nitrous acid, exp. 1). The mutation 
frequency of EMS at 31.3 μg/mL was 159.5-222.2 x 10-6 (1.59-2.22 x 10-4) and was ten 
times more effective when compared with published research: 15.44 x10
-4 
at 36.18 μg/mL 
(Hannan, 1978). The ideal mutagen frequency values of positive controls should decrease 
along the dilution; however, none of the test results showed a dose-response relationship, 
however, there was some indication of mutagenic activity by EMS at the highest 
concentration.  
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The survival rates, listed in Table 5.1 D, were calculated against the number of total viable 
cells in the negative control. It showed inconsistent results and may have beeen affected 
by the overgrowth observed. 
 
In the test candidate groups, samples H1 to H4 showed cytotoxicity against S. cerevisiae 
(see Table 5.1 B). According to the survival rate calculation, no yeast cells survived in the 
presence of 500 μg/mL of each hexane fraction Table 5.1 D) and no growth was observed 
after exposure to 250μg/mL in fraction H4. The cytotoxicity results were consistent with 
the antibacterial results in chapter III, and growth inhibition could be observed on both 
bacteria and yeast cells when the tested strains were exposed to a high concentration of 
fraction H1, H2, H3, and H4.The fractions may contain compounds which interfere with 
mannoprotein functions or inhibit glucan synthesis (Ghannoum, 1999). However, as 
yeasts are eukaryotes, compounds that are toxic to yeast cells may also be toxic to 
human cells. In vivo tests on antifungal drugs (eg.Fluconazole)  exhibited side effects 
such as headache, rash, indigestion and abdominal pain were found when administrating 
orally (Dixon and J., 1996). 
 
5.4.2 Characterisation of mutants 
After the colony counting, all agar plates were kept at 28 oC for another 48 hours to let 
the white colonies develop. After 48 hours, white colonies from the test plates were 
transferred on to minimal medium agar (MV) and minimal medium agar +adenine 
(MV+ade) plates with sterilized toothpicks. Double mutants will grow on MV+ade 
medium, but they will not show the characteristic red colour. 
 
 
 A                        B                    C 
 
Figure 5.7 Mutants of S. cerevisiae. A. Mutants in mutagenicity test; B. white mutants on MV; 
C. white mutants on MV+ade. 
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Ethyl methanesulfonate is a strong mutagenic organic compound used as a positive 
control. The result is displayed in Figure 5.7 A. Red colonies of S. cerevisiae ade2 
were considered as background, and many white mutants were observed. They could 
be caused by reverse mutations at the ade2 gene or forward mutations of other genes 
on the purine biosynthetic pathway (adeX). 
 
The white mutants were carefully transferred using sterilized toothpicks onto the same 
spot on MV and MV+ade agar surface. After incubation, the test results were compared in 
Figure 5.7 B and C. In order to characterize the type of mutations, minimal plus vitamins 
medium (MV) and the minimal plus vitamins + adenine medium (MV+ade) were used. On 
the MV medium, the forward mutants which have adeX gene mutations could not grow 
owing to a lack of adenine. Strains with reverse mutations, which had gained prototrophy 
like wild type yeast cells, could synthesize AMP and appeared as white coloured 
colonies on the surface of the agar. 38 of the 87 separated white colonies appeared to 
have reverse mutations to the wild type genotype. The remaining 49 colonies only 
grew on MV+adenine medium, and appeared to be forward mutants which had ade2 
gene mutations or were double mutants (ade2, adeX). 
 
5.4.3 Genetic stability study of S. cerevisiae ade2 
Due to the unreliable and inconsistent mutagenicity test results shown above, further 
investigations were carried out. In order to eliminate variables that could affect the 
mutagenicity test results, different batches of test material including yeast extract, agar 
and buffers and different yeast culture stock (from generation 1) were used to compare 
the growth and spontaneous mutation rate of ade2 mutants. Several single red colonies 
from the first generation culture (YEPDA showed in blue in Figure 5.9) and second 
generation culture (YEPDA showed in red in Figure 5.9) were spread directly onto YEA 
and inoculated in YEL at the same time. After 24 hours, the liquid yeast cultures were 
spread on the same batch of YEA plates, the YEA and YEL specimens from the first and 
second generation were spread onto the same plate and the differences were compared 
in Figure 5.9 A. Specimens from over-growth wells H2 ( exp. 2, 62.5 and 7.8 μg/mL ), H4 
(exp. 2, 7.8 μg/mL), E4 (exp. 1, 62.5 μg/mL), and B1 (exp. 1, 62.5 μg/mL) in the 
mutagenicity tests were spread on YEA; the white colonies were isolated on YEA and MV 
plates. 
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Figure 5.8 First and secondary generation cultures of S.cerevisiae ade2. Purple: S. cerevisiae 
specimen from NCYC; Orange: Original culture; Blue: first generation; Red second generation. 
Two cultures from the first generation and two cultures from the second generation were 
spread on the same YEA plate for comparison (Figure 5.10 A), the positions of each inoculum 
were showed in red portions. 
 
 
After 48 hours incubation, many white colonies were observed in the YEL cultures from 
both first and second generation cultures (Figure 5.10 A, inside the blue circle). The white 
cells were plated on MV+ade (Figure 5.10 B) and confirmed that white colonies were 
double mutants (ade2, adeX), they still needed adenine to grow but did not show the 
characteristic red colour. 
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   A                                    B 
    
 C                                    D  
 
 
Figure 5.9 Genetic stability evaluation. A. First and second generation cultures from yeast 
extract liquid and agar, white mutants were observed in the circled area; B. Auxotrophic white 
mutants on minimum medium+ade; C. Dilution of new strain from YEL; D. Isolated white 
mutants on YEA, red/white sector colonies were observed in the circled area. 
 
A new haploid S. cerevisiae ade2 mutant strain was purchased from NCYC. The 
culture was incubated in YEL for 24 hours and plated onto YEA. However, many white 
colonies could still be seen after 48 hours of incubation (Figure 5.9 C), indicating that 
the strain had a high background mutation rate; at the same time, a sectored colony 
was found on one of the cultured plates (Figure 5.6 D). The reason for the appearance 
of the sectored colonies was not investigated, but research could be conducted by 
genetic analysis. Sectored colonies may have arisen by spontaneous mutation during 
colony growth. This may be due to mitotic recombination (Aguilera et al., 2000). 
Mitotic recombination was considered to be the primary pathway to repair DNA breaks 
in yeast (Paques and Haber, 1999). 
YEL->YEA G2     YEA  G2 
   YEA  G2    YEL->YEA G2 
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5.5 Conclusion 
The results of the mutagenicity assays on the haploid S. cerevisiae ade2 strain were 
not conclusive. EMS which was used as a positive control, showed some evidence of 
mutagenic activity at the high concentrations (500 µg/mL), but the test compounds 
showed inconsistent mutagenic activity. Fraction H1 to H4 showed growth inhibition 
against S. cerevisiae, indicating that the hexane fraction had toxicological properties. 
New experimental material and new strains were tested separately in order to 
investigate the genetic stability of the S. cerevisiae ade2 mutant. However, none of 
the tests gave a consistent result, and a high background mutation frequency 
suggested that this mutant was not stable and the in vitro test results were not 
reliable. 
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The whole plant of E. annuus was separated using several chromatographic methods. 
The total crude ethanolic extract was partitioned into four major extract groups 
labelled as hexane extract (H), ethyl acetate extract (E), butanol extract (B) and water 
extract (W).  
  
Several compounds were isolated from the E. annuus extracts: gondoic acid; 
hexadecanoic acid; α-spinasterol; erythrodiol; 4-pent-3’-ne-1’-ynyl–pyran-2-one. 
Structure elucidations were carried out using NMR spectroscopy and mass 
spectrometry. Compounds whose structures were not fully elucidated include 
butyrolactone derivative H1-2-6; anthraquinone derivatives B3-7, B3-8; 
4-benzopyrone analogue B3-9 and compound B3-1 and B3-12. Components from 
volatile oily fractions of E. annuus were identified using GC-MS and the structures 
were proposed by matching the known compounds from the mass library, sixteen 
compounds were identified. 
 
Two compounds were separated from this plant for the first time. Erythrodiol (Figure 
6.1 A) was identified by comparing the NMR results to the published data. It is a 
naturally occurring triterpene alcohol, and showed no activity in the antibacterial and 
DNA gyrase assays.  
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Figure 6.1 Structure of Erythrodiol, 4-but-3’-ne-1’-ynyl-6-methyl–pyran-2-one. 
 
A 2-pyrone derivative, 4-pent-3’-ne-1’-ynyl-pyran-2-one was isolated from the hexane 
extract for the first time (Figure 6.1 B). The 4-substituted-6-methyl-2-pyrone 
compounds have previously been synthesized by Fairlamb. According to their 
publications, 4-alkynyl derivatives have inhibitory activities against several wild type 
bacterial and yeast strains, including E. coli, S. aureus and S. cerevisiae. But their 
antibacterial activity tests for those synthetic compounds were measured using disk 
diffusion assays, and difficult to compare with the MIC test results from this MIC 
assays. However, the isolated 4-substituted 2-pyrone derivative in this research had 
MIC value of 128 μg/mL which supported Fairlamb’s findings. In addition, Fairlamb 
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also demonstrated that the 4-alkynyl derivatives had antitumor activity against A2780 
ovarian carcinoma and K562 human chronic myelogenous leukemia cell lines in vitro. 
The IC50 was measured from 1.8-7.0 μM against A2780 cell line and 4.0-20.3 μM 
against K562 cell line (Fairlamb et al., 2004).  
 
The antibacterial activity of separated compounds from this research was evaluated 
against wild type Escherichia coli, Salmonella enterica, Micrococcus luteus, 
Enterococcus faecalis, Staphylococcus aureus and an MRSA strain. Compound 
H1-2-6 separated from the hexane extract showed the best antibacterial activity 
among all test candidates against MRSA. The MIC value was recorded at 64 μg/mL. 
The structure elucidation study showed this compound could be a butyrolactone 
derivative. Compound H1-2-7 was suggested to be 4-pent-3’-ne-1’-ynyl–pyran-2-one. 
(Figure 6.1 B). The MIC value against the MRSA strain was 128 μg/mL. In addition, 
forty-six fractions were tested in antibacterial assays, and this is the first report of 
compounds and extracts from this plant with activity against MRSA. Only the hexane 
fractions showed inhibitory activity against MRSA and they were fractionated to obtain 
the pure compounds mentioned above. Nine fractions from hexane and butanol 
extracts were confirmed as having Gram-negative bacterial inhibition against E. coli 
and S. enterica, however, further fractionation could not be carried out due to the 
limited amount of sample. The positive results indicate that the plant extracts should 
be investigated further as potential antibacterial agents. 
 
The isolated compounds and fractions were also tested for inhibition of DNA gyrase 
activity. Six compounds from the butanol extract, B3-1, B3-7, B3-8, B3-9, B3-11 and 
B3-12, showed inhibition against S. aureus gyrase. The different modes of action of 
inhibition were suggested in accordance with the structural studies: structures of B3-1 
and B3-9 were elucidated by NMR spectroscopy and mass spectrometry. Compound 
B3-9 had a very good IC50 at 5.39-6.18 µg/mL compared to the positive control 
(novobiocin at 3.97-7.18 µg/mL). The structure of B3-9 was suggested to be a C4-OH 
coumarin derivative and therefore may share the same mode of action of coumarin 
DNA gyrase inhibitors by binding to the 24kDa sub-domain of GyrB to block the ATP 
hydrolysis site. Compound B3-1 had an IC50 at 31.27-34.03 µg/mL, compared to the 
positive control (novobiocin at 3.97-7.18 µg/mL). The other compounds B3-7, 8, 11 
and 12 also showed positive activity in DNA gyrase supercoiling assays, but full 
structure elucidation would be needed. 
 
Compounds B3-1 and B3-9 exhibited good gyrase inhibition. These two compounds 
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were isolated from fraction B3. Interestingly B3 only showed a weak inhibition against 
the wild type S. aureus and MRSA (256 µg/mL). It could be suggested that these 
compounds might have difficulty in reaching their gyrase target in the bacterial cell. 
Structure modifications on these potential antimicrobial compounds could be 
considered in the further investigation of this plant.  
 
Necessitating the mutagenicity tests of chemical agents could help to discover 
potential carcinogens in human therapy, E. annuus fractions were tested in the 
mutagenicity assays induced in this research against Saccharomyces cerevisiae ade2. 
S. cerevisiae is usually known as fermenting yeast and it is a unicellular and 
uninuclear eukaryotic organism. S. cerevisiae ade2 is an auxotrophic strain with red 
phenotype colonies. To perform the mutagenicity tests, mutants of S. cerevisiae ade2 
could be identified visually by observing white-coloured colonies, and the mutation 
type could be further determined using different minimal media. However, results were 
inconsistent and S. cerevisiae ade2 exhibited varying mutant frequencies with test 
samples and the controls. A short study of the genetic stability of this strain was 
carried out and the results showed the red mutant had a high background mutation 
frequency. Hexane extracts H1 to H4 showed cytotoxicity against this yeast strain, the 
investigation of potential antifungal compounds were warranted in the future works. 
 
This research supports the traditional use of the Chinese folk medicine Erigeron 
annuus, to treat infections. Compounds and extracts of E.annuus showed 
antimicrobial activity against bacteria including Gram-negative strains Escherichia 
coli,Salmonella enterica; Gram-positive strains Micrococcus luteus, Enterococcus 
faecalis, Staphylococcus aureus, and Methicillin-Resistant Staphylococcus aureus 
strain (MRSA). A mechanism experiment showed that, the isolated compounds and 
fractions from this plant have potential antimicrobial activity by inhibiting bacterial 
gyrase activity. With the increasing trend of multidrug resistant bacterial strains, 
further investigation will be required on the active components of this plant. For 
example, the study of modulation effects and potential efflux pump inhibition. 
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